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Abstract 
 
Access to new cancer medicines, particularly their coverage and affordability, is a matter of 
great concern to payers, patients and the pharmaceutical industry. Yet, little comparative 
evidence on actual use and its determinants is available. This thesis aimed to analyse the 
extent to which access to cancer medicines varies across a sample of European countries, 
what determines these differences, whether they matter, and what are countries doing to 
improve access. These objectives were achieved through the use of quantitative and 
qualitative methods including multilevel mixed effects models, survival analysis and the 
complementary log-log transformation of the Cox proportional hazard model, literature 
reviews and interviews to inform the development of conceptual frameworks, and a 
comparative longitudinal analysis of the implementation of MEAs. Results show that there 
are wide cross-country differences in access to cancer medicines in Belgium, Estonia, 
Scotland, and Sweden. These differences were determined by time to entry of new medicines, 
medical need (i.e. incidence of the disease) and factors affecting treatment decisions (e.g. 
coverage, prices, and financing mechanisms). The added clinical value of medicines 
explained the shorter time to launch in Estonia and higher consumption in Scotland but not in 
the other countries. This emphasises the importance of health technology assessment 
processes in identifying and making cost-effective medicines available and limiting the 
utilisation of non-cost-effective ones. The latter is particularly important given the 
opportunity cost of funding new cancer medicines. Managed entry agreements have 
increasingly been implemented to address issues of uncertainty and high prices when making 
coverage decisions. Through their action on price, effectiveness and use, they are able to 
influence cost-effectiveness and budget impact, two key variables guiding reimbursement 
decisions. Some of the most important contributions from this thesis include: (1) the 
development of a blueprint to analyse access to cancer medicines in Europe quantitatively 
and qualitatively; (2) the identification of likely determinants of differences in access to 
cancer medicines which can guide policy-makers efforts in managing access to new 
therapies; and (3) the development of a conceptual framework for managed entry agreements 
which can support their design and evaluation.  
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1!  Introduction  
Access to essential medicines (medicines that satisfy the priority health needs of the 
population (WHO 2016b)) has been recognised as an fundamental component towards the 
fulfilment of States human right obligations to health (Hogerzeil 2006). Providing access to 
affordable essential medicines in developing countries was one of the targets of the 
Millennium Development Goals (target 8E, 2000-2015) (The official United Nations site for 
the MDG indicators 2012). The importance of access to medicines in the context of universal 
health coverage has been emphasised in the Sustainable Development Goals (SDGs). SDG 
target 3.8  calls for access to safe, effective, quality and affordable essential medicines and 
vaccines for all (United Nations 2016) not just in developing countries. Further, SDC target 
3.b calls for supporting the research and development of medicines and vaccines for 
conditions that affect predominantly developing countries and to ensure access to them in line 
with the full provision of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
agreements (United Nations 2016). Despite these high level recognitions of their importance, 
almost 2 billion people worldwide lack access to essential medicines (United Nations 2008). 
 
In 2012, there were 14.1 million new cancer cases and 8.2 million cancer deaths worldwide 
(Stewart and Wild 2014). The five most common cancer sites in men were the lung, prostate, 
colorectum, stomach and liver; in women, they were the breast, colorectum, lung, cervix and 
stomach (Stewart and Wild 2014). Together with surgery and radiotherapy, chemotherapy, 
targeted therapies and immunotherapies are key components of cancer treatment. Inequalities 
in access to cancer medicines across and within European countries have been highlighted in 
various studies (Cherny et al. 2016, Aggarwal, Ginsburg, and Fojo 2014). 
 
Access to medicines is affected by a range of factors and decisions that occur well before the 
medicine is developed or available on the market. Investment priorities of the pharmaceutical 
industry and public and philanthropic bodies are a key factor in determining the therapeutic 
focus of foundation research and of research and development (R&D). Time to market also 
affects access to medicines for patients due to country variances in availability of expedited 
approval programmes and the criteria to obtain market access and flexibilities for medicines 
with incomplete evidence. Similarly, long pricing and reimbursement processes and 
restrictive coverage criteria can be a barrier to access. Therefore, it is important to take into 
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consideration the whole medicine’s product life-cycle when analysing barriers and enablers 
to access to medicines. 
 
In the following subchapters, I will describe the product life-cycle and discuss factors 
affecting access to medicines at different stages of the cycle. Where relevant, I will also 
highlight specific factors relating to access to cancer medicines. 
 
1.1! Medicines life-cycle and determinants of access 
1.1.1!Research and development (R&D) 
Research and development (R&D) starts with the search for new molecular compounds 
which have an effect on a particular disease. This is done in different ways, including the 
screening of thousands of molecules, the use of existing treatments in new indications or 
therapeutic areas and the design of specific molecular compounds which inhibit or stop the 
disease of interest. Promising molecular compounds are then channelled through a process of 
evidence generation to assess their safety and efficacy (Figure 1).  
 
Figure 1: Medicines product life-cycle 
 
Source: The author 
 
The first step is pre-clinical research, in vitro and in vivo (animals), to establish whether the 
molecular candidate could cause serious toxicity in humans. If the results are positive, no 
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unacceptable levels of toxicity, clinical trials in humans are commenced. The aim of phase I 
clinical trials is to test safety and appropriate dosage in about 20 to 100 healthy volunteers or 
people with the disease (U.S. Food & Drug Administration 2016a). In phase II clinical trials, 
up to several hundred people with the disease are studied from several months to 2 years to 
assess the efficacy and side effects of the medicine (U.S. Food & Drug Administration 
2016a). In phase III clinical trials 300 to 3000 volunteers with the disease are included in 
studies to test the efficacy and monitor adverse reactions over the course of 1 to 4 years (U.S. 
Food & Drug Administration 2016a). In phase IV clinical trials several thousand volunteers 
with the condition are followed to collect additional evidence on safety and efficacy post-
launch (U.S. Food & Drug Administration 2016a).   
 
According to a 2016 study claiming to be the largest study on clinical development success 
rate at the time of writing, the probability for a medicine entering phase I clinical trials to 
successfully complete phase III clinical trials is 11.3% (Thomas et al. 2016). The probability 
for a medicine entering phase I to obtain a marketing authorisation (MA) by the United States 
(US) Food and Drug Administration (FDA) is 9.6% (Thomas et al. 2016). Previous studies 
report similar results (Table 1). However, some studies highlight that the least successful 
stage is Phase II (Thomas et al. 2016, DiMasi et al. 2010, Kola and Landis 2004, Hay et al. 
2014). while others highlight that the least successful stage is Phase III (Abrantes-Metz, 
Adams, and Metz 2004, U.S. Food & Drug Administration 2016a). High failure in phase II is 
justified by this being the last stage before the most expensive and risky phase III begins. The 
expensive and risky nature of phase III is due to the business, legal and ethical ramifications 
of use of a trial compound in humans. Failure of a molecular compound in phase III clinical 
trials represents a large loss for a pharmaceutical company. If phase II shows unpromising 
results, the molecular candidate is therefore unlikely to be advanced to phase III. 
  
19 
 
Table 1: Probability of success 
 
 
FDA 
website 
BioMedTra
cker 2016 
Biomedtrac
ker 2013 
DiMasi et 
al. 2010 
Kola et al. 
2004 
Abrantes-
Metz et al. 
2004 
Medicines 
included NA 
All 
medicines 
identified as 
‘Advanced’ 
and 
‘Suspended
’ in the 
BioMedTra
cker 
database by 
developmen
t phase 
from 
January 
1, 2006 to 
December 
31, 2015 
All 
medicines 
identified as 
‘Advanced’ 
and 
‘Suspended
’ in the 
BioMedTra
cker 
database by 
developmen
t phase 
from 
January 1, 
2003 to 
December 
31, 2011, in 
the 
BioMedTra
cker 
database 
New 
medicines 
with 
available 
dates of 
start of 
phase I for 
which 
phase I was 
started 
between 
1993 and 
2004 for the 
50 largest 
pharmaceuti
cal 
companies 
Success 
rates from 
first-in-man 
(phase 0) 
for then 
large 
pharmaceuti
cal 
companies 
in the US 
and Europe 
between 
1991 and 
2002 
Medicines 
which 
began the 
FDA 
process for 
the first 
time 
between 
1989 and 
2002 
Indications 
included NA All Lead* Lead* Lead* Lead* 
Phase I to II 0.7 0.632 0.665 0.71 0.68 0.807 
Phase II to 
III 0.33 0.307 0.395 0.45 0.38 0.577 
Phase III to 
MA 0.275 0.581 0.676 0.64 0.55 0.567 
Submission 
for MA to 
approval  
0.853 0.864 0.93 0.77 NA 
Phase I to 
approval  0.096  0.19   
Total 
number of 
medicines 
in the 
sample 
NA 9985†  1737 NA 2328 
 
Notes: *Lead: In Biomedtracker this is used to denote the most advanced indication in clinical 
development for a specific drug. †It refers to the number of transitions from one phase of a clinical 
trial to the next 
Source: The candidate based on the literature (U.S. Food & Drug Administration 2016a, Thomas et al. 
2016, Hay et al. 2014, DiMasi et al. 2010, Kola and Landis 2004, Abrantes-Metz, Adams, and Metz 
2004) 
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These percentages are lower for oncology medicines. The likelihood to obtain a FDA 
marketing authorisation for a medicine entering phase I clinical trials was 5.1% for oncology 
vs. 9.6% for all other indications and 26.1% for haematology, the indication with the highest 
marketing authorisation success rate (Thomas et al. 2016). Research-focused pharmaceutical 
companies are essentially determining their R&D portfolios. Given they are profit-seeking 
enterprises, they will focus on therapeutic areas where they expect high returns, ideally, both 
in terms either unit price or volume or both.  
 
The profitability of the therapeutic area has important implications for access to medicines, 
since therapy areas of focus will target diseases with relatively high prevalence and/or high 
unit cost. Both these factors can result in high budget impact for countries and patients which 
means that the likely recipients of such medicines will be countries with a relatively high 
gross domestic product per capita (Chirac and Torreele 2006, Kyle and McGahan 2012). 
Investment in R&D for new antibiotics is also affected by a number of disincentives. These 
include a series of challenges across all stages of development to commercialisation which 
make the market for antibiotics unattractive (Chorzelski et al. 2015). For example, the 
antibiotic market is dominated by off-patent medicines which are recommended for first-line 
treatment (Morel and Mossialos 2010). New on-patent antibiotics would only be prescribed 
after failure of previous treatments (Morel and Mossialos 2010). The risk of antibiotic 
resistance could shorten the life-time of new antibiotics, whose development is particularly 
expensive due to the costly nature of the clinical trials, above average, in this therapeutic area 
(Morel and Mossialos 2010). Further, antibiotics are administered over a short period of time 
(5 days to 2 weeks) and are curative (Morel and Mossialos 2010).  
 
There is also a general disincentive to invest in the development of paediatric formulations 
due to the small market size (less than 10% of total pharmaceutical market), widespread use 
of off-patent medicines and smaller prevalence of chronic diseases in children than adults 
(Milne and Bruss 2008). For example, in the area of oncology, some cancers have been 
traditionally neglected and underfunded. Studies in the UK and US found the following 
common discrepancies in terms of burden of disease vs. research funding. These include 
bladder, oesophageal, liver, lung, pancreatic and stomach cancers in comparison to breast 
cancer, prostate cancer, and leukaemia (Lancet Oncology 2010, Carter and Nguyen 2012, 
Carter, Delarosa, and Hur 2015). 
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Therefore, the paucity of medicines to treat diseases of less wealthy countries, particularly 
low-income tropical countries with a different disease burden from high-income non-tropical 
countries, the current global shortage of antibiotics, and the limited availability of age-
appropriate formulations for paediatric populations result in R&D gaps which represent a 
barrier in access to medicines, as needed products are not available. These research gaps are 
not aligned with the current global pharmaceutical R&D pipeline that often prioritises 
diseases that affect wealthier countries, adults, and are not easily curable through a short-, 
moderately expensive, treatment course. Nonetheless, therapeutic gaps  are also evident in 
high-income countries. The Priority Medicines for Europe and the World 2013 report 
identified a number of treatment gaps which they defined as medicines that exist but are 
expected to soon become ineffective (e.g. due to resistance to antibiotics, antiretroviral 
medicines, and medicines against malaria), medicines that exist but whose delivery 
mechanism or formulation is inappropriate for the patients they are meant to treat (e.g. 
medicines for children and the elderly), and medicines which do not exist or which are 
insufficiently effective (e.g. medicines for neglected tropical diseases and rare diseases) 
(Kaplan et al. 2013). 
 
The recognition of these issues has led to a number of initiatives to rectify the misalignment 
of the global R&D pipeline with the world’s patients’ needs. These include the creation of 
public-private product development partnerships like the Drug for Neglected Diseases 
initiative (DNDi) (Drugs for Neglected Diseases initiative (DNDi) 2016), Medicines for 
Malaria Venture (MMV) (Medicines for Malaria Venture (MMV) 2016), and the Clinical 
Development Partnerships joint initiative by Cancer Research Technology and Cancer 
Research UK (Cancer Research Technology 2016); the provision of funding support, 
covering the whole R&D pipeline from fundamental biology to clinical trials, for cancer with 
high unmet medical need (Cancer Research UK 2016); the introduction of incentives to 
stimulate the pipeline towards areas of unmet therapeutic need (e.g. advanced market 
commitments); and the introduction of regulatory initiatives such as the orphan designation1 
                                                
1 Regulation (EC) No 141/2000 OF the European Parliament and of the Council of 16 December 1999 on 
orphan medicinal products, http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:en:PDF  
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and the Paediatric Regulation2 at the European Union (EU)-level providing various financial 
incentives and waivers to stimulate the development of orphan medicinal products (i.e. for 
the diagnosis, prevention or treatment of conditions affecting not more than 5 in 10 000 
persons in the EU or for which the return on investment would be insufficient to stimulate 
their development (EMA 2016c)) and paediatric medicines. Similar regulatory initiatives are 
also in place in the United States (the Orphan Drug Act, the Best Pharmaceuticals for 
Children Act, and the Paediatric Research Equity Act).  
 
As of 2016, initial results of these initiatives include the delivery of for six new treatments for 
neglected tropical diseases by DNDi (2003-2015) (Drugs for Neglected Diseases initiative 
(DNDi) 2016), a number of achievements by MMV and partners including the development 
of dispersible artemisinin combination therapy for children (2009) and the receipt of WHO 
prequalification for artesunate injection (2010) just to mention a few (Medicines for Malaria 
Venture (MMV) 2016). An evaluation of the advance market commitment (AMC) for the 
development of pneumococcal vaccine found that the AMC had very little effect on speeding 
up the R&D outcomes, particularly marketing authorisation (The Boston Consulting Group 
2015). However, it did contribute to increased availability through additional manufacturing 
capacity and uptake post-launch (The Boston Consulting Group 2015). A 2012 evaluation of 
the Paediatric Regulation found that of the 500 paediatric investigation plans approved by 
EMA since 2008, only a minority of them had been completed at the time of the review. 
However, because development cycles of medicines often last more than 10 years, the review 
concluded that it was too early to draw conclusions about the impact of the regulation 
(European Commission 2012).With orphan medicinal products there is evidence that the 
system has been exploited and that manufacturers first apply for an orphan indication and 
then later apply for a second non-orphan indication (Côté and Keating 2012, Drummond and 
Towse 2014) and withdraw from the orphan status. Further, widespread off-label use has 
been reported in the US (Daniel et al. 2016). Such concerns may be at least in part behind the 
recommendations of the council of the EU on the current legislation on orphan medicinal 
products in its conclusions on strengthening the balance in the pharmaceutical systems in the 
EU and its Member States. They recommend the European Commission to conduct a study 
on the impact of the incentives in EU legislative instruments including orphan medicinal 
                                                
2 Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for 
paediatric use 12 December 2006, http://ec.europa.eu/health/files/eudralex/vol-
1/reg_2006_1901/reg_2006_1901_en.pdf  
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products and paediatrics on innovation, availability, deferred or missed market launches and 
accessibility (Council of the European Union 2016a).  
 
In summary, funding priorities for R&D influence access to medicines by determining the 
therapeutic focus of the R&D pipeline. As the pharmaceutical industry is a profit-seeking 
enterprise, their investment priorities will focus on areas where high returns are expected. 
This reality has created therapeutic gaps in areas of unmet need which are characterised by 
low returns on investment. Public-private partnerships and other initiatives have sought to 
address this issue by providing a series of incentives to promote R&D in critical areas such as 
neglected tropical diseases, orphan medicines, antibiotics, and paediatric formulations. The 
impact of these initiatives is mixed. There are some positive results like the development new 
of products for neglected tropical diseases and improved access to pneumococcal vaccine 
through AMC. However, concerns have been raised about the impact of some of these 
initiatives in improving access, in particular the EU orphan medicines legislation and 
paediatric legislation and in speeding up R&D outcomes. 
 
1.1.2! Medicines regulation with focus on marketing authorisation 
The task of medicines regulatory authorities is to ensure that medicinal products on the 
market are safe and effective. As no medicine is completely safe, in practical term, this means 
that the benefits of taking a medicine should outweigh the risks of taking it. This is done 
through a comprehensive medicine regulatory process covering licensing of pharmaceutical 
establishments, regulation of clinical trials, marketing authorisation, inspection and control of 
the quality of medicines on the market, monitoring of distribution, safety and adverse 
medicines’ reactions, and the provision of independent information on medicines to health 
professionals and the public (Rägo and Santoso 2008).  
 
The presence of substandard, spurious, falsely labelled and counterfeit medicines represents a 
very important barrier to access to quality medicines and patient safety, and no country is 
immune to it ([No authors listed] 2010). However, countries with stringent regulatory 
authorities3 are in a much stronger position to limit entry of such medicines into their markets 
and to take rapid and effective action once they are detected. In countries with weaker 
                                                
3 A Stringent Drug Regulatory Authority (SRA) is a regulatory authority which is either (a) a member of the 
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH); or (b) an ICH Observer or (c) a regulatory authority associated with an ICH member through 
a legally binding mutual recognition (WHO 2011). 
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regulatory systems, this is a much bigger challenge (Caudron et al. 2008). In these countries 
there is also very limited evidence on the extent of the problem, particularly for non-
communicable diseases including cancer (Wirtz et al. 2016). Medicines regulatory 
authorities, together with the International Criminal Policy Organization and international 
community (e.g. WHO, the International Medical Products Anti-Counterfeiting Taskforce) 
and donors have therefore a very important role to play in ensuring the quality of medicines 
available to patients. Use of substandard, spurious, falsely labelled and counterfeit medicines 
can have very serious consequences on patients’ health and wellbeing and lead to resistance 
because of sub-therapeutic dosage (e.g. antibiotics and medicines against malaria) 
(Karunamoorthi 2014, Kelesidis et al. 2007). The latter will in turn reduce the number of 
effective medicines available to treat patients. 
 
Medicines regulatory authorities can operate at national or international level. In Europe, the 
European Medicines Agency (EMA) was created in 1995 to harmonise (EMA 2016d) the 
work of national EU Medicines Regulatory Authorities and ensure that new medicines of 
important public health value, are marketable in all EU countries at the same time. In reality, 
medicines will not be available to patients in different EU countries at the same time due to 
manufacturer’s launch strategies – which are affected by national pricing and reimbursement 
policies - and differences in coverage across countries. However, the work of EMA has 
enabled to overcome one hurdle, marketing authorisation. This is particularly important in 
small markets with limited economic power where, due to limited market attractiveness, the 
manufacturer may have never submitted a marketing authorisation request or submitted one 
with substantial delay. 
 
Within the European Union and selected countries of the European Economic Area, there are 
two main procedures to obtain a marketing authorisation. These include a centralised 
procedure through the EMA and national procedures (EMA 2016d). A centralised marketing 
authorisation provides market access to all EU Member States. Use of the centralised 
procedure is mandatory for medicines treating HIV/AIDS, cancer, diabetes, 
neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases 
as well as the specialised areas of medicines for rare diseases, herbal medicines, medicines 
for children and advanced-therapy medicines (EMA 2016d). The national procedures include 
three different types of applications. The manufacturer can either apply to an individual 
country to obtain a marketing authorisation, as done in most countries worldwide. 
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Alternatively, marketing authorisation may be obtained via the decentralised procedure, 
whereby the medicine is approved by more than one EU Member State at the same time, or 
the mutual recognition procedure, whereby a medicine authorised in one EU Member State 
can be recognised in a second Member State (EMA 2016d). Since 20044, all cancer 
medicines are required to go through the centralised procedure which means that they are 
potentially available in all EU Member States at the same time.  
 
In the EU, there are strict timelines for the authorisation of new medicines (originators), 210 
+ 30 days for the decentralised and national procedures and 90 + 30 days for the mutual 
recognition procedure (The European Parliament and the Council of the European Union 
2004). To shorten times to access for patients, accelerated review options are available in the 
EU and other countries (e.g. US). The EMA accelerated review programme offers a reduction 
from a maximum of 210 days to 150 days to provide a decision on the marketing 
authorisation of medicines of public health importance and representing major therapeutic 
innovation (EMA 2016d). In an effort to expedite entry of medicines for seriously debilitating 
or life-threatening conditions, emergency medicines and orphan medicines in the absence of  
comprehensive data usually required to grant a marketing authorisation, conditional 
marketing authorisation was introduced (EMA 2016d). For medicines treating such 
conditions to be eligible for conditional marketing authorisation, some conditions need to be 
fulfilled. The expected benefits need to outweigh the risks and there is a realistic expectation 
that the manufacturer will be able to provide more comprehensive data on safety and efficacy 
so that a final decision may be reached (EMA 2016d). Medicines approved under exceptional 
circumstances are medicines for which collection of comprehensive data is not feasible (e.g. 
very rare conditions) or unethical. In contrast to conditional marketing authorisation whose 
aim, after collection of comprehensive information, is to obtain a full marketing 
authorisation, a marketing authorisation obtained under exceptional circumstances does not 
generally lead to a full marketing authorisation (EMA 2016d). The adaptive pathways (earlier 
called adaptive licensing) concept was introduced and piloted by EMA between 2014 and 
2016 to enable early access to medicines addressing high unmet medical need. It builds on a 
longer term discussion about moving from a one-off marketing authorisation to a life-cycle 
approach (Eichler et al. 2012, Eichler et al. 2008) and is grounded in the principles of 
                                                
4 REGULATION (EC) No 726/2004 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 
March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for 
human and veterinary use and establishing a European Medicines Agency. http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF  Accessed: 8 November 2016  
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iterative development (gradual expansion of the eligible treatment population as additional 
evidence is collected), and the collection of real-life evidence to supplement clinical trials 
data and early engagement of stakeholders (e.g. patients and HTA bodies) in the medicine’s 
development process (EMA 2016d). Rather than representing a new marketing authorisation 
path, adaptive pathway builds on existing approval mechanisms, particularly conditional 
marketing authorisation (EMA 2016b). If sufficient evidence to support the positive balance 
between benefits and risks is collected, a marketing authorisation will be granted (EMA 
2016b).  
 
In the US there are four expedited review programmes: accelerated approval, breakthrough, 
fast track, and priority review (FDA 2016b). Accelerated approval can be compared with the 
EMA conditional marketing authorisation as it allows early approval of medicines that treat 
serious conditions of unmet medical need based on surrogate endpoints (a marker that 
correlates with the clinical endpoint) (FDA 2016b).  Phase IV confirmatory trials need to be 
conducted by the company after which, a full marketing authorisation may be granted (FDA 
2016b). Breakthrough therapy designation aims to reduce the time needed to develop and 
review a medicine for the treatment of serious conditions if preliminary clinical data supports 
substantial added value over existing standard of care (FDA 2016b). A breakthrough therapy 
is eligible for fast track review. A fast track review is granted to medicines that treat serious 
conditions of high unmet clinical need to facilitate their development, through enhanced 
communication with the FDA during the development process, and accelerate their review by 
applying to the accelerated approval and priority review programmes if eligible (FDA 
2016b). Priority review designation shortens the time of review of the application from 10 to 
6 months. It is granted to medicines with the potential of improving effectiveness or safety of 
the treatment, diagnosis or prevention of serious conditions compared to existing treatments 
(FDA 2016b). 
 
In 2015, 45 new molecular entities were approved in the US of which 31% were approved 
through fast track, 22% through breakthrough procedure, 53% through priority review and 
13% through accelerated approval (some medicines were eligible to more than one expedited 
approval programme) (FDA 2016a). Oncology was the therapeutic area with the highest 
proportion of new medicines approved through expedited approval programmes and second 
after infectious diseases, in terms of number of new medicines approved by the FDA (107 
between 1987-2014) (Kesselheim et al. 2015). 76% of all new cancer medicines approved 
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between 1987 and 2014 were approved through priority review, 48% through fast track, 30% 
through accelerated approval (Kesselheim et al. 2015). 
 
The presence of substandard, spurious, falsely labelled and counterfeit medicines is a 
worldwide problem but some countries are in a better position than others to fight this 
growing threat. In countries with strong regulatory authorities and more generous coverage of 
medicines (whether these benefit all citizens or only a portion of them), the focus is 
increasingly on finding ways to enable faster access to new and potentially more effective 
medicines to patients. A number of challenges remain to be addressed in all countries 
including how to balance early access with the need for data on safety and efficacy. 
 
1.1.3! Pricing and reimbursement 
List prices of medicines in Europe are mostly regulated. This is done through negotiation, 
external reference pricing, value-based pricing, internal reference pricing, generic price 
capping, and regulation of supply chain mark-ups. A number of instruments are used to affect 
the actual total price paid and reduce total budget impact (independently of who pays). These 
include ex-ante price reductions on the list price such as confidential discounts (common in a 
number of European countries) and competitive prices obtained through tendering. Ex-post 
refunds can be implemented as rate-of-return regulation (e.g. UK), price-volume agreements 
(common in a number of European countries (Vogler et al. 2012, Ferrario and Kanavos 
2013)) and performance-based agreements (e.g. Italy). To reduce public expenditure, co-
payments may be introduced or increased. The use of all these regulatory instruments varies 
across countries, type of medicines (e.g. on-patent vs. off-patent, hospital vs. ambulatory, 
prescription vs. over-the-counter) and the actual medicine involved. 
 
Current discussions and initiatives to improve access to new on-patent medicines, including 
new cancer medicines, have largely been focused on how to reduce their prices. Traditional 
tools to reduce prices of branded medicines have been mandatory price cuts, external and 
internal reference pricing, price volume agreements and regulation of generic prices. In the 
past decade, there has been increased interest and discussion on how to use more 
sophisticated pricing and reimbursement tools such as value-based pricing (VBP), 
performance-based agreements and indication-based pricing to increase access to on-patent 
medicines. Further, compulsory licensing, voluntary patent pools and de-linkage of R&D 
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from the final price of the medicine have also been discussed and implemented to improve 
access.  
 
In 2010, the Government of the United Kingdom proposed implementing a system of VBP 
for assessing and pricing branded medicines (The Parliamentary Office of Science and 
Technology 2015). The aim of implementing VBP is to more closely link the price the NHS 
pays for a medicine with the clinical and other benefits it delivers (The Parliamentary Office 
of Science and Technology 2015). Despite the initial hope that VBP would provide a solution 
to challenge the introduction of new and high priced medicines, the expected major pricing 
reform did not materialise. Following two public consultations and the appointment of NICE 
to be responsible for value based assessment, a much modified plan to improve access to new 
medicines emerged. In addition to any methodological changes which may be implemented, 
three concrete changes were suggested by NICE in September 2014 (NICE 2014a). These 
include the establishment of– the Office for Market Access (NICE 2016b), an office for 
innovation within NICE, to advise companies on how to speed up the adoption of new 
medicines, devices and diagnostics by the NHS; the agreement on thresholds for NHS 
willingness to pay for new treatments, particularly special cases such as rare conditions and 
cancer; and the increased use of risk sharing between companies and the NHS through 
commissioning through evaluation for treatments that are not funded by the NHS (NHS 
England 2016b, NICE 2014a). VBP pricing is implemented in Sweden by the Dental and 
Pharmaceutical Benefit Agency (TLV) as part of the health technology assessment (HTA) 
process. If the medicine is considered to be priced over the value it delivers, it can only be 
reimbursed if the manufacturer lowers the price to a level which is comparable to its benefits. 
Sweden is the only country in Europe formally implementing VBP. Most other countries 
incorporate elements of value during the reimbursement process by conducting HTA (Paris 
and Belloni 2013). The use of value based pricing and value-driven pricing systems have 
been suggested in the US to reduce prices and promote research and innovation (Ocana, 
Amir, and Tannock 2016, Bach and Pearson 2015).  
 
In the US, value-driven pricing systems involve the provision of incentives to encourage 
manufacturers to sell their medicines in line with their value and at a price which is 
sustainable for the health care system (Bach and Pearson 2015). This can be achieved through 
positioning medicines on different health insurance tiers based on the extent to which their 
price aligns to value (i.e. higher tier positioning for medicines priced in line with their value 
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and affordable to the health care system), exemption from mandatory discount programmes 
(e.g. the Health Resources and Services Administration, 340B medicines programme 
requiring mandatory discounts up to 50%), regulatory incentives (e.g. increasing the 
exclusivity period of a medicine by the FDA), (Bach and Pearson 2015). Formulary 
positioning according to value and affordability would incentivise the use of medicines on 
high tiers (with low co-payment) as opposed to medicines on lower tiers (with higher co-
payments) for privately insured patients (currently there are some barriers to implement such 
system in Medicare). However, the distribution by industry of vouchers to cover co-payments 
of medicines in lower tiers of insurers’ formularies undermines the incentive of lowering co-
payments to encourage use of medicines priced according to their value (Ross and 
Kesselheim 2013, Dafny, Ody, and Schmitt 2016). Further, other authors have raised concern 
in the use of value to price medicines as this could make some medicines such as antibiotics 
unaffordable (Blumenthal 2016).  
 
Performance-based agreements have been used to enable access to new medicines with 
subsequent price review to align, if necessary, the initial price with evidence on the medicines 
effectiveness in real-life (Garrison et al. 2013). They have been used in some European 
countries, notably Italy (Ferrario and Kanavos 2013). Due to the resource intensive nature of 
these agreements, which require monitoring of patients’ response and claiming funds/stock 
back for non-responding patients, the implementation of these agreements has been limited in 
most European countries. In Italy these agreements are regularly used for expensive hospital 
medicines thanks to the availability of a system of monitoring registries to support their 
implementation and refund claims. 
 
Indication-based pricing involves the application of different prices across multiple 
indications of the same medicine according to the value they deliver. Indication based pricing 
may be implemented as a simple discount on the list price which averages value-based prices 
across different indications (no need to link use to indication), as different list prices for 
different indications of a medicine (Mestre-Ferrandiz et al. 2015), or indirectly through the 
implementation of managed entry and risk-sharing agreements. The feasibility of 
implementing indication-based pricing is largely determined by the ability to link utilisation 
of a particular medicine to different indications, regimens and patient groups (Mestre-
Ferrandiz et al. 2015). In the UK, an assessment of the feasibility of implementing indication-
based pricing concluded that at the time of the assessment, a unique price averaging the value 
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of different indications may be the most feasible approach (Mestre-Ferrandiz et al. 2015). 
However, the potential offered by the Systemic Anti-cancer Therapy dataset5 (SACT 2016) to 
implement individual prices across indications in the future has been recognised by different 
authors (Mestre-Ferrandiz et al. 2015, McNamara and McNamara 2014). In Italy, indication-
based pricing is indirectly implemented through managed entry agreements and the 
monitoring patient registries. Medicines with different indications may be associated with 
different agreements (e.g. payment by result involving a refund for failure of achieving a 
certain pre-agreed outcome and cost-sharing which provides a discount on the first treatment 
cycle) or the same agreement with different features (e.g. payment by result with different 
performance endpoints and time of evaluation) (Carletto 2016).  
 
While unlikely to be a viable solution in Europe (due to external reference pricing and 
parallel trade among other issues), differential pricing based on ability to pay has been used 
to increase access to HIV, tuberculosis and malaria medicines and vaccines in low- and 
middle income countries (Vogler et al. 2015). Despite these positive experiences, authors 
have suggested that it is inferior to competition in lowering prices (Moon et al. 2011). 
Confidential pricing agreements (e.g. confidential discounts, risk-sharing and managed entry 
agreements) offer a way to discriminate prices across countries without altering list prices. 
This is very important to manufacturers as the widespread use of external reference pricing 
(ERP) in Europe, a practice whereby countries set or inform the price of their medicines 
through the prices in other reference countries, has an impact on prices in other countries. 
Studies have found evidence of delayed launches and lack of launches which they attributed 
to the use ERP (Danzon and Epstein 2012, Danzon, Wang, and Wang 2005, Varol, Costa-
Font, and McGuire 2012, Costa-Font, McGuire, and Varol 2015). 
 
Increasingly, there have been calls to delink R&D costs from the final price of new medicines 
(UNITAID 2016, United Nations Secretary-General's high-level panel on access to medicines 
2016). De-linkage can be achieved through grants, prizes and advanced market commitments, 
amongst other incentives (United Nations Secretary-General's high-level panel on access to 
medicines 2016). Finally, voluntary licensing and patent pooling has been used by the 
Medicines Patent Pool to improve access to HIV, hepatitis C and tuberculosis medicines in 
low- and middle-income countries (Medicines Patent Pool 2016). 
                                                
5 A national database collecting comprehensive information on systemic oncological therapies 
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Health technology assessment (HTA) is conducted in a number of European countries and 
beyond to inform coverage decisions. Information on budget impact generally complements 
evidence from HTA which addresses the question of whether the new technology represents 
value for money based on national willingness to pay. A positive coverage decision may be 
contingent on the implementation of a managed entry agreement, particularly financial 
agreements. These are agreements between the payer and manufacturer for the 
reimbursement of a health technology subject to specific financial conditions, use or health 
outcome results (Klemp et al. 2011). A number of these agreements have been implemented 
in Europe (Kwong et al. 2014, Ferrario and Kanavos 2013). Several studies have compared 
HTA decisions across countries, highlighting the divergence in decisions for the same 
technology (Korchagina et al. 2014, Lexchin and Mintzes 2008) and the reasons behind it 
(Nicod and Kanavos 2012, Nicod 2016, Clement et al. 2009), and the misalignment between 
HTA decisions and coverage decisions for orphan medicines (Kawalec, Sagan, and Pilc 
2016). Access to medicines, particularly high cost ones, is largely determined by public 
coverage. However, less attention has been paid in analysing other determinants of access. 
 
To enable access to medicines which are not covered or only covered under special 
circumstances, special funds have been developed in some countries. These include for 
example the Cancer Drugs Fund in England (NHS England 2016a), the Risk-Share scheme 
for rare conditions in Scotland (NSD NHS Scotland 2016) and the Solidarity Fund in 
Belgium (INAMI-RIZIV 2016a).  
 
Prices affect affordability and inclusion in positive reimbursement lists. As such, the methods 
used to set prices have an important indirect impact on access. Likewise reimbursement 
methods and criteria to determine inclusion in the positive list play a central role in 
facilitating or limiting access. The impact of pricing and reimbursement on access is all the 
more important for medicines which are too expensive for patients to pay out-of-pocket either 
in full (for non-reimbursed medicines) or partially (for medicines requiring a co-payments). 
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1.1.4! Post-launch 
The post-launch period is crucial to assess the safety of a medicine in a wider patient 
population than the one included in clinical trials (pharmacovigilance), promote quality use 
of medicines, assess the effectiveness of medicines in real-life, and ensure sustainable access. 
 
1.1.4.1! Pharmacovigilance 
Marketing authorisation is granted to new medicines which are considered to be safe and 
effective based on available evidence, usually clinical trials, prior to market launch. Clinical 
trial data rely on a limited sample of highly selected participants (elderly, people with 
comorbidities tend to be underrepresented and pregnant women and children are generally 
excluded) (Shenoy and Harugeri 2015, Devlin 2010, Blehar et al. 2013). As such the results 
of clinical trials are not necessarily generalizable to a wider patient group. Therefore, safety 
monitoring post-launch and pharmacovigilance play a very important role in identifying, 
quantifying, understanding, and preventing any known and unknown adverse reactions to 
medicines or any other issue linked to the use of a particular medicine (EMA 2016d). Authors 
have suggested that pharmacovigilance is much more than that, it is the “systematic 
monitoring of the process of pre-market review and post-market surveillance, which are 
linked through study design, product labelling, therapeutic outcomes, adverse events, hospital 
and clinician reporting systems, the pharmacy interface, compliance, and a complete 
understanding of real-world evidence.” p. e487 (Pitts et al. 2016) 
 
Medicines for the treatment of cancer are a priority area for pharmacovigilance due to their 
high toxicity and narrow therapeutic window (Pitts et al. 2016). Yet, a review of the evidence 
found a limited number of studies in the field of oncology (Baldo and De Paoli 2014). 
 
1.1.4.2! Quality use of medicines 
There are many tools and approaches to improve quality use of medicines. The WHO 
recommends twelve core interventions. These are the institution of 1) a national multi-
disciplinary national body to coordinate medicine use policies and 2) drugs and therapeutics 
committees in districts and hospitals; 3) the implementation of clinical guidelines and 4) an 
essential medicines list; 5) training in problem-based pharmacotherapy for undergraduate 
students; 6) the requirement for continuous professional education to maintain and renew a 
license for health professionals; 7) supervision, audit and feedback provided to prescribers; 8) 
availability of independent information on medicines,; 9) education about medicines for 
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patients, their carer and the wider society; 10) minimisation and possibly elimination of 
perverse financial incentives leading to poor quality prescribing and medicine’s use; 11) 
appropriate and enforced regulation and 12) sufficient public finances to ensure availability 
of essential medicines and competent staff (WHO 2002). Of particular relevance to the 
appropriate use of cancer medicines are clinical guidelines and formularies. 
 
Clinical guidelines provide evidence-based information to health care professionals on how 
to prevent, diagnose, treat, inform advise and manage a particular health condition (NICE 
2016c). They are based on a systematic review of the evidence on the subject - rated using 
well established approaches such as the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE working group 2016) - and should provide state of the 
art guidance on the management of a condition. In countries with strong implementation, 
clinical guidelines have an important influence on treatment decisions. In some countries, 
national and international guidelines for cancer are used to develop regional or hospital 
guidelines. Clinical guidelines may be accompanied by a medicines’ formulary or essential 
medicines list. These are selections of medicines used to treat the most common medical 
conditions in a particular setting. The aim of developing these lists and using them to inform 
prescribing decisions is to improve quality of care, management and use of medicines, and to 
focus on a cost-effective use of resources (WHO 2016c). Both clinical guidelines and 
formularies may be available at different levels of the health care system. National or 
subnational clinical guidelines will generally reflect international best practices with local 
adaptation to meet budgetary requirements and to reflect the medicines actually reimbursed. 
Evidence on the impact of formularies as part of broader intervention to improve efficiency in 
procurement and quality use of medicines shows increased adherence to recommended 
medicines among primary care doctors from 83% of total prescribing volume in 2003 to 87% 
in 2009 in Stockholm, Sweden (Gustafsson et al. 2011). Further, developing an essential 
medicines list and using it for the selection of medicines in centralised procurement together 
with activities to promote quality use of medicines resulted in 30% savings on annual 
medicines expenditure in Delhi (Chaudhury et al. 2005). 
 
1.1.4.3! Effectiveness in real-life 
Greater availability of real-life data on medicines use and patient outcomes can provide 
information on safety, effectiveness, and patient relevant outcomes. Use of this information 
for comparative assessment studies can provide evidence to update or make a final 
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reimbursement decision and could also be used as a negotiation tool to better align price and 
value of new medicines. These arguments provided the rationale for the introduction of 
various coverage with evidence development agreements in Europe (e.g. performance-based 
agreements in France are occasionally used; coverage with evidence development in the 
Netherlands was discontinued). A number of initiatives are ongoing to collect real-life data to 
inform decision-making in health. These include for example various projects funded by the 
Patient-Centred Outcomes Research Institute PCORI in the US on comparative effectiveness 
research in real-life (PICORI 2016, Kogan et al. 2016, O'Brien et al. 2015), EMA adaptive 
pathways (EMA 2016d) and the Innovative Medicines Initiatives GetReal (IMI 2016). 
Methodological and data collection issues are currently still limiting the impact of real-life 
data on decision-making. As patient data are increasingly digitised the role played by real-life 
data in informing reimbursement decisions and clinical guidelines is likely to become 
increasingly important. 
 
1.1.4.4! Ensuring sustainable access 
Pharmaceutical procurement has an important role to play in securing competitive prices and 
ensuring availability of medicines (Ferrario, Kanavos, et al. 2016b). Strategic procurement 
practices – aimed at increasing efficiency in procurement (e.g. reducing the number of orders, 
generating economies of scale (WHO 2015b)) and creating a competitive environment - can 
reduce expenditure and free resources which can be used to improve access. Horizon 
scanning for new and emerging health technologies (the systematic monitoring of products in 
the R&D pipeline that are likely to enter the market in the next few years), HTA, and analysis 
of the product life-cycle (whether the product is still on-patent, about to go off-patent, or 
already off-patent) can inform negotiations and improve procurement outcomes (Ferrario, 
Kanavos, et al. 2016a). Further, a well-managed procurement cycle can help preventing 
stock-outs and shortages (Amaral and Blatt 2011). Shortages have become an increasingly 
frequent problem worldwide (Tan, Moles, and Chaar 2016a, EAHP 2014, Kweder and Dill 
2013, Gray and Manasse 2012) and the subject of the World Health Assembly resolution 
69.25 in May 2016 which urged WHO Member States and the Director General to take action 
to address this issue (WHO 2016a). They can be caused by manufacturing, supply chain and 
logistical issues, mismatch between supply and demand, economic reasons (e.g. old generic 
products which are not sufficiently profitable to produce or the intention to switch use to a 
patented medicine with the same or similar active ingredient), parallel trade, marketing 
strategies to increase prices (Council of the European Union 2016b, Silverman 2016b, 
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Iyengar, Hedman, et al. 2016, Matrix insight 2012). Shortages can negatively impact 
treatment and health care outcomes if the missing medicines do not have a close substitute. 
Given the multiple causes underlying shortages of medicines, a multipronged approach is 
needed to address them. The most concrete step taken so far to address shortages is the 
development of notification processes in a number of countries at national (e.g. US FDA and 
a number of EU Member States) and international level (e.g. EU EMA), increased dialogue 
with suppliers to understand the reasons for back orders (e.g. Denmark), and attempts by a 
few European countries to reduce parallel trade (Bochenek et al. 2016).  
 
Post-launch activities include pharmacovigilance, ensuring quality use of medicines, 
evaluating effectiveness in real-life and ensuring access to cost-effective medicines and 
sustainable supply. If implemented, these activities can contribute to improved access to 
quality medicines. For example, strategic pharmaceutical procurement and quality use of 
medicines can achieve competitive prices and savings, which, if reinvested, can lead to 
greater access for patients. 
 
1.2! Access to cancer medicines 
1.2.1! Definition of access and global access indicators 
In 1981, Penchansky and Thomas proposed a taxonomic definition of ‘access’ in the context 
of health policy and service research.  They conceive access as a general concept 
summarising five dimensions which characterise the interaction between the patient and the 
health care system, notably availability, accessibility, accommodation, affordability and 
acceptability (also called the five A’s) (Penchansky and Thomas 1982). 
 
The Millennium Development Goal (MDG) 8, 2000-2015, aimed to develop a global 
partnership for development. In particular, sub-target 8E called for: 
“In cooperation with pharmaceutical companies, [to] provide access to affordable essential 
drugs in developing countries (The official United Nations site for the MDG indicators 
2012).” 
 
And was measured by: 
“The proportion of population with access to affordable, essential drugs on a sustainable 
basis is the share of the population that has essential medicines continuously available and 
affordable at public or private health facilities or medicine outlets that are within one hour’s 
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walk from the homes of the population (The official United Nations site for the MDG 
indicators 2012).” 
 
This definition of access to medicines covers three of the dimensions (availability, 
accessibility and affordability) proposed by Penchansky and Thomas (1981). To measure 
progress against this target, a range of indicators have been used. These include the 
percentage of countries with an essential medicines list updated in the past 5 years, 
availability, affordability and pricing of selected essential medicines in public and private 
health facilities, public sector expenditure on pharmaceuticals, availability of pharmaceutical 
policies and legislation which are conducive to better access to essential medicines (MDG 
Gap Task Force 2008, 2015). Due to paucity of data on these indicators in most countries, 
monitoring progress against MDGs target 8E has proven to be challenging. Although target 
8E was still reported on in the MDG task force reports, it disappeared from the 2009-2014 
MDG progress reports and was only mentioned again briefly in the 2015 MDG progress 
report (Gotham, Onarheim, and Barber 2016). 
 
In 2003, the WHO and Health Action International (HAI) published the first edition of 
‘Medicine prices – a new approach to measurement’, followed by an enhanced second edition 
in 2008 on ‘Measuring medicines prices, availability, affordability and price components’ 
(WHO and HAI 2008). A number of surveys worldwide have been conducted since 2003 
using their methods (HAI 2016). The results of these surveys have been an important source 
of evidence in monitoring progress against MDG target 8E (MDG Gap Task Force 2008, 
2010, 2012, 2013, 2011, 2014, 2009, 2015). Unfortunately, not all of the 189 United Nations 
member states which committed to achieve the MDGs are covered. Further, only some of the 
surveyed countries have conducted more than one survey round, hampering efforts to monitor 
progress. 
 
Since 2008, the Access to Medicines Foundation has been publishing the ‘access to 
medicines index‘ every two years (Access to Medicine Foundation 2016).  This index ranks 
major pharmaceutical companies based on their efforts to improve access to medicines in 
developing countries (Access to Medicine Foundation 2016). The index does not publish 
information on common indicators to measure availability, accessibility, accommodation, 
affordability or acceptability. These issues are nevertheless included indirectly in the index 
which assesses seven technical areas (general access to medicine management; market 
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influence and compliance; research and development; pricing, manufacturing and 
distribution; patents and licensing; capacity building; product donation) against four strategic 
pillars which contribute with different weights to the final ranking (pharmaceutical 
companies commitments, 15%; transparency, 25%; performance, 50%; innovation, 10%) 
(Access to Medicine Foundation 2015). For example, the index does not provide indicators of 
individual medicines’ prices or affordability for patients but it does capture whether a 
pharmaceutical company offers equitable pricing strategies which take into account socio-
economic needs and affordability in countries covered by the index. 
 
At country level, a number of household surveys have also been conducted. These tend to 
focus on use/purchasing of medicines and underuse of medicines (Paniz et al. 2010, WHO 
2016d, Bertoldi et al. 2008). This information generally allows to measure availability and 
affordability of medicines. 
 
While it is welcome to have such indicators, they present a number of limitations. The 
infrequency, limited geographical coverage and focus on a limited number essential 
medicines of the WHO/HAI survey and the focus on companies and low and middle income 
countries of the Access to Medicines Index means that there is very little comparable 
information publicly available on access to cancer medicines in high income countries. Most 
of the cross-country publicly available evidence on access to medicines in high income 
countries comes from studies on medicines’ prices, expenditure, use and time to launch using 
commercial data from IMS Health  (Danzon and Chao 2000, Danzon and Furukawa 2003, 
2006, 2008, Kanavos and Vandoros 2011, Varol, Costa-Font, and McGuire 2012, Lanjouw 
2005, Cockburn, Lanjouw, and Schankerman 2014, Danzon, Wang, and Wang 2005, Danzon 
and Epstein 2012, Wilking, Jönsson, and Högberg 2009, Jönsson et al. 2016, Wilking and 
Jönsson 2005, Leopold et al. 2014, Leopold et al. 2012) or other proprietary sources (Kyle 
2007, 2006). These data are commercial and are usually only accessible against payment6. 
Various studies comparing prices of medicines in Europe have been conducted using data 
provided the Pharma Price Information (PPI) service of the Austrian Public Health Institute 
and complemented by publicly available data in non-European countries (Iyengar, Tay-Teo, 
et al. 2016a, Vogler, Vitry, and Babar 2016, Vogler, Zimmermann, and Babar 2016, Vogler, 
Kilpatrick, and Babar 2015, Leopold et al. 2012, Leopold et al. 2013 ). A number of studies 
                                                
6 The IMS Health has, on occasion, given access free of charge to older data for research purposes 
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on utilisation of medicines in Europe have been conducted using non-commercial data, 
however, few focus on cancer and they rarely include the inpatient sector.  
 
1.2.2! Access frameworks 
Various frameworks have been proposed to study access to medicines. These include the five 
A’s framework by Penchansky and Thomas (1981), the four dimensions and indicators 
proposed during the consultative meeting by WHO-Management Science for Health (MSH) 
in 2000 (Center for Pharmaceutical Management 2003), WHO (2003) collective framework 
for equitable access to essential medicines (WHO 2004) updated from 2000 (WHO 2000), the 
access framework proposed by Frost and Reich in 2008 (Frost and Reich 2008) and access to 
medicines from a health system perspective by Bigdeli et al. (Bigdeli, Jacobs, et al. 2013). 
Further, the Ishikawa fishbone diagram developed in 1968 by Kaoru Ishikawa (Kaoru 1976) 
has been applied to study barriers to access to essential medicines indicated for the prevention 
and treatment of postpartum haemorrhage and pre–eclampsia and eclampsia (Ridge, Bero, 
and Hill 2010, Bigdeli, Zafar, et al. 2013, Tran and Bero 2015). 
 
The WHO-MSH framework proposes a set of indicator to measure four dimensions of access, 
physical availability, affordability, geographical accessibility and acceptability (or 
satisfaction) and the crosscutting element of quality of products and services. It therefore 
goes back to the five A’s framework by Penchansky and Thomas (1981). The updated 2003 
WHO framework for equitable access to essential medicines focuses on four dimensions, 
namely, rational selection, affordable prices, sustainable financing and reliable health and 
supply. These include a range of sub-dimensions such as availability of national treatment 
guidelines and national lists of essential medicines, price information, generic policies, out-
of-pocket spending and regulatory control for example (WHO 2004). The access framework 
by Frost and Reich (2008) is also based on the work by Penchansky and Thomas. Their 
framework is structured around the four A’s of architecture, the organizational structure and 
relationships for access; availability, which emphasizes the supply components of access; 
affordability for various stakeholders; and adoption, which includes demand factors and 
acceptance. (Frost and Reich 2008). The most far reaching and comprehensive framework is 
the one developed by Bigdeli et al. (2013) which looks at access to medicines from a health 
system perspective and adopts a holistic view of demand-side barriers, takes into account the 
multiple dynamic relationships between health system building blocks and includes 
leadership and governance of the health sector at local, national and international level 
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(Bigdeli, Jacobs, et al. 2013). Further, it emphasises the role exerted by innovations, market 
forces and international agendas on the health and pharmaceutical sectors (Bigdeli, Jacobs, et 
al. 2013).  
 
These frameworks were developed primarily with a view of studying access to medicines in 
low- and middle income countries – which are disproportionately affected by affordability 
and quality of medicines, responsible use of medicines, and supply chain problems - and are 
not specific to cancer medicines. As such, they are too broad and do not take into account 
some of the peculiarities affecting access to oncology medicines. 
 
Few frameworks exist to study access to cancer or high cost medicines in countries with 
mature health care systems, which may not have major issues in the supply chain, but instead 
struggle more in establishing whether a new medicine represents good value for money, 
securing affordable prices, and inclusion in the list of reimbursed medicines have been 
published. One example is the work by Cohen et al. (2007) which identified eight sub-
dimension of patient access to medicines to conduct an international comparison of access. 
These include marketing authorisation, time of marketing authorisation, reimbursement, cost 
sharing, conditions of reimbursement, time from marketing authorisation to reimbursement, 
the extent to which beneficiaries can choose between different medicines benefit schemes 
(e.g. in the US the medicines benefit package varies between insurers and patients can 
choose), and variation in coverage and cost sharing across the population (Cohen et al. 2007). 
While these factors are important in determining access to medicines, broader barriers to 
access such as access to timely diagnosis and financing of medicines are not included. 
 
Benjamin et al. (2014) developed a conceptual framework of factors influencing patients’ 
access to oral cancer medicines (Benjamin et al. 2014). The framework includes clinical 
aspects, physician’s experience, patient’s preferences, dialogue between the physician and the 
patient, patient characteristics and access to health services (Benjamin et al. 2014). In contrast 
to the framework by Cohen et al. (2007), which is designed to identify determinants of 
differences in access to cancer medicines across countries, the framework by Benjamin et al. 
(2014) is largely designed to compare access determinants between individual patients due to 
the inclusion of a number of patient and physician specific factors. As such, only a few 
national level factors are relevant for cross-country comparisons. More relevant is the 
discussion on system disincentives towards use of oral cancer medicines. The example 
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presented is the hospital per-case payment system in France, which provides an incentive not 
to shift chemotherapy provision through oral cancer medications from the hospital to the 
community to avoid a decrease in revenue (Benjamin et al. 2014). In the US, despite the 
introduction of the Cancer Drug Parity Act in 20067, the complexity of the reimbursement 
system and co-payments may be an important economic barrier for lower income patients to 
access oral cancer medicines (Benjamin et al. 2014). This framework thus sheds light on the 
important role played by financial incentives in limiting or enabling access. 
 
Various literature reviews on access to cancer (Nolte and Corbett 2014), high cost (Wahlster 
et al. 2015) and new medicines (Lublóy 2014, Chauhan and Mason 2008) in high income 
countries have been conducted. These studies classify the identified determinants according 
to various frameworks and structures. Wahlster et al. (2015) classify barriers to access to high 
cost medicines in three levels: macro-, meso-, and micro-. At the macro- level, health system 
barriers such as affordability of the system (e.g. gross domestic product per capita); the 
decision making process for reimbursement (specifically, the use of HTA and time from 
marketing authorisation to reimbursement decision, and other factors influencing the 
decision-making process like lobbying by patient groups); and restriction on access and 
geographical variation in use can affect access (Wahlster et al. 2015). At the meso-level, 
hospital or regional system barriers such as differences in reimbursement of inpatient and 
outpatient medicines, more specifically, differences in budgets and decision-making 
processes across hospitals and/or regions (Wahlster et al. 2015). At the micro-level, patient 
barriers such as physician behaviour and communication in relation to the high costs of these 
medicines for the society, more specifically, the high costs for the patients and the influence 
of high-out-of-pocket costs on patients’ choices (Wahlster et al. 2015). Nolte and Corbett 
(2014) review factors affecting use of cancer medicines, cancer outcomes, differences in 
stage at diagnosis on survival, and health system and service features that may explain 
variation in use of cancer medicines (Nolte and Corbett 2014). Lublóy (2014) reviews 
determinants of uptake of new medicines and classifies them in three levels. At micro-level, 
the socio-demographic and professional characteristics of medical professionals are 
considered (Lublóy 2014). At meso-level, the prescribing characteristics of doctors, the 
marketing efforts of pharmaceutical companies, interpersonal communication among doctors, 
medicines’ attributes, and the characteristics of patients are reviewed (Lublóy 2014). At 
                                                
7 This act requires that health insurance providers offer coverage for oral anticancer medicines equivalent to 
intravenous chemotherapy (https://www.congress.gov/bill/114th-congress/house-bill/2739/text) !
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macro-level, government and health care organisation policies can affect uptake of new 
medicines (the latter group is acknowledged as important but not included in the literature 
review) (Lublóy 2014). As such, it is designed to study access at individual patient level. The 
framework by Chauhan and Mason (2008) reviews determinants of uptake of new medicines 
in secondary care with focus on the UK. They use Bonair and Persson’s framework for the 
diffusion of innovation to classify determinants into: actors (secondary care colleagues, 
clinical investigators, pharma representatives, and patients), environmental factors 
(information/evidence, support structures, and incentives), and characteristics of the medicine 
(effectiveness, side-effects, convenience, cost, and uncertainty) (Bonair and Persson 1996, 
Chauhan and Mason 2008).  
 
While a number of frameworks to analyse determinants of access to medicines have been 
developed, few focus on high-income countries and are specific to cancer medicines. Among 
the available frameworks specific to cancer medicines, only one of the frameworks reviewed 
includes financing of medicines but it is designed to understand determinants of use at patient 
level rather than population level. Further, most of the framework developed are not tested 
against utilisation data. 
 
1.2.3! Determinants of access to cancer medicines in high income countries 
Studies have identified the following determinants of access to cancer medicines in high 
income countries: out-of-pocket payments, country’s wealth indicators, financing of 
medicines including additional funding for cancer medicines, budgetary limitations, HTA and 
coverage decisions, prescribing practices, time of marketing authorisation, availability of the 
necessary skills, specialisation and equipment necessary for the administration of the 
medicine (Kelly et al. 2015, Benjamin et al. 2014, Richards 2010, Cherny et al. 2016, 
Cheema et al. 2012, Groot, Huijgens, and Uyl-de Groot 2006, Kos, Obradovic, and Mrhar 
2008, Mason et al. 2010, OECD 2013, Wilking, Jönsson, and Högberg 2009, Jönsson et al. 
2016, Chamberlain et al. 2014, Blommestein et al. 2014, Dranitsaris et al. 2005, Wilson and 
Cohen 2011, Wilking et al. 2010, Niezen et al. 2006). Not all these studies discuss 
determinants in the terms of utilisation data, some just discuss access in the terms of its 
determinants (e.g. out-of-pocket payments, coverage). 
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1.2.4! Current initiatives to improve access to medicines 
Ensuring access to medicines is high on governments as well as the international agenda as 
confirmed by a number of current initiatives and developments aimed at improving access to 
medicines. In the following subchapters, I will present some of the main ones. 
 
1.2.4.1! Increased voluntary collaboration to manage the introduction of new medicines 
Challenges in managing the introduction of new medicines have prompted various initiatives 
to strengthen voluntary collaboration in horizon scanning, health technology assessment, 
negotiation and strategic procurement of medicines in Europe (Espín et al. 2016, Ferrario, 
Kanavos, et al. 2016a). 
  
There are various levels at which countries can collaborate in pharmaceutical procurement 
(Figure 2). These vary from informed buying, where participating countries share information 
on prices, suppliers and HTA methodologies but also conduct their own procurement 
individually; to centralised contracting and procurement where participating countries 
conduct joint tenders through a central buying unit (Management Sciences for Health 2012).  
 
Figure 2: Levels of collaboration in pharmaceutical procurement 
 
Source: Figure developed by the author based on the classification proposed by Management Sciences for Health at p. 18.10 
of (Management Sciences for Health 2012). Also published in (Ferrario, Kanavos, et al. 2016b) 
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In Europe, a number of initiatives have been set up in recent years to increase voluntary 
collaboration between countries or administrative areas of one country. At the highest level of 
collaboration, joint tenders, a voluntary cooperation between 24 EU governments was 
established to conduct joint procurement of pandemic vaccines and medical countermeasures8 
(European Commission 2014). As of September 2016, this cooperation was evaluating bids 
received of personal protective equipment for health workers, preparing the launch of a joint 
tender for the procurement of Bacillus Calmette–Guérin vaccine and tuberculin, botulinum 
anti-toxin and diphtheria anti-toxin (Sion 2016). It had also accelerated preparations for joint 
procurement of pandemic vaccines (Sion 2016). Further, it is investigating the possibility of 
organising joint procurement of direct acting antiretroviral medicines for Hepatitis C (Sion 
2016). There are also joint procurement initiatives at regional and sub-national levels. These 
include the joint procurement of vaccine among the Baltic countries (preparatory phase as of 
September 2016) (Lobovs 2016) and the joint procurement between England and Scotland of 
recombinant factor VIII and IX (two tenders completed as of September 2016) (McClure 
2016). 
 
The following initiatives span different collaboration levels, from information sharing to 
group purchasing. In April 2015, Belgium and the Netherlands, later joined by Luxembourg, 
have signed a Memorandum of Understanding to collaborate on horizon scanning, HTA, 
information exchange and experiences, pricing and reimbursement including joint negotiation 
(Arickx 2016). On the 17th of June 2016, Austria signed a letter of intent to join the Benelux 
countries and the group is now referred to as ‘Beneluxa’ or ‘coalition of the willing’. In June 
2015, Bulgaria and Romania announced that they intend to jointly procure high cost 
medicines (Petrovsky 2015). During the same month, the Nordic pharmaceutical forum was 
set up (Nye Metoder 2015) aiming to achieve collaboration between payers of medicines in 
Denmark, Iceland, Norway and Sweden, share experiences and tackle common challenges 
jointly around new and expensive medicines, horizon scanning and supply chain safety (Nye 
Metoder 2015). In a further initiative, at the end of a ministerial meeting on 2-3 June 2016 in 
Sofia, the representatives of Bulgaria, Croatia, Estonia, Hungary, Latvia, The Former 
Yugoslav Republic of Macedonia, Romania, Serbia, Slovak Republic and Slovenia signed a 
declaration to collaborate on issues affecting access to medicines. Issues of mutual concern to 
                                                
8 Article 2 of the Joint Procurement Agreement provides that medical countermeasures are "any medicines, 
medical devices, other goods or services that are aimed at combating serious cross-border threats to health, as 
referred to in Decision 1082/2013/EU" (European Commission 2014). 
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the signatories of the Sofia declaration include  the availability of essential medicines, high 
prices of innovative medicines, cost-effectiveness analysis, information sharing and mutual 
transparency in pharmaceutical policy (Representatives of Bulgaria et al. 2016).  
 
Under the Dutch Presidency of the EU, the Council of the EU released a series of 
recommendations on how to strengthen the balance in the pharmaceutical systems in the EU 
and its Member States (The Council of the European Union 2016). In its recommendations, 
the Council invites Member States to strengthen voluntary collaboration, between relevant 
authorities and payers, on pricing and reimbursement issues with the aim to increase 
affordability and improve access (The Council of the European Union 2016). Further, the 
Council invites Member States and the European Commission to explore synergies between 
the work of HTA bodies and payers, and to strengthen collaboration between Member States, 
particularly under the 3rd Joint Action of the European Network of Health Technology 
Assessment (EUnetHTA) (The Council of the European Union 2016). Finally, the European 
Council invites the European Commission to conduct, with the close involvement of Member 
States, an analysis on the impact of incentives to facilitate investment in R&D and marketing 
authorisation provided by the EU legislation on innovation, availability and accessibility of 
both originators and generic medicines (The Council of the European Union 2016). 
 
Building on this momentum, the World Health Organization Regional Office for Europe held 
a consultation on strategic procurement of medicines in Copenhagen in September 2016. The 
aim of the consultation was to assess the willingness of the Region’s Member States to 
voluntary collaborate on strategic procurement, with focus on information sharing. Following 
positive feedback from Member States, the work started during the consultation will continue 
in 2017.  
 
These initiatives demonstrate a growing interest from countries in Europe to increase 
voluntary collaboration on access to new medicines and other medical products. They aim to 
leverage economies of scale (joint negotiation and procurement) and sharing of information, 
experiences and tasks (horizon scanning, HTA, market intelligence, etc.) to obtain more 
competitive prices and enable greater access to medicines, vaccines and other medical 
technologies and goods.  
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1.2.4.2! A forum to discuss fair pricing 
In an attempt to ensure that medical innovation is affordable and accessible to patients, 
medicines (old and new ones) are available when needed, and monopolies on off-patent 
products leading to price manipulation are avoided, the World Health Organization is 
planning a multi-stakeholder meeting including governments, patients and industry to 
develop a fair pricing model for medicines (Kieny 2016, Silverman 2016c). Such model aims 
to deliver affordable prices for countries and patients and a financial return to industry which 
is sufficient to justify further investments in research and development (Kieny 2016). To this 
end, a series of technical reports are being developed to inform the consultation (Silverman 
2016c). These will cover issues of price drivers, in particular manufacturers, price setting 
strategies, R&D costs, processes and policies used by countries to regulate prices and their 
effectiveness and what return of investment is needed to generate sufficient incentives for 
industry to keep engaging in R&D (Silverman 2016c). The aim of the consultation is to push 
the agenda on pricing models forward by proposing new ways of thinking about price, which, 
if linked with the appropriate policies, can contribute to ensure sustainable access to cost-
effective medicines to address patient’s needs (Silverman 2016c).  
 
1.2.4.3! High-Level Panel on Innovation and Access to Health Technologies 
recommendations 
A High-Level Panel on Innovation and Access to Health Technologies was set up in 
November 2015 by the United National (UN) Secretary-General to review and select 
proposals and recommend solutions to address the policy incoherence between intellectual 
property rights, international human rights law, trade rules and public health with the aim of 
improving access to health technologies (United Nations Secretary-General's high-level panel 
on access to medicines 2016). The Panel was composed of 15 world renowned experts in 
different areas relevant to the subject of the report. These were supported by an Expert 
Advisory Group of 25 members (United Nations Secretary-General's high-level panel on 
access to medicines 2016). A public call for proposals on how to strengthen the promotion of 
innovation and access to health technologies was launched and 182 submissions from 
academia, think thanks, patient representatives, industry and members of the civil society 
were received and reviewed (United Nations Secretary-General's high-level panel on access 
to medicines 2016). Shortlisted proposals were selected and proponents invited for further 
queries. These informed the writing and final recommendations of the report.  
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The report makes some bold statements and recommendations. It raises concerns about undue 
pressures from Government and the private sector on countries wishing to implement 
flexibilities included in the TRIPS agreements such as compulsory licensing (United Nations 
Secretary-General's high-level panel on access to medicines 2016). To address this, the Panel 
recommends that such situations should be reported to the World Trade Organization (WTO) 
and that punitive measures should be undertaken against offending WTO Members (United 
Nations Secretary-General's high-level panel on access to medicines 2016). It also highlights 
the issue of evergreening, one example of which is the grant of secondary patents on the basis 
of minor but important changes, as a barrier to generic or competitor entry (United Nations 
Secretary-General's high-level panel on access to medicines 2016). The high-level panel 
recommended WTO Members to make full use of the provisions in Article 27 of the TRIPS 
agreement by adopting and applying rigorous definitions of inventions and patentability that 
prevent evergreening and ensure that patents are only awarded for genuine innovations 
(United Nations Secretary-General's high-level panel on access to medicines 2016). 
 
1.2.4.4! Lancet Commission report on essential medicines for universal health coverage 
The report of the Lancet Commission identified five critical areas essential medicines policies 
should address: paying for a basket of essential medicines, making essential medicines 
affordable, assuring the quality and safety of medicines, promoting quality use of medicines, 
and developing missing essential medicines (Wirtz et al. 2016). A wealth of international 
evidence and experiences are presented to inform the development of sound essential 
medicines policies and support the Commission’s recommendations. A monitoring 
framework is proposed to measure progress against the recommendations of the Commission. 
This is composed of 24 indicators covering the five critical areas identified. The Lancet 
Commission report represents an important reference and agenda setting document which has 
the potential to influence policy and practice. First, it summarises key issues affecting access 
to essential medicines on the path to universal health coverage. Second, it provides a range of 
recommendations and policy options to address these issues. Together, this provides key 
information to policy makers and other stakeholders in the pharmaceutical sector about what 
the issues are and what can be done to address them. Finally, it highlights key evidence gaps 
which should inform future research efforts. It thus contains a number of messages for 
decision-makers, payers, industry, patients, and researchers which can be leveraged on in 
promoting change. Most importantly, the monitoring framework provides a standardised tool 
to measure progress at country level, which is more comprehensive than previously 
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developed indicators to monitor progress in improving access to medicines as part of the 
Millennium Development Goals for example. 
 
1.3! Value frameworks 
In recent years, a number of value frameworks have been developed to assess cancer 
medicines, notably the American Society of Clinical Oncology (ASCO) value framework 
(Schnipper et al. 2016), the European Society of Medical Oncology (ESMO) Magnitude of 
Clinical Benefit Scale (MCBS) (Cherny et al. 2015), the Institute for Clinical and Economic 
Review (ICER Institute) value framework (Institute for Clinical and Economic Review 
2016), the Memorial Sloan Kettering Cancer Center (MSKCC) Drug Abacus Price (Memorial 
Sloan Kettering Cancer Center 2016), and the National Comprehensive Cancer Network 
(NCCN) evidence blocks (National Comprehensive Cancer Network 2016). These 
frameworks have been increasingly discussed and compared in the literature (Chandra, 
Shafrin, and Dhawan 2016, Neumann and Cohen 2015, Schnipper and Bastian 2016, 
Westrich 2016, Basch 2016). The general agreement is that these frameworks are a very 
welcome first step in advancing the discussion around added value and pricing of new cancer 
medicines but need to be refined (Chandra, Shafrin, and Dhawan 2016, Basch 2016, 
Neumann and Cohen 2015, Young 2015). One point raised by various authors is that, despite 
the aim of some of these frameworks (ASCO, ESMO and NCCN)  to inform joint decision-
making between clinicians and patients, not all of them incorporate factors that matter to 
patients (e.g. symptoms, quality of life, work productivity, caregiver burden, unmet need, 
etc.) (Chandra, Shafrin, and Dhawan 2016, Basch 2016, Westrich 2016). Furthermore, these 
frameworks cannot be tailored to individual patient characteristics, weightings of preferences, 
and insurance coverage (Basch 2016, Westrich 2016). For example, although many of these 
frameworks have included patient out-of-pocket costs, they do not allow for customisation 
based on the patient’s insurance plan (Basch 2016). This aspect is very important in the US 
were most of these frameworks are meant to be applied. In addition to patient-centeredness, 
elements of timeliness and equity, which others have identified as elements of value of cancer 
care, are not included (Young 2015). 
 
These frameworks rely on numerous assumptions and arbitrary decisions, particularly 
regarding weighing and combining different dimensions into a final score and consideration 
of subjective expert opinion which make their results less robust (Chandra, Shafrin, and 
Dhawan 2016, Neumann and Cohen 2015, Young 2015). These challenges are in part due to 
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limited data availability (e.g. patient preferences and patient reported outcomes (PROs)) and 
lack of consensus around which dimensions should be included in the measurement of value. 
Concerning the first, it has been suggested that the current frameworks have missed the 
opportunity to highlight information deficits by penalising ratings of medicines which do not 
provide certain information (e.g. important PROs), as a way to incentivise their future 
collection (Basch 2016). In fact, the ASCO 2016 framework only mentions that much work is 
needed in the area of PROs and that future versions of the framework will facilitate 
incorporation of PROs into the estimation of the final value score (Schnipper and Bastian 
2016). The development of such frameworks and their improvement over time should help 
address the second point. In fact, some of the critiques to the ASCO 2015 framework have 
been addressed in its 2016 update. Further critiques include the lack of budget impact 
considerations that are only taken into account in the framework by the ICER Institute. 
However, it was noted that the ICER Institute’s maximum budget impact limit (US$ 904 
million per year) penalises medicines meant to benefit a large number of patients (Chandra, 
Shafrin, and Dhawan 2016, Neumann and Cohen 2015). Authors have also noticed that the 
MSKCC Abacus value based price could have unintended consequences if prices of high-
value medicines are increased but prices of low-value medicines are not decreased (Young 
2015). Another important limitation is the exclusive focus in most frameworks on RCT data 
(excluding the ICER Institute framework which also includes observational data), (Chandra, 
Shafrin, and Dhawan 2016, Westrich 2016). While generally regarded as the gold-standard in 
terms of evidence, RCTs only measure efficacy and not effectiveness in real-life. In addition, 
study design, inclusion criteria and choice of comparator in the RCT can affect the validity of 
the efficacy estimate (Chandra, Shafrin, and Dhawan 2016) and it is therefore important to 
triangulate RCT data with data from other types of studies. Finally, the lack of a system-wide 
perspective on value was raised (Westrich 2016), particularly in relation to additional costs or 
savings to be generated by introducing a new medicine (Chandra, Shafrin, and Dhawan 
2016).   
 
Table 2 compares some of main features of these frameworks. The ASCO, ESMO, ICER 
Institute, and NCCN frameworks all aim to influence clinical practice. In addition, the 
ESMO, ICER Institute and MSKCC aim to influence public policy, in particular discussions 
around value for money. These frameworks strive to achieve their objectives through 
different methods and the estimation of summary indictors like the net health benefit score 
and cost per month of the ASCO framework, the magnitude of clinical benefit scale of the 
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ESMO framework, the level of care value and health system value of the ICER Institute 
assessment, the 'Abacus price' of the MSKCC pricing tool, and the evidence blocks of the 
NCCN framework. 
 
Table 2: Comparison of value frameworks for cancer medicines 
 
Frame
work 
Objective Data 
Dimensions 
included 
Outcome Application 
ASC
O 
Shared decision-
making between 
the patient and the 
clinician which 
takes into account 
patient preferences, 
goals and financial 
circumstances 
Prospective 
randomised 
trials comparing 
a new treatment 
with prevailing 
standard of care  
Clinical 
benefit, 
toxicity, 
symptom 
palliation, 
cost 
Net Health 
Benefit 
Score 
(NHB), cost 
per month 
Clinical 
practice 
ESM
O 
To distinguish 
treatments which 
bring substantial 
improvements in 
survival and/or 
quality of life from 
treatments whose 
benefits are limited 
and to include the 
former in ESMO 
guidelines 
Randomised 
clinical trials 
Clinical 
benefit, 
toxicity 
Magnitude of 
Clinical 
Benefit 
Score 
(MCBS) 
Public 
policy, 
development 
of clinical 
guidelines, 
clinical 
decision-
making, 
assessing the 
clinical 
significance 
of research 
findings 
ICER 
Institu
te* 
To conduct 
evidence-based 
reviews of health 
interventions to 
help clinicians and 
patients knowing 
what works 
Clinical trials, 
observational 
studies 
Comparative 
clinical 
effectiveness
, incremental 
cost for 
better 
clinical 
outcome, 
other 
benefits or 
disadvantage
s, contextual 
consideration
s 
Care value 
Clinical 
practice, 
public policy 
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Frame
work 
Objective Data 
Dimensions 
included 
Outcome Application 
 
MSK
CC 
To determine 
appropriate prices 
for cancer 
medicines based on 
the value of a 
medicine  
FDA package 
insert 
Current 
price, 
efficacy, 
toxicity, 
novelty, 
R&D rarity, 
burden of 
disease, 
unmet need, 
prognosis, 
budget 
impact  
Value-
adjusted 
price 
Pricing of 
medicines 
NCC
N 
Shared decision-
making between 
the patient and the 
clinician which 
takes into account 
the patient's own 
value system 
RCTs, non-
randomised 
trials, meta-
analysis or 
systematic 
reviews, clinical 
case reports, 
case series and 
clinical 
experience 
Efficacy, 
safety, 
quality of 
evidence, 
consistency 
of evidence 
and 
affordability 
NCCR 
evidence 
blocks 
Clinical 
decisions 
 
Notes: *generic framework, not specific to cancer medicines 
Source: The candidate based on (National Comprehensive Cancer Network 2016, Cherny et al. 2015, 
Schnipper et al. 2016, Institute for Clinical and Economic Review 2016, Memorial Sloan Kettering 
Cancer Center 2016) 
 
There are different ways in which these frameworks can contribute to improved access to 
cancer medicines. Frameworks that aim to influence clinical practice by guiding shared 
decision-making between clinicians and patients, may lead to a different treatment choice 
than if no framework had been applied and the decision was taken solely by the doctor. The 
ESMO framework aims to give prominence to medicines with a high magnitude of clinical 
benefit score in their clinical guidelines. ESMO clinical guidelines are an important reference 
in Europe and worldwide and have thus the potential to influence clinical practice in a 
number of countries. The provision of a user-friendly comparison tool like the NCCN 
evidence blocks can help patients and their clinicians in deciding on the best treatment 
course. Indeed, prioritisation according to the magnitude of benefit has been suggested as a 
guiding principle in developing national essential medicines lists (Magrini et al. 2015). The 
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evidence and methodologies used to generate the final scores in each of these frameworks 
therefore have a key impact on their ratings and potentially on access, which makes their 
continuous improvement crucial. 
 
There are several ways in which these frameworks may influence access, including, 
influencing pricing and reimbursement processes. Dissemination of evidence on clinical and 
economic added value can be used by payers in pricing negotiations thus potentially 
influencing pricing and reimbursement decisions, depending on the time this information 
becomes available. ESMO also suggests that medicines with a high magnitude of clinical 
benefit score should be prioritised for accelerated reimbursement review (Cherny et al. 2015). 
Further, evidence from these frameworks can be used by payers as a credible benchmark 
when negotiating prices with manufacturers. If their use becomes widespread, these 
frameworks can have an important impact in identifying medicines with high clinical added 
value which should be prioritised for use in clinical practice over medicines with more 
limited clinical added value. 
 
The development of value frameworks is part of broader discussion around prioritisation of 
treatment which takes into account value for money, financial sustainability, and patients’ 
preferences. There are examples of frameworks to guide commissioning and prescribing 
decisions in line with value well before the recent efforts by ASCO, ESMO and others. 
Before the National Institute for Health and Care Excellence (NICE) in England started to 
issue guidance on use of medicines in the NHS, clinicians and health authorities had to find 
ways to deal with lack of national guidance. This is still in part the case nowadays for 
medicines not assessed by NICE. A consortium of six health authorities in Greater 
Manchester developed evidence thresholds based on cost-effectiveness to guide 
commissioning decisions in the late nineties (Foy et al. 1999). In the 1997-8 priority list for 
commissioning, the consortium agreed to fund all medicines rated as having clinical-
effectiveness over and above existing treatments (Foy et al. 1999). Their impact assessment 
of new interventions was based on survival and quality of life, compared, where possible, 
with standard treatment (Foy et al. 1999). Other treatment outcomes assessed included 
tumour response rates, symptom responses, side effects, and overall costs (Foy et al. 1999). 
Another prioritisation effort from England in the pre-NICE era was the development of an 
approach to guide commissioning decisions for new treatments for advanced cancer. This 
was done by a group of clinicians and health authorities in South London around the same 
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time as the Greater Manchester consortium. The South London approach was based on 
survival, quality of life and strength of evidence (Ferguson et al. 2000). Although a specific 
funding threshold was not defined, the authors reported that the estimation of the additional 
funding made available after the prioritisation exercise was largely based on the cost of 
providing treatments prolonging median survival by 3 months or more and improving quality 
of life (Ferguson et al. 2000). This evidence should be based on at least one high-quality RCT 
and supporting non-randomised phase II data, ideally meta-analysis or two-high quality RCTs 
(Ferguson et al. 2000). The ASCO working group on clinically meaningful outcomes for 
cancer clinical trials, came to similar conclusions. Each of the four therapeutic sub-groups of 
experts – on pancreatic, lung, breast and colon cancer - identified 2.5 to 6 months 
improvement in median overall survival as the minimum incremental improvement over 
standard therapy that would represent a clinically meaningful outcome (Ellis et al. 2014). 
This work informed the definition of the categorical scores and weights of the clinical benefit 
component of the ASCO value framework (Schnipper et al. 2015). 
 
Value frameworks have also been developed in other areas of cancer care particularly in 
preventive and non-pharmacotherapeutic areas. Examples include value frameworks on how 
the value of cancer screening strategies varies with their intensity (Harris et al. 2015), as well 
as frameworks for prostate brachytherapy, proton beam therapy and robotic-assisted 
prostatectomy based on clinical and PROs over time-driven activity-based costing (Thaker, 
Pugh, et al. 2016, Thaker, Ali, et al. 2016), and for head and neck cancer treatment (de Souza 
and Seiwert 2014). 
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2! Gaps in the literature and hypotheses, research question, structure of 
the thesis 
2.1! Gaps in the literature and hypotheses 
2.1.1! Frameworks to study access to cancer medicines in high income countries 
The review of the literature on access to cancer medicines highlighted the paucity of 
frameworks to study access to cancer medicines. The majority of available frameworks were 
designed to study access to essential medicines in low- and middle income countries (Center 
for Pharmaceutical Management 2003, WHO 2004, Frost and Reich 2008). One framework 
focused specifically on cross-country comparison of access in high-income countries but 
included a limited number of broad factors and was not specific to cancer (Cohen et al. 2007). 
Few studies include financial arrangements at hospital level (Benjamin et al. 2014) and 
hospital level clinical guidelines and practice as possible determinants of variations in use.  
 
2.1.2! Variations in access to cancer medicines and their determinants 
There is a limited number of studies comparing utilisation of cancer medicines across 
countries (Richards 2010, Kelly et al. 2015, Wilking, Jönsson, and Högberg 2009, Jönsson et 
al. 2016, Wilking and Jönsson 2005, Kos, Obradovic, and Mrhar 2008). However, not all of 
them used statistical methods to test correlation between possible determinants of use and 
actual use of cancer medicines (Richards 2010, Kelly et al. 2015, Wilking, Jönsson, and 
Högberg 2009, Wilking and Jönsson 2005, Kos, Obradovic, and Mrhar 2008). If they used 
them there were methodological limitations (e.g. very small sample (Jönsson et al. 2016)) or 
the focus was on understanding subnational variations in use of cancer medicines (Crawford 
et al. 2012, Patel et al. 2007, Crawford et al. 2009, Wilking et al. 2010). Only a few papers 
presenting utilisation data employed a qualitative framework to systematically compare 
health system features that may affect access to cancer medicines (Groot, Huijgens, and Uyl-
de Groot 2006). Further, some studies analysed determinants of access to cancer medicines 
but did not measure actual utilisation levels (Benjamin et al. 2014, Cherny et al. 2016, Cohen 
et al. 2007).  
 
2.1.3! Interventions to improve access to cancer medicines 
In response to high prices of new cancer medicines, many countries have introduced changes 
in their pricing and reimbursement policies as well as procurement strategies in an attempt to 
improve access. One such example is the introduction of managed entry agreements, a 
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heterogeneous group of agreements between payers and manufacturers to facilitate access to 
new medicines in a context of uncertainty, high prices and budgetary limitations. A number 
of cross-sectional studies and discussion papers have been published on the subject of 
managed entry and risk-sharing agreements, yet limited evidence is available on their 
governance structure and their impact. Discussions around access to cancer medicines have 
tended to focus on prices and coverage decisions. Less attention has been given to the role of 
strategic procurement in improving access to cancer medicines. . Learning from existing 
experiences in strategic procurement at national and international level can provide useful 
lessons learned for improving access to cancer medicines.  
 
 
2.1.4! Hypotheses 
The review of the literature highlighted the limitations of existing frameworks to study access 
to cancer medicines in high-income countries, limited evidence on variations in use of cancer 
medicines in Europe and their determinants and limited evidence on how countries are 
addressing challenges in access to cancer medicines. Based on the evidence reviewed and the 
identified literature gaps, the following hypotheses were formulated. The first three 
hypotheses focus on variations in access and their determinants, while the last two focus on 
countries’ responses to improve access: 
1.! Variations exist in access to cancer medicines across different European countries and 
these can be substantial 
2.! Differences in access are determined by a number of factors beyond HTA 
recommendations. These include for example prices of medicines, how medicines are 
financed including special funding arrangements and limitations on the number of 
patients treated, and the sector/s where they are dispensed  
3.! Variations in access to medicines do not always reflect the added clinical value of 
new medicines 
4.! Managed entry and risk-sharing agreements are increasingly used to facilitate entry of 
new medicines however their impact on time to entry, use and reduction of 
uncertainty is still largely unknown 
5.! A number of countries have used elements of strategic procurement to increase access 
to medicines. However, more efforts are needed at national and international levels to 
increase the efficiency of procurement and ensure sustainable access to medicines at 
affordable prices  
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2.2! Aim and research questions 
The literature review highlighted the need for formal testing of the impact of possible 
determinants of variations in access to cancer medicines, the lack of a qualitative framework 
to study access to cancer medicines in high-income countries, and the limited evidence 
available on countries responses to existing challenges. These led to the formulations of five 
hypotheses. Based on the literature reviewed and the hypotheses derived from the identified 
gaps in the literature, the overarching aim of this thesis is to systematically examine 
differences and determinants of access to cancer medicines, their significance and countries 
responses’ to improve access. To address this aim, four research question were formulated. In 
the following paragraphs, I outline the four research questions and explain how the individual 
empirical chapters contributed to address each of them. 
 
1.! Are there differences in access to cancer medicines across European countries and 
how large are they?!
This research question is addressed by (i) investigating time to entry for new cancer 
medicines in four European countries using survival analysis and the complementary 
log-log transformation of the Cox-proportional hazard model (Chapter 4), (ii) 
analysing utilisation of cancer medicines and their determinants in three European 
countries by means of longitudinal multilevel models (Chapter 5), and (iii) developing 
a framework to help understand utilisation differences focusing on HER-2 targeted 
medicines for breast cancer building on interviews and a review of the relevant 
literature, clinical guidelines as well as national official websites (Chapter 6).!
2.! What determines these differences?!
Using the quantitative methods described, Chapter 4 tests the correlation between 
time to launch and possible determinants, Chapter 5 tests the correlation between 
variations in utilisation and possible determinants, and Chapter 6 uses a qualitative 
framework to explore possible reasons for the observed variations in utilisation.!
3.! Do these differences in access matter?!
Chapter 4 and 5 test the correlation between two indicators of the added clinical value 
of new medicines and time to entry and use. These indicators are the rating by the 
independent Drug Bulletin Prescrire and the ESMO Magnitude of Clinical Benefit 
Scale rating.!
4.! How are countries responding to these challenges to improve access?!
56 
 
Having identified some of the existing challenges in access to cancer medicines in 
selected European countries, Chapter 7 and 8 investigate how countries are 
responding to these challenges. Chapter 7 studies the implementation of managed 
entry agreements in four European countries by means of a comparative longitudinal 
analysis of the implementation of MEAs, reviews the governance structures around 
them and proposes a framework to understand how MEAs influence key decision-
making variables of coverage decisions. Chapter 8 reviews the role of strategic 
procurement through a literature review and contacts with staff involved in national 
pricing negotiations and procurement. 
!
Finally, Figure 3 shows how each empirical chapter contributed to the aim of this thesis. 
!
Figure 3: Conceptual framework of the PhD thesis 
!
!
2.3! Structure of the thesis 
This thesis is composed of nine chapters. The first chapter reviewed the literature on 
determinants of access to cancer medicines along the product life-cycle, frameworks to study 
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access to cancer medicines, determinants of access current initiatives to improve access and 
the development of value frameworks. Chapter 2 summarised the gaps identified in the 
literature and presented the hypotheses and research questions of this thesis. Chapter 3 
provides an overview of the methods used in the individual chapters of this thesis. Chapter 4 
to 8 are the publishable papers of this thesis, some of which have already been published 
while others are being peer-reviewed. Their structure includes the following sub-sections: an 
introduction, methods, results, discussion and conclusions. Chapter 4 studies time to entry for 
new cancer medicines from EU-wide marketing authorisation to patients access in Belgium, 
Estonia, Scotland and Sweden. Chapter 5 analyses the determinants of utilisation differences 
for cancer medicines in Belgium, Scotland and Sweden. Chapter 6 develops a framework to 
understand differences in utilisation of HER-2 targeted medicines for breast cancer. Chapter 
7 studies how countries deal with uncertainty and high prices of new medicines by 
conducting a comparative analysis of the use of managed entry agreements in Belgium, 
England, the Netherlands and Sweden. Chapter 8 reviews the role of strategic procurement in 
increasing access to cancer medicines. Finally, Chapter 9 draws the overall conclusions of 
this thesis and their policy implications, summarises the main limitations of this research and 
proposes future areas of research.   
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3! Methods 
This thesis used a mix of quantitative and qualitative methods including longitudinal 
multilevel models, survival analysis and the complementary log-log transformation of the 
Cox proportional hazard model, literature reviews, interviews, and a comparative longitudinal 
analysis of the implementation of MEAs. While the specific methods used in each paper are 
described in more detail in Chapters 4 to 8, this section provides an overview and more 
details about the extensive data extraction process to develop the four quantitative databases 
used in this thesis. These include a longitudinal database of 46 cancer medicines to study time 
to launch, a longitudinal database of 31 medicines to study differences in utilisation across 
countries, a longitudinal database on use and determinants of HER-2 targeted therapies for 
breast cancer, and longitudinal data on the introduction and implementation of managed entry 
agreements. 
 
3.1! Measuring access to medicines 
As described in the introduction, access to medicines has been measured in different ways.  
Due to difficulties in measuring accessibility, accommodation, and acceptability, studies on 
access to medicines have often focused on physical availability of the medicine in pharmacies 
and/or health facilities and affordability for patients. In this context, a number of studies on 
price comparisons have also been conducted. In this thesis, I focus on different aspects of 
access to cancer medicines and its determinants. In Chapter 4, I investigate access from the 
perspective of availability on the market in the study countries (i.e. time to entry). In Chapters 
5 and 6 I study access by comparing levels of utilisation of cancer medicines in the study 
countries and their determinants. Chapter 7, analyses the contribution of managed entry 
agreements in improving access by managing high prices and uncertainty around cost-
effectiveness and quality use of medicines. Finally, Chapter 8 reviews country experiences in 
improving procurement outcomes (e.g. obtaining more competitive prices, improving 
selection and use of medicines, reducing the number of stock-outs) in an attempt to improve 
access to medicines. 
 
3.2! Study countries for this thesis and geographical coverage 
The core study countries of this thesis are Belgium, Estonia, Scotland, and Sweden (Chapters 
4 to 6). These were chosen based on availability of non-commercial data on utilisation of 
cancer medicines in both, hospital and ambulatory settings and the intention to include a mix 
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of Western and Eastern European countries to study variations in access of cancer medicines. 
Key information and indicators on these countries is provided in Appendix 1. The thesis as a 
whole draws from the experience of other European and non-European countries to learn 
about approaches used worldwide to improve access to medicines (Chapters 7 and 8) and 
inform the conclusions (Chapter 9) of this thesis. Specifically, Chapters 4 to 6 investigate 
determinants of access to new cancer medicines in the study countries of this thesis. Chapters 
7 and 8 study some of the approaches different countries – the study countries and other 
European and non-European countries - are using to improve access to medicines. Chapter 8 
in particular adopts a global scope with the intention of identifying good practices in 
improving access to medicines through strategic procurement, independently of where they 
are implemented. It was not possible to include Estonia in Chapter 5 due to lack of publicly 
available data on reimbursement by medicine-indication (dates and decisions). It was not 
feasible to obtain this information for 31 medicines on request due the extensive time it 
would have required the Estonian Health Insurance Fund to extract these data. 
 
3.3! Development of a database on time to launch of new cancer medicines and 
possible determinants 
In Chapter 4, I analyse time to entry of new cancer medicines in the four study countries of 
this PhD. I obtained quarterly data on utilisation of a sample of 46 cancer medicines in 
hospital and ambulatory sectors covering the period 2000-2015 as indicated in Table 3. The 
sample of cancer medicines includes all medicines falling under anatomical therapeutic 
chemical (ATC)-L01 (antineoplastic agents)/L02 (endocrine therapies), which received EU-
wide marketing authorisation between 2000 and 2014. As the focus of this thesis is on new 
cancer medicines, I excluded generics and new brands of previously approved international 
non-proprietary names (INNs). I also excluded orphan medicines as this group of medicines 
is quite distinct, it is mostly associated with very high entry prices and targets at least initially 
a small patient population. As current practice, research on orphan medicines is generally 
conducted on this medicines group only and would therefore require separate analysis.  
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Table 3: Data collected on the use of cancer medicines in the study countries 
 
  Data source Variables Frequency Time period 
B
el
gi
um
 
National Institute for 
Health and Disability 
Insurance (RIZIV-
INAMI) 
ATC level 5 
(active 
ingredient), 
defined daily 
doses, 
expenditure 
Quarterly 
Q1 2001 - Q2 2015 (ambulatory 
sector); Q1 2002 - Q2 2015 (hospital 
sector) 
Es
to
ni
a Estonian State 
Agency of Medicines 
INN, ATC-5, 
brand name, 
number of 
packs, pack 
size, strength, 
expenditure 
Quarterly 
Q1 2000 - Q1 2015 (ambulatory and 
hospital sectors) 
Sc
ot
la
nd
 Information Services 
Division (ISD) 
Scotland 
INN, number 
of units (e.g. 
tablets, vials), 
strength 
Monthly 
April 2004 - August 2015 
(ambulatory sector); April 2007 - 
May 2015 (hospital sector) 
Sw
ed
en
 Swedish eHealth 
Agency 
(eHälsomyndigheten) 
ATC-5, brand 
name, 
number of 
units (e.g. 
tablet, vial), 
number of 
packs, pack 
size, strength, 
expenditure 
Monthly 
January 2000 - December 2014 
(ambulatory and hospital sectors) 
 
Notes: Q: quarter 
 
These data were used to identify the first quarter in which a medicine was first used (launch 
time) in each country. Dates of EU-wide marketing authorisation for the first approved 
indication of each medicine, whether the medicine was approved under conditional marketing 
authorisation, the ATC group at level 5 (active ingredient), and the company name of the 
marketing authorisation holder were obtained from the European Medicines Agency Public 
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Assessment Reports available on the EMA website. I requested dates of manufacturer 
submissions of a reimbursement dossier for the first submitted indication to the relevant 
authority in each country (the National Institute for Health and Disability Insurance in 
Belgium, the Estonian Health Insurance Company and the Estonian Ministry of Social 
Affairs, the Scottish Medicines Consortium, the Swedish Dental and Pharmaceutical Benefits 
Agency). Dates of reimbursement decision or HTA recommendation were generally available 
on the websites of these authorities with the exception of Estonia where they had to be 
requested. In Estonia, reimbursement requests are handled separately depending on whether 
the medicine is submitted for reimbursement in the hospital or ambulatory sector. 
Reimbursement requests for the ambulatory sector are made by manufacturers, whereas 
reimbursement requests for the hospital sector are done by clinicians. I therefore requested 
this information separately to each relevant authority. A few rounds of follow-up were 
required to obtain full information (e.g. the initial information provided contained some gaps 
relating to the date of submission and/or reimbursement and inconsistencies which needed 
clarification). Information on manufacturer headquarters was identified through the 
company’s website. This was included to test whether having a local manufacturer 
headquarters correlated with increase probability of launch. Since there are only two generic 
manufacturers (i.e. no manufacturers of branded medicines) in Estonia and findings from a 
previous study suggested that having a local sales representative increases the likelihood of 
launch (Ferrario, Reinap, et al. 2016), I used this information for Estonia instead of local 
manufacturer’s headquarters used in the other countries. The list of local sales representative 
in Estonia was obtained from the website of the Estonian Association or Pharmaceutical 
Manufacturers (APME 2016). As Scotland is part of the UK, no distinction was made 
whether the manufacturer was based in England or in another jurisdiction of the UK. 
 
The expected volume was estimated based on actual defined daily doses (DDDs)9 consumed 
in the relevant pharmacological subgroup (ATC level 3), lagged by one quarter. The same 
approach was used in other studies (Costa-Font, McGuire, and Varol 2015, Danzon and 
Epstein 2012) due to lack of data on the number of expected patients in each country studied. 
DDDs were estimated using information on total milligrams (mg) of active ingredient used 
divided by the reference DDD and multiplied by thousands. Since DDD for cancer medicines 
are mostly not defined by the WHO Collaborating Centre on Drug Statistics Methodology, 
                                                
9 “The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults.” 
http://www.whocc.no/ddd/definition_and_general_considera/ (accessed 15 November 2016) 
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the DDD of the Belgian Centre for Pharmacotherapeutic Information (CPI), (2016) were used 
instead. If they were not defined by the CPI, the German Institute of Medical Documentation 
and Information (DIMDI 2016) was used instead. If not defined by the CPI or the DIMDI, I 
used the smallest approved formulation by the EMA. Substantial data cleaning was required 
to estimate the total mg of active ingredient of each INN included in the analysis. This is 
because each country reports data in a different way and uses different codes for its variables. 
As a result, follow-up with the relevant authority (INAMI in Belgium, ISD in Scotland, TLV 
and eHälsomyndigheten in Sweden, and SAM in Estonia) was required to verify whether the 
national variables had been interpreted correctly. In Scotland, volume is measured based on 
the number of units (e.g. vial, tablet) dispensed. In Belgium, volume is measured based on the 
number of pricing units dispensed, which may not always correspond to the actual unit 
dispensed (e.g. vial, tablet). For example, trastuzumab, a targeted medicine for the treatment 
of breast and stomach cancer, is available as powder for infusion (150 mg) and, as of June 
2013, also as subcutaneous injection (600 mg/ 5 ml). Until 2013, the unit of pricing for the 
infusion was 150 mg, as of 2013, a second unit of pricing for the infusion, 75 mg, was 
introduced. So although the strength of the vial was 150 mg in both cases, in the second case, 
the number of units reported (‘Quantity 2013’: 68,619; Table 4) refers to 75 mg rather than 
150 mg.  
 
Table 4: Excerpt of dispensing data as reported in Belgium 
 
Setting 
DENO2 
(brand name) 
CONDI (unit of 
pricing) 
Mode of 
administration 
Quantity 
2011 
Quantity 
2012 
Quantity 
2013 
Hospital 
HERCEPTI
N 
1 flacon injectable x 
150 mg trastuzumab INJECTION 85,756 94,188 74,629 
Hospital 
HERCEPTI
N 
75 mg x 150 mg 
trastuzumab INJECTION 0 0 68,619 
  
In Sweden, both the number of doses and packs are reported (Table 5). The number of doses 
equals the number of tablets (e.g. Afinitor), capsules, or vial of concentrate powder without 
solvent (e.g. Alimta) per pack times the number of packs dispensed. However, this is not the 
same for vials of concentrates for infusion with solutions (e.g. Avastin). In this case, the 
number of doses represents the number of millilitre solution (not the number of vials) times 
the number of packs.  
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Table 5: Excerpt of utilisation data as reported in Sweden 
 
Product Channel Year 
Total 
expenditures 
(measured 
in pharmacy 
selling 
prices) 
Doses Packs 
Patient co-
payment 
SEK 
Afinitor, tablett 10 mg 
Novartis Sverige AB - 30 
tablett(er) Hospital 2012 4,666,625 3,750 125 0 
Afinitor, tablett 5 mg 
Novartis Sverige AB - 30 
tablett(er) Dosage 2012 210,400 240 8 209,590 
Afinitor, tablett 5 mg 
Novartis Sverige AB - 30 
tablett(er) 
Prescriptio
n 2012 10,993,400 12,540 418 
10,738,38
1 
Alimta, pulv till konc till inf-
vätska, lösning 500 mg Eli 
Lilly Sweden AB - 1 styck Hospital 2012 67,252,827 5,231 5,231 0 
Alimta, pulv till konc till inf-
vätska, lösning 500 mg Eli 
Lilly Sweden AB - 1 styck 
Outpatient 
- order 2012 326,436 24 24 0 
Avastin, konc till inf-vätska, 
lösning 25 mg/ml Roche AB 
- 16 milliliter 
Prescriptio
n 2012 96,536 128 8 0 
Avastin, konc till inf-vätska, 
lösning 25 mg/ml Roche AB 
- 16 milliliter Hospital 2012 47,695,207 64,383 4,024 0 
Avastin, konc till inf-vätska, 
lösning 25 mg/ml Roche AB 
- 4 milliliter 
Outpatient 
- order 2012 9,995 12 3 0 
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Understanding these peculiarities in the reporting of different countries was crucial to 
accurately estimate the number of DDDs dispensed and required careful inspection of the 
datasets and follow-up with competent authorities in the study countries. 
 
The expected price per DDDs was estimated based on the average price (weighted by 
volume) per DDD in the pharmacological subgroup (ATC level 3). Information on prices was 
obtained by dividing the expenditure for each medicine-strength-formulation by the total 
number of DDD consumed and multiplied by thousand. No expenditure data were provided 
by IDS Scotland due to the confidential nature of the discounts provided to the NHS. I did 
ask for gross expenditure but this was not available and could not be provided. I therefore had 
to embark on an extensive data extraction process of list prices from historical hard-copies of 
British National Formulary available for in-house use only at the Wellcome Library. British 
pounds and Swedish krona were converted into Euros using the historical exchange rates on 
the OANDA website (OANDA website 2016). A weighted average price per DDD was then 
calculated for each pharmacological subgroup and quarter. 
 
In Chapter 4 on time to launch, data on FDA expedited approvals were extracted from 
different lists on the FDA website (accelerated approval (US Food and Drug Administration 
2016a), breakthrough (US Food and Drug Administration 2016b), fast track (US Food and 
Drug Administration 2016d), and priority review (US Food and Drug Administration 
2016e)). In addition, I consulted the medicine’s search function of the FDA (US Food and 
Drug Administration 2016c) and the annual new drug approvals reports published by the 
FDA since 2011 (U.S. Food & Drug Administration 2016b). I compared my findings with 
information from a study on drug development and FDA approval published in the New 
England Journal of Medicine (Darrow and Kesselheim 2014) for cross-validation. Sometimes 
additional expedited programmes were granted for new formulations and/or new indications a 
few years from the first approval. I did not include these programmes for the estimation of 
the expedited programme variable I used in the complementary log-log analysis on the hazard 
(probability) of launch in Chapter 4. Instead, I only took into account expedited programmes 
up to the EMA approval. The rationale behind is that these programme are unlikely to play 
role in signalling high value of a medicine and potentially expediting time to entry in the EU 
since they occurred after EMA approval. An annual subscription to the independent Drug 
Bulletin Prescrire was purchased to access data on all medicines assessments to extract the 
rating of additional clinical value in comparison to available treatments in the EU given by 
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Prescrire (2016). The ESMO magnitude of clinical benefit scale ratings for solid tumours 
were extracted from a peer-reviewed paper published by ESMO (Cherny et al. 2015).  
 
3.4! Survival analysis 
Many statistical methods assume that rates at which events occur are constant over the time 
period studied (Kirkwood and Sterne 2003). However, this is often not the case and statistical 
methods that allow deviating from this assumption should therefore be employed. For 
example, in Chapter 4, I conduct a longitudinal study on time to launch of new medicines (i.e. 
the time a new medicine is first used in a particular country). In this case, the probability a 
medicine will be launched in a particular country following marketing authorisation is not 
constant but changes over time. Statistical methods for survival analysis enable to describe, 
explain, or predict the probability of an event happening and the timing (Allison 2010). For 
example, it enables to estimate the hazard rate, the instantaneous probability of an event 
occurring at a particular point in time (h(t)) as well as the survival function (S(t)), the 
probability of an individual not to experience the event of interest (e.g. death or launch of a 
medicine) up to and including time t (Kirkwood and Sterne 2003). Most importantly survival 
analysis allows to handle right censoring, which defines observations (individuals) for whom 
the time of the event is not known because it has not occurred by the end of the observation 
period (Allison 2010). An important assumption is that censored and not censored individuals 
have the same probability of surviving (Kirkwood and Sterne 2003). In other words, that the 
probability of being censored is independent from the probability of the event of interest 
happening. This is called non-informative censoring. 
 
Survival curves can be estimated using life tables and the Kaplan-Meier method. Life tables 
are used when the timing of the event of interest occurs is only known approximately by a 
discrete time period (e.g. the medicine was launched in the first quarter of 2014 but we do not 
know the exact day the medicine was launched). An example of how a life table is 
constructed is provided in Table 6 using data from Chapter 4 on time to launch of new 
medicines. 
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Table 6: Example of a life table using data from Chapter 4 on time to launch 
 
Interval 
month (i) 
since a 
medicine 
obtained a 
EU-wide 
marketing 
authorisatio
n (MA) 
Number 
of 
medicine
s at the 
beginnin
g of the 
interval 
(ai), i.e. 
with MA 
but not 
launched 
yet 
Number 
of 
medicine
s 
launched 
during 
the 
interval 
(di) 
Number 
of 
medicines 
censored 
during the 
interval 
(ci), i.e. 
not 
launched 
by the end 
of the 
observatio
n period 
Number 
of 
medicine
s at risk 
of being 
launched 
ni=ai-
(ci/2) 
Probabilit
y of a 
medicine 
being 
launched 
ri=di/ni 
Probabilit
y of non-
launch 
sx=1- ri 
Cumulative 
probability 
of non-
launch 
from time 
of EU-wide 
marketing 
authorisatio
n S(x)=S(i-
1)* sx 
0 46 1 1 45.5 0 1 1 
1 44 0 1 43.5 0 1 0.98 
2 43 1 1 42.5 0.02 0.98 0.96 
3 41 7 0 41 0.17 0.83 0.79 
4 34 5 1 33.5 0.15 0.85 0.67 
5 28 8 1 27.5 0.29 0.71 0.48 
6 19 1 1 18.5 0 1 0.45 
7 17 3 0 17 0.18 0.82 0.37 
8 14 1 0 14 0.07 0.93 0.35 
9 13 1 0 13 0.08 0.92 0.32 
10 12 0 1 11.5 0.00 1.00 0.32 
11 11 2 0 11 0.18 0.82 0.26 
12 9 0 1 8.5 0.00 1.00 0.26 
13 8 1 0 8 0.13 0.88 0.23 
14 7 0 0 7 0 1 0.23 
15 7 1 1 6.5 0.15 0.85 0.19 
16 5 1 0 5 0.20 0.80 0.15 
17 4 1 0 4 0.25 0.75 0.12 
18 3 0 0 3 0 1 0.12 
19 3 0 0 3 0 1 0.12 
20 3 0 0 3 0 1 0.12 
21 3 0 1 2.5 0 1 0.12 
22 2 0 0 2 0 1 0.12 
23 2 0 0 2 0 1 0.12 
24 2 0 0 2 0 1 0.12 
25 2 0 0 2 0 1 0.12 
26 2 0 0 2 0 1 0.12 
27 2 1 0 2 0.50 0.50 0.06 
28 1 0 0 1 0 1 0.06 
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Interval 
month (i) 
since a 
medicine 
obtained a 
EU-wide 
marketing 
authorisatio
n (MA) 
Number 
of 
medicine
s at the 
beginnin
g of the 
interval 
(ai), i.e. 
with MA 
but not 
launched 
yet 
Number 
of 
medicine
s 
launched 
during 
the 
interval 
(di) 
Number 
of 
medicines 
censored 
during the 
interval 
(ci), i.e. 
not 
launched 
by the end 
of the 
observatio
n period 
Number 
of 
medicine
s at risk 
of being 
launched 
ni=ai-
(ci/2) 
Probabilit
y of a 
medicine 
being 
launched 
ri=di/ni 
Probabilit
y of non-
launch 
sx=1- ri 
Cumulative 
probability 
of non-
launch 
from time 
of EU-wide 
marketing 
authorisatio
n S(x)=S(i-
1)* sx 
29 1 0 0 1 0 1 0.06 
30 1 0 0 1 0 1 0.06 
31 1 0 0 1 0 1 0.06 
32 1 0 0 1 0 1 0.06 
33 1 0 0 1 0 1 0.06 
34 1 0 0 1 0 1 0.06 
35 1 0 0 1 0 1 0.06 
36 1 0 0 1 0 1 0.06 
37 1 0 0 1 0 1 0.06 
38 1 0 0 1 0 1 0.06 
39 1 0 0 1 0 1 0.06 
40 1 0 0 1 0 1 0.06 
41 1 0 0 1 0 1 0.06 
42 1 0 0 1 0 1 0.06 
43 1 0 0 1 0 1 0.06 
44 1 0 0 1 0 1 0.06 
45 1 0 0 1 0 1 0.06 
46 1 0 0 1 0 1 0.06 
47 1 0 0 1 0 1 0.06 
48 1 0 0 1 0 1 0.06 
49 1 0 0 1 0 1 0.06 
50 1 0 0 1 0 1 0.06 
51 1 0 0 1 0 1 0.06 
52 1 0 0 1 0 1 0.06 
53 1 0 0 1 0 1 0.06 
54 1 0 0 1 0 1 0.06 
55 1 0 0 1 0 1 0.06 
56 1 0 1 0.5 0 1 0.06 
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The expected time from EU-wide marketing authorisation to launch is given by 0.5+∑S(x) 
(formula to estimate life expectancy) and equals 11 quarters (2.85 years) in the above 
example. 
 
The Kaplan-Meier method is used when the exact timing of the event is known (e.g. day). 
The advantage of this method is that it avoids the assumption that individual lost to follow up 
are censored half-away through the discrete time period (e.g. mid-month or mid-quarter) 
which is the assumption made using life tables. Table 7 shows how the survival curve is 
estimated using the Kaplan-Meier method. The expected time to submission is again given by 
the formula 0.5+∑S(x) and equals 680 days (1.86 years). 
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Table 7: Example of Kaplan-Meier estimate of the survival curve using data from 
Chapter 4 on time to submission of a pricing and reimbursement dossier 
Time in 
days (t) 
Number 
of 
medicines 
at risk of 
being 
submitted 
(nt) 
Number of 
submissions 
at time t (dt) 
Number of 
lost to 
follow-up 
at time t 
(ct), i.e. no 
submission 
by the end 
of the 
observation 
period 
Risk of 
submission 
(rt) 
Probability 
of non-
submission 
st=1-rt 
Submission 
(survivor) 
function 
S(t)=S(tprevious)*st 
0 44 5 0 0.11 0.89 0.89 
8 39 1 0 0.03 0.97 0.86 
10 38 1 0 0.03 0.97 0.84 
11 37 1 0 0.03 0.97 0.82 
14 36 1 0 0.03 0.97 0.80 
17 35 1 0 0.03 0.97 0.77 
20 34 1 0 0.03 0.97 0.75 
21 33 1 0 0.03 0.97 0.73 
25 32 1 0 0.03 0.97 0.70 
42 31 1 0 0.03 0.97 0.68 
50 30 1 0 0.03 0.97 0.66 
56 29 1 0 0.03 0.97 0.64 
80 28 1 0 0.04 0.96 0.61 
87 27 1 0 0.04 0.96 0.59 
94 26 1 0 0.04 0.96 0.57 
96 25 1 0 0.04 0.96 0.55 
119 24 1 0 0.04 0.96 0.52 
129 23 1 0 0.04 0.96 0.50 
165 22 1 0 0.05 0.95 0.48 
192 21 1 0 0.05 0.95 0.45 
196 20 1 0 0.05 0.95 0.43 
210 19 0 1 0.00 1.00 0.43 
271 18 1 0 0.06 0.94 0.41 
300 17 1 0 0.06 0.94 0.38 
315 16 1 0 0.06 0.94 0.36 
415 15 1 0 0.07 0.93 0.34 
417 14 1 0 0.07 0.93 0.31 
490 13 1 0 0.08 0.92 0.29 
539 12 1 0 0.08 0.92 0.26 
576 11 1 0 0.09 0.91 0.24 
768 10 1 0 0.10 0.90 0.22 
872 9 1 0 0.11 0.89 0.19 
937 8 1 0 0.13 0.88 0.17 
991 7 0 1 0.00 1.00 0.17 
1079 6 1 0 0.17 0.83 0.14 
1136 5 1 0 0.20 0.80 0.11 
1738 4 1 0 0.25 0.75 0.08 
1914 3 1 0 0.33 0.67 0.06 
2270 2 1 0 0.50 0.50 0.03 
5220 1 0 1 0.00 1.00 0.03 
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The cumulative hazard function (also known as hazard rate or failure rate) is the total hazard 
experienced up to time t and is calculated by summing the risks at each time the event occurs 
(H(t) = ∑!"#$# and H(t) = - log(S(t))). If the time when the event of interest happens (e.g. 
launch of a medicine in a particular country) is only known on a discrete scale (e.g. months or 
quarters) a linear transformation of the Cox-proportional hazard model is needed to estimate 
the hazard function (Costa-Font, McGuire, and Varol 2015). This is the complementary log-
log transformation (cloglog). In Chapter 4, I use the Kaplan-Meier method to estimate time to 
submission of a reimbursement dossier (t1- t0) and time to reimbursement decision (t2- t1) as 
time of EU-wide marketing authorisation (t0), time of submission (t1) and time of 
reimbursement decision (t2) are all known up to the exact day. I use the life table method to 
estimate time to launch (t3- t0) as time of launch (t3, first use of a medicine in the country) is 
only known on a discrete scale (month or quarter). Similarly, I use the complementary log-
log function to estimate the hazard of launch and test the impact of a set of variables on the 
probability of launch due to the discrete nature of the launch data. 
 
3.5! Development of a database on utilisation of cancer medicines and possible 
determinants 
In Chapter 5, I analyse variations in use of cancer medicines across countries and their 
determinants. I selected a sample of 31 cancer medicines (ATC-L01/L02) which obtained 
EU-wide marketing authorisation between 2000 and 2013. As in Chapter 4, I excluded 
generics, orphan medicines, and new brands of previously approved international non-
proprietary names (INNs). I used data on dispensing of medicines as a proxy for utilisation. 
The source of the data is  the same as Chapter 4 (see Table 3) with two additional variables 
for Belgium (number of pricing units and strength) and the exclusion of Estonia due to lack 
of data on the number of reimbursed indications over time. Medicines utilisation was the 
dependent variable in the longitudinal multilevel model in Chapter 5. 
 
The model included a total of nine independent variables. This includes six continuous 
variables, notably the number of years since a medicine obtained EU-wide marketing 
authorisation for the first indication; the number of years since a positive reimbursement 
decision was awarded for the first indication; the median price per DDD; time (year 1-6); 
total pharmaceutical expenditure per capita and year (euros); and the average rating of 
clinical added value across all indications assessed by the independent Drug Bulletin 
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Prescrire (1-7 were 1 represents highest level of added clinical value, 6 the lowest level and 7 
reserved judgment due to insufficient evidence) 
 
In the following paragraphs, I will describe the data source for these variables and, where 
relevant, how they were estimated. I extracted information on the date of EU-wide marketing 
authorisation for the first indication and, if applicable, the date of authorisation of additional 
cancer indications (only authorisation of indications for different types of cancer (e.g. 
stomach cancer) than previously (e.g. breast cancer) approved were counted, not extension of 
indications within already approved cancers (e.g. new early breast cancer, previously only 
metastatic cancer)). This was a rather onerous exercise as it required to go through a number 
of European Public Assessment reports associated with a particular medicine to identify the 
date when new cancer indications were approved. I extracted information on the date of 
positive reimbursement decision for each reimbursed indication (defined as different types of 
cancer) of a medicine from the websites of national competent authorities. In contrast to 
Chapter 4, which only takes into account the date of positive reimbursement decision for the 
first indication, in Chapter 5 I also extracted information on all subsequently approved cancer 
indications until December 2014. Information on the implementation of managed entry 
agreements was obtained from Chapter 7. 
 
Data on the use of medicines in each country indicated the setting in which medicine was 
dispensed. In Belgium and Scotland utilisation data distinguish between use in the 
ambulatory vs. hospital sector. In Sweden four different channels of distribution are possible 
(prescription, outpatient order, dosage and hospital). Prescription is the regular procedure 
whereby a patient visits a doctor, receives a prescription, and goes to a pharmacy to obtain 
the medicine. Outpatient order is when, for example, the primary care unit has ordered the 
drug and dispense it to the patient in the doctor-patient meeting. Dosage is when the package 
is manipulated by the pharmacist and the patients receive tablets/other form rather than a 
package. This option is common with elderly patients. Upon advice of TLV, these channels 
were identified as ambulatory use (prescription, outpatient order and dosage) and hospital 
use.  
  
Price per DDD for each medicine (ATC-5) was estimated by dividing expenditure by the total 
number of DDDs used. For medicines with more than one strength and/or formulation, this 
was calculated as a weighted average of the relative proportions of different forms of the 
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same INN used. Again for Scotland, price information from the British National Formulary 
extracted in Chapter 4 was used. As an indicator of the added clinical value of a medicine, 
data on medicine rating by the independent Bulletin Prescrire from Chapter 4 were used. 
Pharmaceutical expenditure per 1000 capita was estimated using data on total pharmaceutical 
expenditure in a given country and year, divided by the number of inhabitants in a given year. 
 
3.6! Longitudinal multilevel model 
The resulting panel dataset on utilisation of cancer medicines and the determinants to be 
tested in the regression model covered the time period from 2008 to 2013. Panel data or 
longitudinal data are repeated measurements, taken on the same subject, in this case the same 
medicine, over time (Rabe-Hesketh and Skrondal 2012). Multilevel regression analysis can 
capture variation between subjects and over time (Rabe-Hesketh and Skrondal 2012). Chapter 
5 analyses annual data on the use of medicines (‘subjects’, level 1) in three different countries 
(level 2) between 2008 and 2013 (repeated measurements). To analyse these data, a mixed 
effects model – including a fixed and a random component - was chosen after several 
consultations to discuss model options with staff from the Methodology and Statistics 
Department at the LSE.  
 
yijk = αkj + βkXijk + t + t2 + k + t*k + t2*k + vk + uj + eijk         
 
where i=year, j=medicine and k=country, Xijk is a vector of all the independent variables 
included, uj is the medicine specific random effect, vk is the country specific fixed effect and 
eijk is the error term. 
 
In this model, each medicine has its own intercept uj + eijk (random component). Time is 
included as a linear and as a squared term (t + t2) to allow for non-linear increase in use over 
time. A country specific fixed effect takes into account unmeasurable differences between 
countries (k). The interaction between time and time squared (t*k + t2*k) allows for different 
slopes and therefore different magnitude of increase or decrease in utilisation in each country 
and over time. The logarithm of DDD per 1000 capita was used in the model due to non-
normal distribution of the untransformed dependent variable (yijk). This model was fitted in 
Stata 13 using the mixed command (StataCorp 2013) to test whether there was a correlation 
between utilisation of cancer medicines and the variables included in the model. 
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3.7! Population of the framework on determinants of access to HER-2 targeted 
therapies 
Using information from the literature on the determinants of access to cancer medicines, in 
Chapter 6, I developed a framework to identify possible determinants of access to HER-2 
targeted therapies for breast cancer (trastuzumab, lapatinib, pertuzumab and trastuzumab 
emtansine). The framework was divided into determinants of medical need (burden of 
disease) and treatment decisions (diagnosis, clinical guidelines, pricing and reimbursement, 
financing and patient characteristics). A review of national websites (official statistics 
websites, cancer registry websites, competent authority in pricing and reimbursement 
websites, health insurance websites) and relevant literature (e.g. WHO Observatory health in 
transition reports and peer-reviewed literature) was conducted to populate the framework. 
Interviews served two main purposes, first, to complement missing information from the 
literature, in particular regarding financial arrangements for cancer medicines at hospital level 
and hospital level clinical guidelines. Second, it served to validate, clarify if needed, and 
update information from official websites and the literature.  
 
3.8! Interviews 
In Chapter 6, individual telephone interviews were conducted with up to two oncologists 
specialised in breast cancer in the countries studied. Two oncologists from different 
geographical areas (capital and another main cancer centre) were interviewed in Belgium 
(Brussels and Leuven), Estonia (Tallinn and Tartu), Scotland (Edinburgh and Glasgow) and 
Sweden (only one oncologist from Gothenburg accepted the invitation to talk despite two 
more were invited). More information on the interviewee’s profiles is provided in Chapter 6. 
Interviews followed a semi-structured questionnaire with some core questions common 
across countries and some additional questions in countries where information from the 
literature required validation or clarification. Interviews lasted between 30 to 45 minutes and, 
in some cases, were followed by email exchange if clarifications or further data were needed. 
I transcribed interviews as they were conducted.  
 
3.9! Development of a database on managed entry agreements 
A comparative longitudinal analysis of the implementation of MEAs on the implementation 
of managed entry agreements was conducted in Chapter 7. A database on all managed entry 
agreements implemented in Belgium, England, the Netherlands, and Sweden was developed. 
Data on managed entry agreements implemented in Belgium, England and Sweden 
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implemented as of late 2011/ January 2012 (depending on the date the country responded to 
the survey) from a study conducted by the author (Ferrario and Kanavos 2013) was used as a 
basis to develop the database. I also contacted the competent authorities I worked with as part 
of this previous study, to update the data up to December 2012 and to include all agreements, 
up to the first agreement ever implemented in the country, including any discontinued 
agreements. I searched the list of patient access schemes in England (to update the findings) 
(NICE 2016a) and Scotland (SMC 2015). I used this information to analyse the number of 
active agreements over time (‘prevalence’) and the number of new agreements introduced 
each year (‘incidence’). I conducted a review of governance frameworks around managed 
entry agreements in each country studied and followed up with competent authorities if 
clarifications were needed. 
 
3.10! Literature review 
Chapter 8 conducts a comprehensive literature review to evaluate the impact of different 
pharmaceutical procurement methods on prices, volume, stock-outs and quality use of 
medicines. The PICO(ST) framework (population, intervention, comparison group, outcome, 
setting and type of study) was originally developed to review the medical literature to address 
a clinical question but it has also been used to answer a non-clinical question. It is 
recommended for use in systematic reviews of interventions by Cochrane collaboration (The 
Cochrane Collaboration 2011). I applied it to develop a search strategy to address the 
following question (Table 8). 
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Table 8: PICOST framework 
 
PICOST Description (inclusion criteria) Key words for literature search 
Population/people 
involved 
Any institutional body or agent 
conducting public procurement of 
medicines (Ministries of Health, 
national and international 
procurement bodies, hospitals, etc.) 
pharmaceuticals OR drugs OR 
medicines OR "medicinal 
products" OR "medicinal 
product" OR "pharmaceutical 
products" OR "pharmaceutical 
product" OR medicaments OR 
medicament 
Intervention Public procurement of medicines 
including open tender, restricted 
tender, competitive negotiation and 
direct procurement 
tender OR tendering OR 
procurement OR negotiation 
OR "reverse auction" OR 
“preference policy” OR 
"rebate contracts" OR 
rabattvertäge OR 
rabattvertraege 
Comparison This could take different forms (e.g. 
tender prices vs. pharmacy 
purchasing prices) 
- 
Outcome Price, expenditure, availability 
(including supply security), quality 
use of medicines 
price OR prices OR 
expenditure OR availability 
OR volume OR “sustainable 
supply” OR "stock-outs" OR 
shortage OR “quality use” OR 
“rational use” OR “quality of 
care” OR “appropriateness of 
care” 
Situation/setting High-income countries, hospital 
and ambulatory sectors 
- 
Type of study RCTs, quasi-experimental, cohort 
and case-control studies, cross-
section study, descriptive studies 
- 
 
I decided not to include search-terms relating to comparison group and type of study as these 
may not be clearly specified in all eligible articles in order not to limit the scope of the studies 
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included. I did not include search terms for setting due to the global scope of the review. The 
identified keywords were used to search the following databases or search engines (PubMed, 
Web of Science and Google Scholar). A title and abstract screening were conducted to 
exclude studies which did not meet the inclusion criteria outlined in Table 8. The prisma 
diagram is available in Chapter 8 (I retrieved 1190 papers and reports across three databases 
(PubMed, Web of Science and Google Scholar). 341 were excluded because duplicates. 
Following title and abstract screening to exclude papers that did not meet the inclusion 
criteria outlined in the PICOST framework, another 820 articles were excluded. A total of 29 
papers were selected for inclusion. Follow-up of references let to the inclusion of another 8 
papers. The final number of articles and reports included was 37 (Figure 17). 
 
). 
 
3.11! Contributions of this thesis 
I developed four quantitative databases through extensive data extraction processes from 
publicly available data sources for the purpose of this thesis. These were complemented by a 
wealth of data that were not readily available in the public domain but had to be requested to 
competent authorities in pricing and reimbursement, health insurance organizations and 
clinicians. These two processes resulted in the creation of previously not available data to 
analyse and compare use of cancer medicines, their determinants and strategies to improve 
access in Europe and beyond.  Further, I developed comparable evidence on utilisation of 
cancer medicines using data not readily available in the public domain and which required 
extensive cleaning and standardisation in order to be compared. Finally, this thesis provides 
evidence on countries with limited published data on access to cancer medicines (Estonia).  
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4! Time to entry for new cancer medicines: From EU-wide marketing 
authorisation to patients access in Belgium, Estonia, Scotland and 
Sweden (Paper 1) 
4.1! Summary 
In this chapter, I aim to do three things. First, to quantify the time from EU-wide approval to 
first use (launch) of a medicine and number of launches in Belgium, Estonia, Scotland, and 
Sweden as of June 2015. Second, to assess whether possible delays and lack of launches 
affected medicines with high or low expected additional clinical benefit. Third, to identify 
possible determinants of the probability of a medicine to be launched. I do this by using 
survival analysis and the complementary log-log transformation of the Cox proportional 
hazard model. I collected the following data from official sources, personal contacts with 
competent authorities and the literature: dates of EU-wide marketing authorisation (t0), 
manufacturer submission for reimbursement (t1), coverage decision (t2), first use (t3) and 
medicine ratings by the independent drug bulletin Prescrire, the ESMO magnitude of clinical 
benefit and FDA expedited approval in the study countries for a sample of 46 cancer 
medicines which obtained EU-wide marketing authorisation between 2000 and 2014. I find 
that on average, the expected time from EU-wide marketing authorisation (t0), to first use of a 
medicine (t3), was shortest in Sweden, 14.3 months, followed in Belgium 26.8 months, and 
was longest in Estonia, 63.9 months. In the all country model, medicines with shorter times to 
submission for reimbursement, local manufacturers headquarter (or local sales 
representative), an FDA priority review or a combination of expedited approval programmes, 
and medicines launched in Scotland and Sweden, were associated with higher hazard of 
launch. Longer times since EU-wide approval initially correlate with an increased hazard but 
as time further elapses they negatively affect the hazard of launch. My findings show wide 
disparities in the time new cancer medicines become available in different European 
countries despite a common marketing authorisation date. The average time to first launch 
and the number of non-launches is particularly are particularly long/high in Estonia. The lack 
of correlation between time to launch and Prescrire and ESMO ratings suggests that more 
efforts are needed to ensure that launch of medicines with high clinical added value is 
prioritised over medicines with uncertain value.  
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4.2! Introduction 
The patient access to new medicines in Europe W.A.I.T. indicator shows that, for medicines 
approved between 2011 and 2014, the median time from European Union (EU)-wide 
marketing authorisation to patient access ranged from 42 days in Germany to 895 days in 
Lithuania (EFPIA 2015). Out of the 135 medicines within the scope of the analysis, 113 were 
available in Denmark vs. 28 in Lithuania (EFPIA 2015). 
 
In the EU, a marketing authorisation may be granted by European Commission based on the 
scientific advice of the European Medicines Agency (EMA). This process, known as the 
centralised procedure, was introduced in 1995 and since 2004 it is compulsory for new cancer 
medicines not approved before 20 May 2004 (European Parliament and European Council 
2004). It involves a single application, a single evaluation and a single authorisation 
throughout the EU (EMA 2015). Once an EU-wide marketing authorisation has been granted, 
a medicine can in principle be marketed in every EU country and selected countries of the 
European Economic Area (Iceland, Liechtenstein, and Norway).  
 
In practice, patient access to new prescription medicines, particularly costly ones, will be 
severely limited if the medicine is not covered by the publicly funded health care system. 
Manufacturers will therefore generally make a reimbursement application to the national 
competent authorities of the countries in which they intend to market their medicines. Given 
that pricing and reimbursement is a national competence, processes and requirements vary 
across the EU. The overall timeframe within which pricing and reimbursement procedures 
should be completed however is set by European Commission in the Transparency Directive 
to 180 days for innovative products and 90 days for generic products (The Council of the 
European Communities 1988).  
 
Studies on launch of new medicines have shown that price regulation, weak intellectual 
property rights, small market size and low expected prices were correlated with longer time 
lags between the first global launch and individual country launches (Table 9). 
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Table 9: Literature review on time to launch of new medicines 
 
Medicines included Time period and 
geographical coverage 
Findings Reference 
85 new chemical entities 
covering different 
therapeutic areas 
Launches between 1994 
and 1998 in the outpatient 
sector in 25 countries 
Only 55% of the potential launches occur. The 
United States (US) experienced the highest number 
of launches (n=73) and a mean lag of 4.2 months, 
while Japan experienced the lowest number of 
launches (n=12) with mean lag of 23.5 months. 
After controlling for a number of variables, the 
study finds that expected prices or market size 
affect both the number of launches and time to 
launch. 
(Danzon, 
Wang, and 
Wang 2005) 
1482 unique molecules 
covering different 
therapeutic areas 
Launches between 1980 
and 2000 in G7 nations 
(United States, Japan, 
Germany, France, Italy, 
the United Kingdom, and 
Canada) 
Market characteristics alone correctly predict entry 
for only about 30% of the sample. Including firm’s 
characteristics however improves this prediction 
substantially. A new chemical entity is 1.5 times 
more likely to be launched in markets that share a 
border or a language of a manufacturer’s country of 
headquarters. 
(Kyle 2006) 
1444 new chemical or Launches between 1980 This study confirms the influence of price (Kyle 2007) 
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Medicines included Time period and 
geographical coverage 
Findings Reference 
molecules entities and 2000 in 28 countries 
(21 of which were OCED 
members at the time the 
study was conducted) 
regulations on launch patterns in the country 
imposing them and beyond. 
836 new pharmaceuticals Launches between 1982 
and 2002 in 68 countries at 
all income levels 
Only 20% to 50% of all drugs launched globally 
were on the market in any country after 10 years. 
The percentage was 60% to 85% for high revenue 
blockbuster medicines. Price regulation and 
intellectual property rights were found to affect 
launch times. 
(Lanjouw 
2005) 
642 new chemical entities 
covering different 
therapeutic areas 
Launches between 1983 
and 2002 in up to 76 
countries at all income 
levels 
Only 41% of the total products were launched in 
more than 25 countries. Price regulation was found 
to delay entry, while more extensive patent 
protection, health policy institutions and economic 
and demographic factors were found to reduce time 
to entry. 
(Cockburn, 
Lanjouw, and 
Schankerman 
2014) 
22397 new chemical 
entities 
Launches between 1999 
and 2008 in 20 countries 
(major OECD markets 
This study finds that price regulation, market size, 
and regulation affect launch times of new 
medicines. Their effect is however counteracted by 
(Costa-Font, 
McGuire, and 
Varol 2015) 
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Medicines included Time period and 
geographical coverage 
Findings Reference 
plus South Africa) firm’s economies of scale, the therapeutic 
importance of specific product innovations and 
market size. 
New molecular entities 
(sample size not stated) 
New molecular entities 
which obtained marketing 
authorisation between 
2009 and 2013 across 18 
developed countries 
Large variation in time to launch (90 to 430 days) 
and time to reimbursement from launch (90 to 540 
days) among 18 developed countries were found in 
this study. Countries were classified in three 
groups: fast launch and reimbursement, fast launch 
but slow reimbursement, slow launch but fast 
reimbursement after launch. In countries with slow 
launch, first-in-class molecules and oncology 
medicines were, on average, launched faster than 
other molecules.  
(Hickson et al. 
2015) 
New molecular entities 
(sample size not stated), 
formulations and 
combinations with EMA 
approval between January 
2009 and May 2014 
Launches between January 
2009 – March 2013 and 
launches between April 
2013 to May 2014 in 
France, Germany, Italy, 
Spain, UK, USA. 
Longer post-regulatory times were found in Italy 
and Spain for products launched between April 
2013 to May 2014 vs. previous years. Oncology 
medicines seem to be approved faster than others in 
the UK (16 vs. 20 weeks) and the same applies to 
orphan drugs in France (46 vs. 50 weeks). 
(Mycka et al. 
2014) 
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Medicines included Time period and 
geographical coverage 
Findings Reference 
29 drugs marketed 
between July 1987 and 
March 1990 (D’Sa 1994; 
D’Sa 1995); new chemical 
entities available 
worldwide between 1978 
and 1987 
Teaching and non-teaching 
hospitals in British 
Columbia, Canada (D’Sa 
1994, D’Sa 1995); Israel 
(Sax 1989) 
Other studies have focused on differences in 
formulary adoption within one country (D’Sa 1994; 
D’Sa 1995), and differences in launch times 
between a particular country and major markets 
(Sax 1989). 
(D'Sa, Hill, 
and Stratton 
1994, D'Sa, 
Hill, and 
Stratton 1995) 
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Few of these studies focus specifically on time to entry of new cancer medicines in Europe 
and its determinants. Cancer is a major contributor to the global burden of disease. In 2012, 
there were 14.1 million new cancer cases and 8.2 million cancer deaths worldwide (Stewart 
and Wild 2014). Together with surgery and radiotherapy, chemotherapy, targeted therapies 
and immunotherapies are a key component of cancer treatment. Despite their importance, 
variations in access to cancer medicines across and within European countries have been 
highlighted in various studies (Cherny et al. 2016, Aggarwal, Ginsburg, and Fojo 2014). 
Differences in access may be driven by many factors, one of which is time to entry of new 
medicines in individual European countries. A better understanding of the time required for 
new cancer medicines to enter different EU-markets and whether time to entry correlates with 
the added clinical value of a medicine is therefore important to improve access.  
 
Further, none of the studies reviewed included Estonia where there is scarce evidence on the 
extent of perceived delays in entry of new cancer medicines and their importance. As the 
country is conducting a review of its pharmaceutical system with the view of identifying 
areas where more could be done to improve access to medicines (Ferrario, Reinap, et al. 
2016), it is timely to shed light on this issue. Previous studies tended to benchmark delays 
against the date of first global launch. However, some of the medicines studied may not even 
have a marketing authorisation in all the study countries at the time the first global launch 
occurs. Finally, launch delays or lack of launch matter if the medicine is likely to bring 
significant added value to patients, or if a medicine with the same therapeutic value enters the 
market at same price or lower price than the comparator as it promotes competition. We 
found limited attempts at linking launch delays with the associated added value of a 
medicine. Some studied did include measures of therapeutic importance like the mentions of 
a medicine in medical journals indexed by Medline (Kyle 2007, 2006), global molecule sales 
and total markets launched in (Costa-Font, McGuire, and Varol 2015), inferior or superior 
molecules based on mechanism of action and input from physician and the literature (Danzon 
and Epstein 2012) which may not necessarily correlate with higher therapeutic benefit. 
   
In this study, we analyse time to entry of cancer medicines (ATC-L01/L02) which obtained 
central EU-wide marketing authorisation between 2000 and 2014 in a selection of medium-
sized European markets (Belgium, Estonia, Scotland and Sweden). In particular, we aim to 
address the following objectives. First, to quantify the time from EU-wide approval to first 
use (launch) of a medicine and number of launches in the study countries as of June 2015. 
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Second, to assess whether possible delays and lack of launches affected medicines with high 
or low expected additional clinical benefit. Third, to identify possible determinants of the 
probability of a medicine to be launched.  
 
4.3! Methods 
This study examines four time points in a medicine’s life-cycle to estimate time to entry and 
its components. The reference date is the date an EU marketing authorisation was issued (t0) 
(Figure 4).  
 
Figure 4: Overview of times studied 
 
 
 
The first time lag is determined by the number of days elapsed between t0 and the date the 
manufacturer submits a reimbursement dossier (t1). The second time lag measures the number 
of days needed for the assessment of the medicine (t2- t1)10 while the third time lag represents 
time from EU-wide marketing authorisation to first use of the medicine (t3- t0). In all the 
study countries, a national level coverage decision is not needed before the medicines can be 
prescribed, meaning that use often precedes the final coverage decision for the first 
indication. We therefore decided not to include the t3- t2 lag in the analysis. 
 
4.3.1! Selection of study countries and medicines and data sources 
Belgium, Estonia, Scotland, and Sweden were chosen as study countries for their diversity in 
terms of expected launch times and number of launches, and data availability (i.e. access to 
procurement data for the hospital and outpatient sectors). Despite the convenience nature of 
the sample, we believe the four countries represent a very interesting study group  given the 
expected differences in times to launch and number of launches (due to different pricing and 
reimbursement processes but most importantly different levels of health care spending per 
                                                
10 This does not include time stops and can therefore not be considered as a reference for compliance with the 
EU-Transparency Directive. 
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capita, Table 10). Despite their diversity, all countries have a relatively small population size 
in comparison to larger EU countries and they all have system of mandatory health insurance 
in place.
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Table 10: Similarities and differences in key elements of the public health insurance system in the study countries 
 
 Belgium Estonia Scotland Sweden 
Mandatory health 
insurance 
Yes, financed mainly 
through social security 
contributions and 
administered by sickness 
funds 
Yes, funded mainly 
through payroll 
contribution and 
administered by the 
national health insurance 
fund 
Yes, tax funded and 
administered by the 
national health service 
(NHS) 
Yes, mainly tax funded 
and administered by the 
county councils 
Total health expenditure 
per capita, PPP$ per 
capita, WHO estimates 
4392 1668 3066 5219 
Public health 
expenditure as 
percentage of total health 
expenditure 
78% 79% 83% (UK) 84% 
Pricing External reference pricing, 
negotiation 
External reference pricing, 
negotiation 
Rate-of-return regulation, 
branded medicines spend 
cap (since 2014) for 
medicines included in the 
Pharmaceutical Pricing 
Value-based pricing, 
negotiation 
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Regulation Scheme 
(voluntary agreement 
between the Association of 
the British Pharmaceutical 
Industry and the UK 
Department of Health) 
Use of managed entry 
and risk-sharing 
agreements 
Yes Yes Yes Yes 
Use of HTA in coverage 
decisions for cancer 
medicines 
Yes, all new cancer 
medicines (for which the 
manufacturer makes a 
reimbursement 
submission) are reviewed 
by National Institute for 
Health and Disability 
Insurance who conducts an 
HTA and budget impact 
analysis 
Decisions on coverage of 
cancer medicines used in 
hospitals are made based 
on submissions by 
oncologists. Elements of 
HTA may be included in 
the submission. If an HTA 
analysis is not included in 
the submission, the 
Estonian Health Insurance 
Fund conducts one (for 
hospital medicines, for 
Yes, all new cancer 
medicines (for which the 
manufacturer makes a 
HTA submission) are 
reviewed by the Scottish 
Medicines Consortium 
(SMC) which assesses the 
manufacturer HTA 
submission and budget 
impact analysis 
Most new cancer 
medicines (for which the 
manufacturer makes a 
HTA submission) are 
reviewed by NT-council 
with support from TLV 
(conducting the economic 
evaluation) 
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outpatient medicines HTA 
is always included in the 
manufacturer submission 
Purchasing of medicines Discounts off the list price 
may apply at hospital level 
Discounts off the list price 
may apply at hospital level 
Discounts off the list price 
may apply at hospital level 
Discounts off the list price 
may apply at hospital 
level.  
 
Sources: WHO Health for all database, WHO Global health expenditure database (£ per Int$), Nuffield Trust data (health expenditure per capita 
Scotland). 
Note: Health expenditure per capita in Scotland in 2014 was calculated as the average of the reported expenditure by the Nuffield Trust in the 
reporting periods 2013/14 and 2014/15 divided by the £ per Int$ in 2014 from the WHO Global health expenditure database. 
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Using the anatomic therapeutic chemical (ATC) search function for European Public 
Assessments Reports on the website of the EMA, we identified all antineoplastic (ATC-L01) 
and endocrine (ATC-L02) medicines authorised by the EMA (112 medicines). We did not 
include immunostimulants (ATC-L03) medicines because only some of these medicines are 
indicated for cancer treatment. Medicines which were either withdrawn post-approval, 
suspended or refused were not included. We selected all medicines authorised by the EMA 
between 2000 and 2014 (total: 99). Further, we excluded generic (22) and orphan medicines 
(24). There were no biosimilar medicines or medicines approved under exceptional 
circumstances but there were six medicines approved with a conditional marketing 
authorisation (see supplementary material for definition) in the remaining sample of 53 
medicines (different branded names). We excluded 7 medicines which were new brands of 
INNs approved before 2000. The final sample of medicines (different INNs) included in the 
analysis was 46.  
 
We define the time a medicine first becomes available (launch) as the month or quarter in 
which a new medicine was first procured either in hospital or ambulatory settings. Data on 
medicines utilisation were provided by national competent authorities (The Estonian State 
Medicines Agency (SAM), The National Institute for Health and Disability Insurance in 
Belgium (INAMI-RIZIV), NHS Scotland (ISD) and Swedish eHealth Agency 
(ehälsomyndigheten)). These data were available on a monthly basis from (April) 2007 to 
2014 in Scotland and from 2000 to 2014 in Sweden and on quarterly basis from the first 
quarter of 2002 to the second quarter of 2015 in Belgium and from the first quarter of 2000 to 
the first quarter of 2015 in Estonia. The data covered both hospital and ambulatory settings. 
In Scotland and Belgium, data for the ambulatory sector was available up to 2000 and 2001 
respectively. 
 
The choice of variables was based on the literature reviewed in the introduction (e.g. 
expected price and volume, therapeutic group, time since marketing authorisation). The effect 
of price regulation on time to launch has been established in previous studies and all the 
countries included in this study regulate prices in one way or another. Therefore assessing the 
impact of price regulation would have not added value to the existing literature. Instead what 
this study adds are stronger indicators of added value (Prescrire and ESMO-MCBS which 
actually consider clinical added value) as opposed to previous studies which looked at, for 
example, the number of citations in Medline as a proximal indicator of the importance of the 
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medicine. We further contribute to the existing literature by adding, conditional marketing 
authorisation, time of submission of a reimbursement dossier and award of expedited 
approval by the FDA which were not included in previous studies on time to entry. Table 11 
provides summary statistics of the variables used in the survival analysis.  
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Table 11: Descriptive statistics of the variables used in the survival analysis 
 
Medicines (common across countries, N=46) Total Frequency Mean Median SD Min Max 
Categorical variables            
Medicine approved with conditional marketing authorisation   
   
  
-Yes 6 13.0%   
   
  
-No 40 87.0%   
   
  
Therapeutic group (baseline: other antineoplastic agents L01X)   
   
  
-L01B Antimetabolites 3 6.5%   
   
  
-L01C Plant alkaloids and other natural products 2 4.3%   
   
  
-L01D Cytotoxic antibiotics and related substances 1 2.2%   
   
  
-L01X Other antineoplastic agents 36 78.3%   
   
  
-L02B Hormone antagonists and related agents 4 8.7%   
   
  
FDA expedited approval programme   
   
  
-No EAP 9 19.6%   
   
  
-Fast track only 3 6.5%   
   
  
-Priority review only 11 23.9%   
   
  
-Combination 23 50.0%        
Continuous variables               
Year of EU-wide marketing authorisation (2000-2014)     2009 2011 4.5 2000 2014 
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Country specific variables Total Frequency Mean Median SD Min Max 
Belgium (44 medicines, 407 medicine-quarters at risk)               
Local manufacturer headquarters               
-Yes 2 4.3%   
   
  
-No 42 95.7%   
   
  
Expected price per DDD (lagged 1 quarter) in the therapeutic class (ATC-3) 
in Euro     76.7 24.5 100.4 0.00 389.1 
Expected volume (lagged 1 quarter) at therapeutic class (ATC-3) in 
thousands DDDs     306.6 239.5 418.2 0.00 2361.8 
T1-T0 (quarters) (N=41 medicines with submission)     3.1 0.9 4.6 0.008 18.6 
T2-T1 (quarters) (N=39 medicines with decision)     6 3.7 4.7 1.9 21.4 
Estonia (46 medicines, 634 medicine-quarters at risk)               
Local sales representative               
-Yes 31 67.4%   
   
  
-No 15 32.6%        
Expected price per DDD (lagged 1 quarter) in the therapeutic class (ATC-3) 
in Euro     65.9 11.5 154.3 0 2432.9 
Expected volume (lagged 1 quarter) at therapeutic class (ATC-3) in 
thousands DDDs     18.4 13.4 27.6 0 248.6 
T1-T0 (quarters) (N=30 medicines with submission)     5.7 3.9 6.7 0.01 35.5 
T2-T1 (quarters) (N=19 medicines with decision)     10.6 8.9 7.9 2.8 38.5 
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Scotland (N=31, 173 medicine-quarters at risk)               
Local manufacturer headquarters               
-Yes 6 15.2%   
   
  
-No 25 84.8%        
Expected price per DDD (lagged 1 quarter) in the therapeutic class (ATC-3) 
in Euro     106.6 80.4 91.1 0 261.54 
Expected volume (lagged 1 quarter) at therapeutic class (ATC-3) in 
thousands DDDs     93.7 30.7 213.3 0 1023.6 
T1-T0 (quarters) (N=25 medicines with submission)     1.2 0.7 1.4 0.08 5.6 
T2-T1 (quarters) (N=19 medicines with decision)     2.5 1.8 1.5 1.2 7.6 
Sweden (N=46, 279 medicine-quarters at risk)               
Local manufacturer headquarters               
-Yes 0 0%   
   
  
-No 46 100%        
Expected price per DDD (lagged 1 quarter) in the therapeutic class (ATC-3) 
in Euro     93.8 25.8 100.9 0 389.1 
Expected volume (lagged 1 quarter) at therapeutic class (ATC-3) in 
thousands DDDs     159.6 138.3 292.5 0.00 2601.42 
T1-T0 (quarters) (N=32 medicines with submission)     2.4 0.5 5 0.008 26.3 
T2-T1 (quarters) (N=32 medicines with decision)     4.5 2.8 5.2 1.2 28.3 
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The date of EU-wide marketing authorisation for cancer medicines (ATC-L01/L02) approved 
between 2000 and 2014 was obtained from the European Public Assessments Reports (EMA 
2015). Manufacturers’ submission dates for reimbursement were only available online for 
Belgium (INAMI-RIZIV 2015) while for all the other countries they had to be requested to 
national competent authorities (The Estonian Health Insurance Fund (EHIF) and the Estonian 
Ministry of Social Affairs (MoSA), Scottish Medicines Consortium (SMC), and The Swedish 
Dental and Pharmaceutical Benefit Agency (TLV)). Decision dates and the outcome of these 
decisions were mostly available from competent authorities’ websites (INAMI-RIZIV 2015, 
TLV 2016c, SMC 2016a) apart from Estonia where they had to be requested to the EHIF and 
MoSA. Both date of submission and date of decision refer to the first indication of a medicine 
which was submitted and obtained a positive coverage decision in each country. Expected 
volume, measured in thousands defined daily doses (DDD) in the therapeutic class (ATC-3, 
pharmacological subgroup) one quarter prior EU-wide marketing authorisation, was 
estimated using utilisation data. Where available, the defined daily doses by the World Health 
Organization Collaborating Centre on Drugs Statistics Methodologies were used (WHO 
Collaborating Centre for Drug Statistics Methodology 2016). If these were not available, the 
following additional resources were used in this order: the Belgian Centre for 
Pharmacotherapeutic Information (2016), the German Institute of Medical Documentation 
and Information (DIMDI 2016), or we used the smallest approved formulation by EMA. 
Expected prices per DDD were estimated using utilisation data in Belgium, Estonia and 
Sweden were information on expenditure was provided. It was not possible to obtain 
information on expenditure for hospital medicines in Scotland due to the confidential nature 
of the discounts offered at that level. Historical British National Formulary prices (2000-
2015) were used instead. The estimated average prices per thousand DDDs were weighted by 
volume. Information on manufacturers was taken from the European Public Assessments 
Reports, we then search online where the headquarters of company was located. Since there 
are no originator manufacturers in Estonia, availability of local sales representatives was used 
instead of local manufacturer headquarters. The list of manufacturers with local sales 
representatives was taken from the Association of Pharmaceutical Manufacturers in Estonia 
(APME 2016). Data on the US Food and Drug Administration (FDA) expedited approval 
programmes (accelerated approval, breakthrough, fast track and priority review) was 
extracted from the FDA website, the FDA novel drug summaries and a review of FDA 
Approvals between 1938 and 2013 (Darrow and Kesselheim 2014). This formed the pre-
launch evidence on the expected clinical added value of the medicine. Post-launch data was 
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extracted from two sources, the independent Drug Bulletin Prescrire (2016) and the European 
Society of Medical Oncology (ESMO) magnitude of clinical benefit scale (MCBS) (ESMO 
2015) (see Supplementary material for information on these two rating systems). Prescrire 
and ESMO-MCBS were chose because they are independent authoritative reviews of clinical 
effectiveness, they have been used in other studies (Vitry, Shin, and Vitre 2013, Lexchin 
2015, 2014, Jönsson et al. 2016), and, in the case of ESMO-MCBS, were peer-reviewed.  
 
4.3.2! Survival analysis 
Survival analysis is the method of choice for analysis of time to event data where the 
probability of the event happening over time is not constant, the data are usually continuous, 
the data may be incomplete (censoring), and the data are always larger or equal to zero. 
Standard regression analyses do not handle censoring (they just exclude incomplete 
observations) and may be inadequate to handle data that is only positive and has a non-
normal distribution (unless the data are transformed). 
 
Life table methods were used to estimate the expected time from EU-wide marketing 
authorisation to first use (T3-T0) of the medicines included in the sample. Data on time of first 
use was available by month or quarter and life table methods enables to handle such discrete 
time intervals. In contrast, Kaplan-Meier methods require events to occur on a continuous 
scale (e.g. day) which was available for T0, T1, T2 but not T3. If the event of interest 
(submission, positive decision, or first use) did not occur at the end of the observation period 
(June 2015), the observation was considered censored (or lost to follow-up) in the survival 
analysis. I refer to medicines which were not launched by June 2015 as ‘non-launched’ 
bearing in mind that they could still be launched in the future. 
 
Regression analysis of survival data involves the estimation of the hazard of the event of 
interest to occur. The hazard rate is the instantaneous probability of an event occurring at a 
particular point in time (h(t)), in this case the probability at a particular time t that the 
medicine will be launched. The Cox-proportional hazard model is used for continuous events, 
while for discrete event the complementary log-log model is used (cloglog):  
 
hjk (t) = 1 − exp (−exp (h0(t) + zjktβ + ƴt + ck)   or 
 
cloglog(hjkt) = h0(t) + zjktβ 
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where hjk(t) is the hazard at time t for medicine (j) and country (k) and h0(t) is the baseline 
hazard and β summarises the independent regression variables. 
 
A time dependency parameter (ƴt) was included in the model which measures time (in 
quarters) since EU-wide approval, a linear and quadratic specifications were added as well as 
country fixed effects (ck). The final dataset for the cloglog analysis includes one observation 
for each medicine-quarter at risk, i.e. from the quarter in which the medicine receives EU-
wide marketing authorisation to the quarter when the medicine is launched (non-censored 
medicines) or the end of the observation period (June 2015) for censored medicines. The 
dependent variable is specified as a binary variable taking the value of 0 in all quarters before 
launch and 1 in the quarter the medicine is launched. We run an all-country model (with four 
variants for different samples) and four country models (with two variants for different 
samples) using the statistical software Stata® 14.1, StataCorp. 
 
4.4! Results 
4.4.1! Descriptive analysis 
The descriptive analysis addresses the objectives of quantifying the time from EU-wide 
approval to first use (launch) of a medicine and number of launches in the study countries as 
of June 2015 and to assess whether possible delays and lack of launches affected medicines 
with high or low expected additional clinical benefit.  
 
On average, the expected time from EU-wide marketing authorisation (T0), to first use of a 
medicine (T3), was shortest in Sweden, 14.3 months (43 launches, 3 non-launches), followed 
in Belgium 26.8 months (39 launches, 7 non-launches), and was longest in Estonia, 63.9 
months (27 launches, 19 non-launches). For medicines which obtained EU-wide marketing 
authorisation after April 2007, the average time to launch in Scotland was 12.7 months (29 
launches, 2 non-launches). Sample-wide (46 medicines, including also medicines for which 
date of first use was not known), only 2 medicines were not used between April 2007 and 
June 2015 in Scotland. No medicine was not available in any country, two medicines were 
not available in 3 countries, 6 medicines were not available in 2 countries and 13 medicines 
were not available in one country as of June 2015. Figure 5 provides the distribution of 
launches and non-launches by time and Prescrire rating (see Appendix 3 for break down by 
ESMO-MCBS rating). 
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Figure 5: Time to launch and distribution of launches and non-launches by Prescrire 
rating 
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In Sweden most medicines with Prescrire rating (N=43) are launched within one year of 
marketing authorisation (n=37), followed by Scotland (n=16), Estonia (n=9), and Belgium 
(n=8). In Belgium most medicines are launched between one to two year of marketing 
authorisation (n=19), while in Estonia, a number of medicines included in our sample had not 
yet been launched as of June 2015 (n=16).  
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4.4.2! Regression analysis 
The regression analysis tests the correlation between possible determinants of the probability 
of a medicine to be launched. 
 
In the all country model 1, medicines with shorter times to submission for reimbursement, 
local manufacturers headquarter (or local sales representative), an FDA priority review or a 
combination of expedited approval programmes, and medicines launched in Scotland and 
Sweden, were associated with higher hazard of launch (Table 12). Longer times since EU-
wide approval initially correlate with an increased hazard but as time further elapses they 
negatively affect the hazard of launch. Most of these variables remain significant in the all 
country model 2 (subsample of medicines with submission) and all country model 3 
(subsample with Prescrire rating). Model 2 includes time from submission to decision but the 
latter does not seem to affect the hazard of launch. Rating by Prescrire does not affect the 
hazard of launch in model 3, meaning that higher ratings of clinical added value by Prescrire 
were not associated with higher hazard of launch. In model 4 (subsample of medicines with 
ESMO-MCBS rating), the hazard of launch does not seem to be affected by the ESMO-
MCBS rating and the only significant variables are the country dummies, meaning that the 
hazard of launch is different between countries, and the time since EU-wide marketing 
authorisation. The latter model is based on a smaller sample as ESMO-MCBS ratings were 
only available for a limited number of medicines for the treatment of solid cancer tumours. 
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Table 12: Cloglog regression analysis 
 
Model 1: Full sample Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.09*** 0.015 
-
6.72 0 
-
0.12679 
-
0.06954 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with CMA 0.16 0.28126 0.58 0.56 -0.39 0.71 
Local manufacturer headquarter or sales representative (Estonia), baseline (no local headquarter/representative) 
-Local headquarter/representative 0.83* 0.32 2.58 0.01 0.20 1.46 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites 0.48 0.44 1.09 0.28 -0.38 1.34 
-L01C Plant alkaloids and other natural products -0.37 0.44 
-
0.84 0.402 -1.24 0.5 
-L01D Cytotoxic antibiotics and related substances -0.06 0.82 
-
0.08 0.94 -1.66 1.53 
-L02B Hormone antagonists and related agents 0.64 0.36 1.78 0.07 -0.06 1.35 
Expected price in the therapeutic class (ATC-3), lagged 
one quarter 0.0015 0.001 1.29 0.19 -0.0008 0.004 
Expected volume at therapeutic class (ATC-3) in thousands 
DDDs, lagged one quarter 5.13E-08 
2.80E-
07 0.18 0.854 
-4.97E-
07 
6.00E-
07 
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Model 1: Full sample Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
FDA expedited approval programme (EAP, baseline: no 
EAP)             
-Fast track only 0.44 0.46 0.96 0.34 -0.46 1.35 
-Priority review only 0.77* 0.31 2.48 0.013 0.16 1.38 
-Combination 1.08*** 0.29 3.78 0 0.52 1.65 
Year of marketing authorisation -0.03 0.03 
-
0.99 0.32 -0.09 0.03 
Belgium 0.65 0.36 1.82 0.07 -0.05 1.34 
Scotland 1.57*** 0.33 4.8 0 0.93 2.22 
Sweden 3.07*** 0.40 7.6 0 2.28 3.86 
Time since EU-wide approval (quarters) 0.35*** 0.06 5.61 0 0.23 0.48 
Time since EU-wide approval (quarters), squared -0.01 0.003 
-
4.35 0 -0.02 -0.007 
Constant -4.64 0.67 -6.9 0 -5.96 -3.32 
Log likelihood  = -341.60817 
LR test of rho=0: chibar2(01) = 5.0e-05         Probability >= chibar2 = 0.497 
Number of observations  =  1,493 
Number of groups  =  167 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
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Model 2: Subsample with submission Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.08 0.07 
-
1.24 0.22 -0.21 0.05 
T2-T1, quarters -0.06 0.06 
-
1.03 0.30 -0.18 0.06 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with CMA 0.47 0.32 1.49 0.14 -0.15 1.10 
Local manufacturer headquarter or sales representative (Estonia), baseline (no local headquarter/representative)  
-Local headquarter/representative 1.17*** 0.38 3.07 0.00 0.42 1.91 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites 0.15 0.50 0.30 0.76 -0.83 1.14 
-L01C Plant alkaloids and other natural products -1.19* 0.53 
-
2.25 0.02 -2.22 -0.15 
-L01D Cytotoxic antibiotics and related substances             
-L02B Hormone antagonists and related agents 0.35 0.40 0.87 0.38 -0.43 1.12 
Expected price in the therapeutic class (ATC-3), lagged 
one quarter 0.001 0.001 0.98 0.33 -0.001 0.004 
Expected volume at therapeutic class (ATC-3) in 
thousands DDDs, lagged one quarter 0.0001 0.0003 0.25 0.80 -0.001 0.001 
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Model 2: Subsample with submission Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
FDA expedited approval programme (EAP, baseline: no EAP) 
-Fast track only 0.67 0.50 1.35 0.18 -0.31 1.64 
-Priority review only 0.72* 0.34 2.11 0.04 0.05 1.39 
-Combination 1.04*** 0.32 3.20 0.00 0.40 1.68 
Year of marketing authorisation -0.01 0.04 
-
0.24 0.81 -0.08 0.06 
Belgium 0.79 0.46 1.71 0.09 -0.12 1.70 
Scotland 1.84*** 0.48 3.79 0 0.89 2.79 
Sweden 3.35*** 0.57 5.86 0 2.23 4.47 
Time since EU-wide approval (quarters) 0.45*** 0.08 6.03 0 0.31 0.60 
Time since EU-wide approval (quarters), squared -0.01*** 0.00 
-
4.16 0 -0.02 -0.01 
Constant -5.18 0.92 
-
5.64 0 -6.98 -3.38 
Log likelihood  = -266.21368 
LR test of rho=0: chibar2(01) = 3.7e-05                Probability >= chibar2 = 0.498 
Number of observations   =   797 
Number of groups  =  128 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
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Model 3: Subsample with Prescrire rating Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.10*** 0.01 
-
6.62 0.00 -0.13 -0.07 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with CMA 0.21 0.29 0.74 0.46 -0.35 0.78 
Local manufacturer headquarter or sales representative (Estonia), baseline (no local headquarter/representative) 
-Local headquarter/representative 0.85* 0.33 2.54 0.01 0.20 1.50 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites 0.35 0.47 0.74 0.46 -0.57 1.26 
-L01C Plant alkaloids and other natural products -0.27 0.45 
-
0.60 0.55 -1.15 0.61 
-L01D Cytotoxic antibiotics and related substances -0.24 0.85 
-
0.29 0.78 -1.90 1.42 
-L02B Hormone antagonists and related agents 0.43 0.41 1.04 0.30 -0.38 1.23 
Expected price in the therapeutic class (ATC-3), lagged 
one quarter 0.002 0.001 1.55 0.12 -0.001 0.004 
Expected volume at therapeutic class (ATC-3) in 
thousands DDDs, lagged one quarter 0.0000001 0.0000003 0.20 0.84 
-
0.0000005 0.000001 
FDA expedited approval programme (EAP, baseline: no EAP) 
-Fast track only 0.81 0.50 1.60 0.11 -0.18 1.80 
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Model 3: Subsample with Prescrire rating Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
-Priority review only 0.77* 0.33 2.34 0.02 0.12 1.41 
-Combination 1.05*** 0.32 3.29 0.00 0.42 1.67 
Year of marketing authorisation -0.01 0.03 
-
0.35 0.72 -0.08 0.06 
Belgium 0.65 0.37 1.77 0.08 -0.07 1.36 
Scotland 1.57*** 0.34 4.60 0.00 0.90 2.24 
Sweden 3.16*** 0.43 7.44 0.00 2.33 4.00 
Time since EU-wide approval (quarters) 0.36*** 0.06 5.60 0.00 0.23 0.49 
Time since EU-wide approval (quarters), squared -0.01*** 0.00 
-
4.35 0.00 -0.02 -0.01 
Prescrire rating -0.13 0.11 
-
1.19 0.23 -0.33 0.08 
Constant -4.21 0.86 
-
4.88 0.00 -5.89 -2.52 
Log likelihood  = -323.78502 
LR test of rho=0: chibar2(01) = 7.2e-05                Probability >= chibar2 = 0.497 
Number of observations = 1,440 
Number of groups = 155 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
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Model 4: Subsample with ESMO-MCBS Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.04 0.02 
-
1.90 0.06 -0.08 0.001 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with CMA -0.18 0.39 
-
0.45 0.65 -0.94 0.59 
Local manufacturer headquarter or sales representative (Estonia), baseline (no local headquarter/representative) 
-Local headquarter/representative 0.66 0.43 1.54 0.12 -0.18 1.49 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites 0.09 0.77 0.12 0.90 -1.42 1.61 
-L01C Plant alkaloids and other natural products -1.06 0.62 
-
1.71 0.09 -2.28 0.16 
-L01D Cytotoxic antibiotics and related substances             
-L02B Hormone antagonists and related agents 0.19 0.50 0.37 0.71 -0.79 1.16 
Expected price in the therapeutic class (ATC-3), lagged 
one quarter -0.003 0.002 
-
1.35 0.18 -0.01 0.001 
Expected volume at therapeutic class (ATC-3) in 
thousands DDDs, lagged one quarter 
-
0.0000004 0.0000004 
-
0.99 0.32 
-
0.000001 0.0000004 
FDA expedited approval programme (EAP, baseline: no EAP) 
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-Fast track only -0.06 0.64 
-
0.09 0.93 -1.30 1.19 
-Priority review only 0.39 0.58 0.68 0.50 -0.74 1.53 
-Combination 0.73 0.56 1.29 0.20 -0.38 1.83 
Year of marketing authorisation -0.04 0.05 
-
0.86 0.39 -0.14 0.05 
Belgium 0.95* 0.44 2.16 0.03 0.09 1.82 
Scotland 1.77*** 0.42 4.24 0.00 0.95 2.59 
Sweden 3.46*** 0.54 6.38 0.00 2.40 4.53 
Time since EU-wide approval (quarters) 0.40*** 0.08 4.87 0.00 0.24 0.57 
Time since EU-wide approval (quarters), squared -0.01*** 0.004 
-
3.02 0.00 -0.02 0.00 
ESMO-MCBS rating 0.02 0.15 0.16 0.87 -0.27 0.32 
Constant -4.09 0.99 
-
4.13 0 -6.03 -2.15 
Log likelihood = -208.15312 
LR test of rho=0: chibar2(01) = 0.00                   Probability >= chibar2 = 1.000 
Number of observations = 524 
Number of groups = 102 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
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In the country level model 1 (full sample model), time to submission is significant in all 
countries (see Appendix 8). Manufacturers with a local sales representative are more likely to 
launch in Estonia. High expected prices increased the hazard of launch in Belgium and 
Sweden and decreased it Scotland. Expected volume was only significant in Estonia. FDA 
expedited approval programmes were significant in Scotland and Sweden.  
 
In the country level model 3, time to submission is significant in Belgium, Estonia, and 
Sweden. Manufacturers with local sales representative is significant in Estonia. Expected 
price was significant in Belgium, Scotland and Sweden while expected volume was only 
significant in Estonia. Use of FDA expedited approval programmes increased the hazard of 
launch significant in Scotland and Sweden, while higher additional clinical value, as 
estimated post-launch by Prescrire, not significantly correlated with a higher hazard of launch 
in any country. In all country level models 1 and 3, longer times since EU-wide marketing 
authorisation initially correlate with higher hazard of launch, while in the longer term, they 
correlate with decreased hazard of lunch. The year of marketing authorisation, negatively 
correlated with the hazard of launch in Estonia. This means that medicines which received 
EU-wide marketing authorisation in recent years were less likely to be on the market. There 
was no correlation between the age of the medicine (year of EU-wide marketing 
authorisation) and the hazard of launch in the other countries.  
 
4.5! Discussion 
Shorter times from EU-wide marketing authorisation to submission for reimbursement were 
positively correlated with increased hazard of launch in most model specifications. The 
majority of the cancer medicines included are predominantly dispensed in hospitals, 
including day-units. In Belgium, Scotland, and Sweden, manufacturers submit applications to 
obtain national coverage for hospital medicines. An early submission for reimbursement 
suggests that the manufacturer has a strong interest in entering the market quickly. In Estonia, 
applications to the inpatient service list are made by clinicians therefore manufactures are in 
principle not able to influence this process. Potentially, manufacturers could try and influence 
clinicians to make a submission but there is no evidence on whether this is happening or not. 
Scotland does horizon scanning and actively invites manufacturers to submit newly approved 
indications to SMC for assessment. Belgium may also proactively invite manufacturers. 
However, the impact of these activities on the likelihood of submission and launch is 
unknown. In addition to the small market size, limited expenditure on health per capita and as 
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share of gross domestic product in Estonia is likely to impact the probability of early launch 
of new cancer medicines. Estonia is also the country where manufacturers seem to have 
fewer opportunities to promote early entry of new cancer medicines, through formal 
channels, since only clinicians can make a submission for reimbursement.  
 
Conditional marketing authorisation was not associated with lower hazard of launch in any 
model specifications. A study on differences in HTA recommendations for oncology 
medicines which received a conditional marketing authorisation vs. standard marketing 
authorisation found no differences in HTA outcome between these two groups (Lipska et al. 
2015). Taken together these findings suggest that for oncology medicines in Europe, receving 
a conditional marketing authorisation does not necessarily delay entry nor makes the 
medicine less likely to receive a positive reimbursement decision. In Estonia, manufacturers 
with a local sales representative are more likely to launch as confirmed by previous findings 
(Ferrario, Reinap, et al. 2016). We did not find any correlation between having a local 
manufacturer headquarters and the hazard of launch (a positive correlation was found in 
previous studies (Costa-Font, McGuire, and Varol 2015, Danzon, Wang, and Wang 2005, 
Kyle 2006, 2007, Danzon and Epstein 2012)). One reason may be the relatively small number 
of locally manufactured medicines in the sample.   
 
In the all country model, expected prices do not affect the hazard of launch, this is likely to be 
due to limited price variation across the four study countries. In Belgium and Sweden, higher 
expected prices are correlated with shorter time to launch, while in Scotland, they correlate 
with longer time to launch. Confidential discounts through patient access schemes are 
common for cancer medicines in Scotland and may be the explanation for this finding since 
we could not adjust for them. 
 
Only in Estonia was expected volume associated with higher hazard of launch. Results from 
previous studies are mixed, some did find a correlation with expected volume (Costa-Font, 
McGuire, and Varol 2015, Danzon, Wang, and Wang 2005), other did not (Danzon and 
Epstein 2012).  
 
Expedited approval programmes by the FDA were associated with a higher hazard of early 
launch in Scotland and Sweden. Award of an expedited review programme relies on pre-
market data which may not always be a good predictor or post-launch effectiveness. In a 
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study from Canada, pre-market priority review was not associated with post-market 
therapeutic value (Lexchin 2015). There was no correlation between Prescrire rating or the 
EMSO-MCBS rating and the hazard of launch in any country.   
 
In line with previous findings (Costa-Font, McGuire, and Varol 2015) and in contrast with 
others (Danzon and Epstein 2012), we find that the hazard of launch first increases and then 
decreases as time from EU-wide marketing authorisation elapses.  
 
4.5.1! Limitations 
There are limitations in this study. For example, while analysis of time to first use gives an 
indication of the speed with which new medicines become available in a particular country, it 
does not say anything about the level of use, for which indication the medicine is used, i.e. 
there may be access for one indication but not for others, and whether this meets patients’ 
needs and possible inequalities in access to medicines within a country. It is therefore 
important to analyse also actual utilisation levels, ideally by indication although available 
data on use of hospital medicines by indication are very limited. We did not have data on 
medicines utilisation by month prior 2007 for hospitals in Scotland and thus had to conduct 
part of the analysis based on a subsample of medicines for Scotland. Use of British National 
Formulary prices is likely to have led to an overestimation of the prices paid in the NHS 
Scotland as these do not include discounts which remain in commercial confidence. If the 
manufacturer headquarters or having a local sales representative (Estonia) changed from the 
time the medicine was approved for EU-wide use to the time the study was conducted, we 
would have considered the new headquarters or current status of having a sales representative 
in Estonia and not the one at the time of approval. Change of headquarters is unlikely to have 
affected many companies during the time period studied. 
 
4.6! Conclusion 
This study provides cross-country and country-level evidence on correlates of higher hazard 
of launch of new cancer medicines in selected European countries. In contrast to previous 
studies, we use a common benchmark (EU-wide marketing authorisation), when the medicine 
can potentially be marketed in all EU-countries and find that shorter time to submission for 
reimbursement, having a local sales representative, pre-launch evidence of added clinical 
value and need, and a short time gap since EU-wide marketing authorisation increase the 
hazard of launch in most model specifications. The effect of therapeutic group, expected 
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prices and volume varies across countries and model specifications. These findings suggest 
that more efforts are needed to ensure that launch of medicines with high clinical added value 
is prioritised over medicines with uncertain value and that limited expected volume in very 
small markets like Estonia, may cause delays in entry of new medicines. Horizon scanning 
and early dialogue with manufacturers through EMA channels and national initiatives are 
likely to help identifying medicines expected to bring high added clinical value. Strategic 
purchasing and joint procurement between regional groups (e.g. the Baltic countries) could 
help addressing issues of small volumes and various countries in Europe are already working 
in this direction with the aim of combining volume and securing competitive prices through 
joint negotiation and data sharing (Ferrario, Kanavos, et al. 2016b).  
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5! Determinants of utilisation differences for cancer medicines in Belgium, 
Scotland and Sweden (Paper 2) 
5.1! Summary 
Little comparative evidence is available on utilisation of cancer medicines in different 
countries and its determinants. In this chapter, I develop a statistical model to test the 
correlation between utilisation and possible determinants in selected European countries. I 
use a sample of 31 medicines for cancer treatment which obtained EU-wide marketing 
authorisation between 2000 and 2012. I obtained annual data on medicines’ utilisation and 
expenditure covering in- and outpatient public sectors between 2008 and 2013 from national 
authorities in each country. I extracted information on the date of positive reimbursement 
decision for the first indication of a medicine, number of indications reimbursed in each year, 
co-payments, use of managed entry agreements, setting where the medicine was dispensed 
and price per defined daily dose from medicines’ utilisation and expenditure data, health 
technology assessment reports, personal contacts with competent authorities and clinicians, 
the literature and assessment by the independent drug review organization Prescrire. I used 
these data to fit a longitudinal mixed effect model to test possible determinants of medicines 
utilisation in Belgium, Scotland and Sweden. In the all country model, I find that the number 
of indications reimbursed positively correlated with increased use of medicines (one 
indication=2.6, 95% CI [1.8-3.6]; two indications=2.4, 95% CI [1.4-4.3]; three 
indications=4.9, 95% CI [2.2-10.9]; all p<0.01), years since EU-wide marketing authorisation 
(1.2, 95% CI [1.02-1.4]; p<0.05), price per DDD (0.9, 95% CI [0.998-0.999], p<0.01), and 
Prescrire rating (0.5, 95% CI [0.3-0.9], p<0.05) after adjusting for time and other covariates. I 
conclude that the most important correlates of increased utilisation in a sample of cancer 
medicines introduced in the past 15 years in Belgium, Scotland and Sweden were medicines 
coverage and time since EU-wide marketing authorisation. Prices had a negative effect on 
utilisation in Belgium and Sweden suggesting that they represent a barrier to access. The 
positive impact of financial managed entry agreements in Scotland suggests that the use of 
confidential discounts removes the regressive effect of list prices on use.   
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5.2! Introduction 
Managing the introduction of new high priced cancer medicines is a challenge for countries at 
all levels of development. On the one side payers want to provide access to new and 
potentially more effective medicines, while on the other they need to ensure the financial 
sustainability of their health care systems, value for money and an equitable distribution of 
the available resources.  
 
In Europe, decisions regarding the reimbursement of new high cost medicines are 
increasingly made using health technology assessment (HTA). While important differences 
exist in the way individual countries implement HTA, they all include in their analysis and 
decision-making process information on the efficacy and effectiveness and, to different 
extents, information on the price of the new medicine. This technique does not only enable to 
determine the cost-effectiveness a medicine according to the licensed indication, it can also 
help identifying the patient subgroup in which the medicine is most cost-effective. Limiting 
access to such subgroup of patients is one tool countries are using to manage the introduction 
of new medicines. 
 
Another way to manage entry is to delay the assessment of new medicines. This may be done 
with an explicit rationing objective, it may be caused by the time involved in conducting 
HTA but it may also be due to the lack of submission of a reimbursement dossier by the 
manufacturer. These factors can lead to a medicine not being reimbursed at all in a particular 
country or to reimbursement being limited to a subset of all licensed indications. Lack of a 
national level positive decision on reimbursement, or lack of a legal requirement to 
implement such decision at local level, can lead to disparities in availability of the medicine 
for patients within countries. In this context, local authorities or hospitals will decide whether 
or not to fund the medicine and it could possibly lead to no availability at all. 
 
Increasingly, countries are using managed entry agreements (MEAs) to facilitate access while 
trying to limit budget impact and improve cost-effectiveness in a context of uncertainty 
(Ferrario and Kanavos 2013, Klemp et al. 2011, Ferrario and Kanavos 2014). The way 
medicines are financed has also an impact on access and can influence their uptake. 
Availability of top-up funding for new high cost medicines can incentivise prescribing and 
use over medicines which are funded by hospital budgets. The effect of prospective payment 
systems like diagnostic-related groups is most likely dependent on their design (Sorenson et 
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al. 2014). Special funds earmarked for particular products have been established in some 
countries. Examples include the cancer drugs fund in England (NHS England 2016a), the 
risk-share scheme for orphan medicines and the rare disease fund in Scotland (NSD NHS 
Scotland 2016, Scotland Government 2013) and the rare disease fund in Belgium (INAMI-
RIZIV 2016a). The latter aim to increase availability of high cost medicines which may be 
otherwise not available or whose financing would put individual institutions in financial 
difficulties. 
 
The setting, ambulatory or hospital, where the medicine is prescribed and dispensed can 
determine whether a co-payment applies or not and potentially influence levels of utilisation 
too. While co-payments for cancer medicines (particularly when these medicines are 
dispensed in hospitals) are not common in Western European countries, their use and the 
extent of cost-sharing may influence utilisation. In some countries, third party payers may 
require prescribing doctors to obtain prior authorisation by a physician designated by the 
payer, before the medicine can be prescribed.  
 
Beyond pricing and reimbursement, disease burden, demographics, access to timely 
diagnosis, clinical practice, access to specialist care, whether the disease is a national priority 
and cultural factors including defensive medicine also have an impact on use of new high 
priced medicines and may lead to differential uptake across countries (Richards 2010, Nolte, 
Newbould, and Conklin 2010, Nolte and Corbett 2014, Lambrelli and O’Donnell 2009, 
Sullivan et al. 2011).  
 
While the factors influencing access and use of cancer medicines have been to a certain 
extent identified and discussed in the literature, less evidence is available on the actual levels 
of cancer medicines use across different countries and most importantly their determinants. 
 
Differences in the use of cancer medicines between selected high income countries have been 
investigated in an international study on medicines use in 2008/09 and its update in 2013/14 
(Richards 2010, O’Neill and Sussex 2014). A study on endocrine therapies for breast cancer 
investigated patterns of use in eight Western European countries plus Australia over the 
period 2001-2012 (Kelly et al. 2015). A series of comparative longitudinal studies on patient 
access to cancer medicines in Europe have been conducted covering the time period from 
1993 to 2014. These studies looked at differences in expenditure and, for selected medicines, 
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also milligrams (mg) per case and defined daily doses per case (Wilking and Jönsson 2005, 
Wilking, Jönsson, and Högberg 2009, Jönsson et al. 2016). Possible determinants of 
utilisation differences or lack of differences have been investigated using a qualitative 
approach (benchmarking possible determinants against quantitative data) (Richards 2010, 
Kelly et al. 2015, Groot, Huijgens, and Uyl-de Groot 2006, Kos, Obradovic, and Mrhar 
2008). A study on utilisation of orphan medicines vs. non-orphan medicines used t-test to 
assess whether an association existed between orphan medicine status and variability in use 
across countries (Stolk et al. 2009). Some correlation analysis was conducted in the 2016 
update of the study on uptake of oncology medicines in Europe which noted that uptake of 
innovative medicines largely depends on the country’s gross domestic product and the level 
of health care spending per capita (Jönsson et al. 2016). However, the authors also noted that 
differences in use across countries with similar economic status exist (Jönsson et al. 2016).  
 
Reasons for the limited number of studies including utilisation of cancer medicines data and 
using statistical methods are likely to include, but are not limited to, the difficulties in 
accessing data on medicines dispensed in hospitals from public sources and the cost of 
accessing from private ones. Further, the difficulty and sometimes impossibility of assigning 
a numerical value to all possible determinants of use to test as part of a statistical model. 
The aim of this study is therefore to test the correlation between utilisation of cancer 
medicines (mostly dispensed in hospital settings) and possible determinants of utilisation of 
cancer medicines in selected European countries. The study contributes to the existing 
literature by providing updated longitudinal evidence on use of cancer medicines in Europe 
and by developing a multilevel model to test the correlation between utilisation and likely 
determinants adjusting for important covariates.  
 
5.3! Methods 
5.3.1! Sample selection and variable definition 
Three countries were selected based on access to data from public sources: Belgium, Scotland 
and Sweden. Despite the convenience nature of the sample, the three countries represent a 
suitable study group, they are all part of the European Union, have comparable levels of gross 
domestic product per capita and spending on health per capita, benefit of a comprehensive 
system of universal health coverage and have a population size ranging from more than 5 to 
11 million inhabitants in 2013 (Appendix 1).  
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Using the anatomic therapeutic chemical (ATC) search function for European Public 
Assessment Reports available from the website of the European Medicines Agency (EMA), I 
identified all antineoplastic (ATC-L01) and endocrine (ATC-L02) medicines authorised in 
the European Union (EU) and the European Economic Area countries (Iceland, Liechtenstein 
and Norway). I did not include medicines which were withdrawn post-approval, suspended or 
refused. The unified list (ATC-L01 and L02) contained 106 medicines (different brand 
names). I selected all medicines which obtained EU marketing authorisation between 2000 
and 2012 (total: 76). In an attempt to have a homogenous, yet sufficiently large, sample (at 
least 30 medicines), we excluded generics (17), orphan medicines (as classified by EMA at 
the time of data extraction) (19), biosimilar medicines (zero) and medicines approved under 
exceptional circumstances (zero after excluding orphans), (Figure 6). Uptake of these 
medicines is likely to be influenced by different factors than for the majority of other 
medicines included and this would require a separate analysis for each of these three groups. 
There were five medicines approved with a conditional marketing authorisation in the 
remaining sample of 40 medicines. We excluded five medicines which were new brands of 
international non-proprietary names (INNs) approved before 2000. Finally, after extracting 
data on utilisation from the three study countries, we excluded four medicines for which there 
was no use during the study period (2008-2013) in two or more study countries. The final 
sample of medicines (different INNs) included in the analysis was 31 (Appendix 5).  
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Figure 6: Selection of cancer medicines to be included in the study 
 
 
Although the subject matter of this study was cancer, I did not include immunostimulant 
medicines (ATC – L03) because only some of these medicines are indicated for cancer 
treatment. Further, even if a medicine is indicated for the treatment of cancer, the other 
indications may not be and my data did not allow to disaggregate medicines use by 
indication.  
 
5.3.2! Data sources 
Quantitative (e.g. mg of medicines dispensed, date of reimbursement for the first indication) 
and qualitative (e.g. positive vs. negative reimbursement decision, implementation of MEAs) 
data were used to build the statistical model. Data on medicines utilisation (pack size, number 
of packs, strength per quarter or month) in ambulatory and hospital settings by INN and 
brand (Belgium and Sweden) and by INN only (Scotland) between 2008 and 2013 was 
obtained from the National Institute for Health and Disability Insurance (INAMI-RIZIV) in 
Belgium, the Dental and Pharmaceutical Benefits Agency (TLV) and eHälsomyndigheten in 
Sweden and the National Health Service (NHS) in Scotland. The list of MEAs for each 
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country was sourced from a previous Chapter 7 for Belgium and Sweden  and the Scottish 
Medicines Consortium website for Scotland (SMC 2015). Prices per defined daily dose 
(DDD) were estimated from expenditure data provided by INAMI-RIZIV in Belgium and 
TLV in Sweden and using historical prices from the British National Formulary in Scotland. 
DDDs from the Belgian Centre of Pharmacotherapeutic Information (CBIP 2016) were used 
since the ATC/DDD Index of the WHO Collaborating Centre  for Drug Statistics 
Methodology does not define DDDs for most cancer medicines. Additional data on the study 
variables were extracted from the websites of national competent authorities (e.g. HTA 
reports and ministerial decisions) (INAMI-RIZIV 2015, TLV 2016c, SMC 2016a) and 
personal contacts with these authorities or clinicians and from the utilisation data provided by 
the countries.  
 
The variables extracted included the date when a positive reimbursement decision (Belgium 
and Sweden) or positive recommendation for use (Scotland) for the first indication of a 
medicine was made, the number of indications (measured as different types of cancer) 
covered or recommended for use in each of the study years, use and type of a MEA, setting 
where the medicine was dispensed and patient co-payments. While decisions in Belgium and 
Sweden - relate to reimbursement and in Scotland they relate to use within the national health 
system, for the sake of simplicity the term used henceforth is ‘reimbursement’ or ‘coverage’. 
In Sweden, a reimbursement decision is usually made by TLV for outpatient medicines and 
by the county councils (the latter, in recent years were increasingly made through the NT-
council, a body representing all the county councils) for hospital medicines. Some medicines 
are not assessed by any of these two bodies but recommended as part of national guidelines. 
National guidelines aimed at supporting resource allocation decisions are developed by the 
National Board of Health and Welfare (NBHW), these are not clinical guidelines but can and 
are also used as clinical guidelines. Further, since 2011, national guidelines on breast, 
prostate, colorectal and lung cancer are developed by professional organisations under the 
regional cancer centre. Before 2011 each professional group was responsible for cancer care 
programmes. We therefore checked guidance by the NBHW, the regional cancer centre and 
contacted clinicians responsible for the cancer care programmes before 2011. 
 
5.3.3! Data analysis 
The study included a total of nine independent variables. This includes six continuous 
variables, notably (a) the number of years since a medicine obtained EU-wide marketing 
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authorisation for the first indication; (b) the number of years since a positive reimbursement 
decision was awarded for the first indication; (c) the median price per DDD; (d) time (year 1-
6); (e) total pharmaceutical expenditure per capita and year (euros); and (f) the average rating 
of clinical added value across all indications assessed by the independent Drug Bulletin 
Prescrire (1-7 were 1 represents highest level of added clinical value, 6 the lowest level and 7 
reserved judgment due to insufficient evidence) (2016). Three categorical variables are also 
included, namely (a) the number of reimbursed indications (zero to three); (b) the setting 
where the medicine was dispensed (1=hospital only, 2=ambulatory only, 3=both); and (c) use 
of a MEA (1=no MEA, 2=health outcome based MEA, 3=financial, 4=combination), which 
were modelled as dummies. The all country model included also dummy variables for 
countries and interaction terms between countries and time. 
 
We used DDDs per 1,000 population to measure utilisation of cancer medicines. In order to 
compute the total number of DDDs consumed, we calculated the total mg of active ingredient 
dispensed for a particular INN. We used the DDD defined by the Belgian Centre of 
Pharmacotherapeutic Information (CBIP 2016) and divided the total mg by the Belgian 
DDDs.  
 
The resulting longitudinal data set was analysed in Stata 13 using the mixed command to 
allow for random slopes (Rabe-Hesketh and Skrondal 2012). To allow for non-linear increase 
in utilisation over time we used a non-linear polynomial function with t2 as an additional 
predictor (Hedeker and Gibbons 2006). The between-medicines variability is treated as a 
random effect (i.e. as a random-intercept term at the medicine level): 
 
yijk = αkj + βkXijk + t + t2 + k + t*k + t2*k + uj + vk + eijk         
 
where i=year, j=medicine and k=country, Xijk is a vector of all the independent variables 
included, uj is the medicine specific random effect, vk is the country specific fixed effect and 
eijk is the error term. 
 
Random effects model unobserved between-subject (in this case medicines) variation as 
random, while fixed effects model unobserved variation between subjects (in this case 
countries) as constant (Rabe-Hesketh and Skrondal 2012). Interactions allow for differential 
increase (slope) between subjects. In this case they allow for time to have a different effect on 
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utilisation growth in each country. The logarithm of medicines use was modelled because of 
non-normal distribution of the non-transformed dependent variable.  
 
5.4! Results 
5.4.1! Descriptive analysis 
The median time since EU-wide marketing authorisation in the sample was 5.6 years (N=31 
medicines, min=1.3 years, max=13.3 years) as of December 2013. At that time, the median 
time since a positive reimbursement for the first indication of the 31 medicines included was 
made was 3.9 years (N=30, min=0.45 years, max= 10.5 years) in Belgium, 3.7 years (N=16, 
min=0.23, max=11.2) in Scotland and 4.2 years (N=21, min=0.1, max=12.7) in Sweden.  
Some medicines had not been assessed by Scottish Medicines Consortium in Scotland (1) and 
either TLV or NT-council or NBHW or professional bodies in Sweden (9); other medicines 
were assessed and rejected (1 Belgium, 12 Scotland and 1 Sweden) as of December 2013. 
Until a few years ago, the adoption and utilisation of new cancer medicines in Sweden used 
to be at the discretion of the oncologists and their institutions. In the last few years, national 
guidance has increasingly become available through professional bodies, the NBHW, the NT-
council and TLV. Out of the total 31 INNs studied, Belgium recommended at least one 
indication for 30 of them, Scotland 18 and Sweden 21. 
 
Belgium had the highest number of indications covered (n=39, 83% of total indications with 
EU-wide approval, N=47) as of December 2013, followed by Sweden (n=25, 53% of total) 
and Scotland (n=19, 40% of total) (Figure 7). This does not mean that the other indications 
were only available if the patient paid out-of-pocket, but that there was no national level 
reimbursement decision. Individual hospitals or local authorities may then decide to make the 
medicine available to all or selected patients. 
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Figure 7: Cumulative number of indications covered versus approved EU indications 
(both measured as different types of cancer) 
 
In Belgium, cancer medicines are fully reimbursed by compulsory health insurance. 
Similarly, but not limited to cancer medicines, there are no co-payments or charges on 
prescription medicines in Scotland. In Sweden, prescription medicines dispensed in hospitals 
are reimbursed at 100%, while prescription medicines dispensed in pharmacies are subject to 
a deductible plus a co-payment. Outpatient-orders, when for example the primary care unit 
has ordered a medicine and dispense it to the patient during the consultation, are not subject 
to co-payments. Since there were no co-payments in Belgium and Scotland and very minimal 
co-payments in Sweden (maximum annual co-payment for one year is about EUR 240 (SEK 
2,200) for all medicines (TLV 2016a)), this variable was not included in the statistical model.  
Five, nice, four medicines were part of a MEA in Belgium, Scotland and Sweden, 
respectively. These included five combination agreements in Belgium, eight financial and 
one combination agreements in Scotland and three combination and one health outcome 
agreements in Sweden. 
 
In all three countries, the largest volume share amongst the medicines in the sample 
(measured as total number of DDDs) was dispensed in hospital settings (including day care 
units) in all years (Figure 8). In 2013, this share was highest in Scotland (98%), followed by 
Belgium (74%) and Sweden (66%). Sweden had the highest number of medicines dispensed 
in both hospital and ambulatory settings (25) followed by Belgium (6) and Scotland (4).  
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Figure 8: Setting where medicines were dispensed by share of DDDs and number of 
medicines 
 
The following figures (Figure 9) show medicines use as the number of DDDs dispensed per 
1,000 population between 2008 (or the year when utilisation of the medicine was first 
recorded) and 2013 by ATC-level 3 pharmacological subgroup.  Belgium had the highest per 
capita use of ‘other antineoplastic agents’ (L01X), the group to which most study medicines 
belong (N=23) in all years, while Sweden had the highest per capita use of ‘hormone 
antagonist and related agents’, (L02B) (N=3) and ‘plant alkaloids and analogues’ (L01C), 
(N=2). Scotland, closely followed by Sweden, had the highest per capita use of 
‘antimetabolites’ (L01B) included in the study sample (N=3). 
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Figure 9: Number of DDD consumed per 1,000 capita 
 
 
The median price per DDD was highest in Belgium (EUR 116.5, min= EUR 2.9, max= EUR 
3966.6), followed by Sweden (EUR 90.3, min= EUR 2.4, max= EUR 2724.4) and lowest in 
Scotland (EUR 88.1, min=3.6, max=5030.2). The median Prescrire rating across all the 31 
medicines included in the study was 5, which corresponds to ‘nothing new’. The medicine 
with the highest rating was imatinib with a rating of 2, representing ‘a real advantage’, for 
four of the six indications evaluated. A number of medicines (11) had a Prescrire rating of 6, 
which stands for ‘not acceptable’. 
 
5.4.2! Statistical analysis: Longitudinal mixed-effects model 
In the all country model, the number of indications reimbursed (1 indication=2.6,95% CI 
(1.8-3.6); 2 indications=2.4,95% CI (1.4-4.3); 3 indications=4.9, 95% CI (2.2-10.9); all 
p<0.005) and the number of years since marketing authorisation (1 year=1.2, 95% CI (1.1-
1.4), p-value < 0.05) positively correlated with increased use of medicines after controlling 
for time and other covariates (Table 13). Price per DDD (0.9, 95% CI (0.998-0.999), p-value 
< 0.05) and the low added clinical value had a regressive effect on utilisation (0.5, 95% CI 
(0.3-0.9), p-value < 0.05). Having controlled for time and country effects, no correlation was 
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found with the number of years since a positive reimbursement decision for the first 
indication was given, the existence or not of managed entry agreements, or the level (or the 
log) of total pharmaceutical expenditure.  
 
Table 13: All country model 
 
 
Exp(β) [95% CI] p-value 
Years since EU-wide marketing authorization 1.202* 1.021 1.405 0.026 
Years since positive reimbursement decision 0.998 0.980 1.015 0.795 
Number of disease areas covered 
-1 2.599** 1.840 3.633 0.000 
-2 2.425* 1.377 4.259 0.002 
-3 4.904** 2.192 10.913 0.000 
Use of managed entry agreements (baseline: no MEAs) 
-Health outcome MEA 0.962 0.393 2.627 0.933 
-Combination MEA 1.590 0.693 3.653 0.274 
-Financial MEA 1.539 0.831 2.852 0.171 
Setting where the medicine is dispensed (baseline: Hospital) 
-Ambulatory 0.460 0.156 1.368 0.163 
-Hospital and ambulatory 0.720 0.495 0.954 0.087 
Price per DDD 0.999* 0.998 0.999 0.001 
Prescrire rating 0.545* 0.337 0.881 0.013 
Pharmaceutical expenditure per 1000 capita 1.000 1.000 1.000 0.837 
Year 0.925 0.605 1.412 0.716 
Year2 1.019 0.945 1.098 0.626 
Country (baseline: Scotland) 
Sweden 4.711* 0.343 57.111 0.034 
Belgium 4.393 0.372 3.785 0.255 
Sweden x Year 1.185 0.593 1.896 0.772 
Belgium x Year 1.062 0.790 1.188 0.839 
Sweden x Year2 0.969 0.868 1.091 0.761 
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Belgium x Year2 0.973 0.003 5469.815 0.642 
constant 3.896 1.000 1.000 0.712 
 
Results for the country level models showed that the following variables were positively 
correlated with increased utilisation: the number of disease areas covered in all countries, 
years since EU-wide marketing authorization in Scotland and Belgium, use of managed entry 
agreements in Scotland, the setting where the medicine was dispensed in Sweden (Table 14). 
The variables that negatively influenced use were: the price per DDD in Belgium and Sweden 
and the low value of a medicine in Scotland.  
 
Table 14: Country models 
a)! Belgium 
 
Exp(β) [95% CI] p-value 
Years since EU-wide marketing authorization 0.890 0.653 1.213 0.461 
Years since positive reimbursement decision 1.284 0.900 1.833 0.168 
Number of disease areas covered 1.000 1.000 1.000 
 -1 2.648** 1.788 3.923 0.000 
-2 3.876** 2.119 7.090 0.000 
-3 6.802** 3.095 14.951 0.000 
Use of managed entry agreements (baseline: no MEAs) 
-Combination MEA 1.043 0.389 2.797 0.934 
Setting where the medicine is dispensed 
-Hospital and ambulatory 0.595 0.112 3.146 0.541 
Price per DDD 0.998** 0.997 0.999 0.000 
Prescrire rating 0.610 0.366 1.017 0.058 
Pharmaceutical expenditure per 1000 capita 1.000 1.000 1.000 0.480 
Year 1.049 0.744 1.481 0.784 
Year2 0.972 0.916 1.033 0.363 
constant 1882.717 0.001 3399451731.077 0.305 
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b)! Scotland 
Scotland Exp(β) [95% CI] p-value 
Years since EU-wide marketing authorization 1.289* 1.115 1.490 0.001 
Years since positive reimbursement decision 1.011 1.000 1.022 0.061 
Number of disease areas covered 
    -1 1.832 0.967 3.471 0.063 
-2 1.180 0.322 4.329 0.803 
-3 38.205** 2.395 609.506 0.010 
Use of managed entry agreements (baseline: no MEAs) 
   -Combination MEA 1.100 0.272 4.446 0.894 
-Financial MEA 3.249* 1.554 6.791 0.002 
Setting where the medicine is dispensed 
    -Hospital and ambulatory 1.174 0.602 2.288 0.638 
Price per DDD 0.998 0.995 1.001 0.193 
Prescrire rating 0.552* 0.367 0.832 0.004 
Pharmaceutical expenditure per 1000 capita 1.000 1.000 1.000 0.710 
Year 1.066 0.788 1.440 0.679 
Year2 0.976 0.935 1.019 0.267 
constant 2.598 0.028 240.853 0.679 
 
c)! Sweden 
Sweden Exp(β) [95% CI] p-value 
Years since EU-wide marketing authorization 1.361** 1.139 1.616 0.000 
Years since positive reimbursement decision 0.902 0.787 1.034 0.140 
Number of disease areas covered 
    -1 2.316* 1.279 4.221 0.006 
-2 3.320 1.000 11.023 0.050 
Use of managed entry agreements (baseline: no MEAs) 
   -Health outcome MEA 3.287 0.826 13.197 0.091 
-Combination MEA 0.888 0.326 2.411 0.816 
Setting where the medicine is dispensed 
    -Ambulatory 0.519 0.174 1.537 0.238 
-Hospital and ambulatory 1.685* 1.048 2.713 0.031 
Price per DDD 0.998** 0.954 2.691 0.000 
Prescrire rating 0.784 0.522 1.174 0.242 
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Pharmaceutical expenditure per 1000 capita 1.000 1.000 1.000 0.103 
Year 4.688 0.779 28.078 0.090 
Year2 0.788 0.595 1.045 0.090 
constant 77652.576 0.044 140363314266.971 0.125 
 
5.5! Discussion  
Overall, Belgium and Sweden had the highest level of utilisation (measured as DDD/1000 
capita) for non-orphan cancer medicines which obtained EU-wide marketing authorisation 
between 2000 and 2012. Belgium had the highest absolute number of DDDs consumed per 
1000 capita in 2012 and 2012. This does not seem to be explained by the burden of disease 
since Sweden has generally a lower incidence rate than Belgium and Scotland (apart for 
melanoma) and that Scotland has the highest incidence among the three countries for a 
number of cancers (e.g. breast, bronchus and lung, liver, oesophagus, pancreas and stomach)  
(Appendix 6). In Sweden and Scotland medicines used in hospitals are financed through the 
hospital budget and may be used before a national level decision on reimbursement is made. 
In contrast in Belgium, with the exception of compassionate use, pricing and reimbursement 
have to be completed before doctors can prescribe a medicine in hospital settings. However, 
once this is completed, hospital medicines are reimbursed separately by INAMI and are not 
part of the fixed hospital budget. This may explain why Belgium has higher per capita use 
than Sweden between 2011 and 2013 and generally a higher use than Scotland despite the 
latter has often a higher disease burden. 
 
The 2010 report to the United Kingdom (UK) Department of Health used rankings to 
compare use of selected medicines across various therapeutic areas among 14 OECD 
countries in 2008/09 (Richards 2010). An update of the 2010 report was released in 2014 
providing data for 2012/13 (O’Neill and Sussex 2014). The two analyses included the UK 
and Sweden but not Belgium. Although I cannot really compare my results with the UK 
Department of Health study due to differences in the medicines included, countries studied 
and methods of analysis, I can at least observe that utilisation of cancer medicines in Sweden 
was usually higher than in Scotland in my sample. In the Department of Health study, 
Sweden ranked 9th in terms of cancer medicines use and the UK ranked 10th (with some 
differences within the cancer class, e.g. use of endocrine therapies was higher in the UK than 
Sweden). Further, I can confirm the importance of HTA outcomes, included in my model as 
years since a positive reimbursement decision was made and indications covered, in 
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determining levels of utilisation. I can also confirm the absence of correlation between, in my 
study pharmaceutical expenditure per capita, in the case of the UK Department of Health 
report health expenditure per capita, and utilisation. 
 
The number of indications covered positively correlated with increased utilisation in all 
models although not all levels of increase were significant. The effect was smallest in 
Sweden possibly because before 2010, and to a certain extent still today, decisions on 
whether to fund or not a cancer medicine have been made by the respective county councils 
in the absence of national level guidance. Today there is increasing coordination in decision-
making thanks to the centralisation of cancer in six centres of excellence and closer 
collaboration between TLV and NT- council. The likely impact of coverage decisions on 
prescribing and use was also mentioned in a longitudinal study on endocrine therapies (Vitry, 
Thai, and Lu 2011) and the role of reimbursement and funding arrangements for governing 
access to myeloma treatment in England has been highlighted (Mehta and Low 2007). 
 
Time since EU-wide marketing authorisation had a positive effect in all countries but 
Belgium. One explanation could be that in Belgium, reimbursement is a more important 
factor than years since marketing authorisation. Use in both hospital and ambulatory settings 
vs. hospital only had a positive effect in Sweden where it applies to most medicines included 
in this study. Interestingly, the price per DDD had a regressive effect in Belgium and Sweden 
but not in Scotland where, in contrast, low value medicines had a regressive effect. One 
possible explanation for the lack of negative impact of prices in Scotland may be the 
implementation of MEAs (all with a financial component for the medicines with MEA in this 
sample) which off-set the high list price per DDD. The 2016 update of the study on the 
uptake of new cancer medicines in Europe observed a correlation between the ESMO-MCBS 
and actual uptake, however this was not statistically significant and the number of medicines 
represented for most non-curative score levels was very small (score 1, n=0; score 2, n=3; 
score 3; n=3, score 5, n=1), only score 4 had 10 medicines represented (Jönsson et al. 2016).  
Finally, it is worth noting that large differences between and within country in access are not 
just limited to medicines but as a recent analysis by the OECD showed, affect a number of 
medical procedures (OECD 2014). 
 
Not all possible determinants of utilisation of cancer medicines are readily convertible into a 
numeric value that can be tested as part of a statistical model. Examples include cultural 
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factors and clinical practice. Other determinants may be measurable but not readily available 
at medicine level between 2008 and 2013. For example, inclusion of access to timely 
diagnosis could be measured by looking at the average stage at which patients are diagnosed. 
However, the required data are not simple to obtain for different countries and several 
medicine-indication combinations and would require utilisation data by indication. This study 
therefore had to limit the number of variables included to those for which data were available 
at the required level and frequency in the three study countries.  
 
There are a number of limitations in our study. First, it was not possible to include incidence 
of different types of cancer in the model. The majority of the medicines included in the 
sample were approved for the treatment of different cancer indications which are associated 
with different incidence levels. Only availability of utilisation data by ICD-10 code would 
have therefore enabled to link, in a reliable way, use with incidence. Second, it is well-known 
that list prices (e.g. British National Formulary) and undiscounted expenditure figures do not 
reflect what health payers pay for medicines (Vogler et al. 2012). Nevertheless, list prices are 
still the starting point for negotiation and the presence of special pricing arrangements at 
national level is captured by the MEA variable. Further, it would have simply been 
impossible to access real discounted prices on 31 cancer medicines in three different 
countries. Third, again due to lack of data at indication level but also lack of cost-utility 
estimates for all the medicines in each country, I could not include in the model the 
incremental cost-effectiveness ratio estimated for different indications in each country. 
Fourth, the number of dispensed doses does not necessarily mean that they were all 
consumed. Considering the high cost of new cancer medicines and the severity of cancer, it is 
unlikely that wastage will have significantly affected the results. Fifth, I did not have access 
to dispensing data within countries and, therefore, could not control for differences in 
dispensing at that level, which may be significant.  
 
5.6! Conclusions 
Access to new medicines ought to be targeted to medicines which bring a meaningful added 
value to patients in comparison to existing therapies. Use of medicines with modest 
therapeutic improvement, mostly at higher prices than existing treatments, draws resources 
away from potentially more effective interventions. It is therefore important that competent 
authorities assess added therapeutic value and enable access to medicines with high value and 
limit access to those with low value. This study showed that the most important correlates of 
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increased medicines utilisation in a sample of cancer medicines introduced in the past 15 
years were medicines coverage and time since EU marketing authorisation. Prices had a 
negative effect on use meaning that they can represent a barrier for access. The lack of a 
regressive effect of prices on utilisation in Scotland, and the positive impact of financial 
MEAs, suggests that the latter may remove the regressive effect of list prices on use. Scotland 
was also the only country where low clinical added value of a medicine was correlated with 
reduced utilisation suggesting that existing entry arrangements in place, particularly HTA and 
clinical guidelines, seem to guide towards use of high value products and limiting access to 
low value ones. However, it is also important to note that Scotland had the lowest level of use 
for most medicines raising the question as to whether the other two countries have too 
generous access requirements or whether the former has too restrictive ones. Only an analysis 
of patient level data including prescribing information would enable to answer this question. 
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6! A framework to understand differences in utilisation of HER-2 targeted 
medicines for breast cancer (Paper 3) 
6.1! Summary 
Differences in the level of utilisation of cancer medicines across Europe have been 
highlighted in various studies. However, there is limited evidence on their causes. In this 
study, I use the case of HER-2 targeted therapies for breast cancer to analyse cross-national 
differences in utilisation in Belgium, Estonia, Scotland and Sweden. I developed a framework 
to identify determinants of the use of HER-2 targeted therapies (trastuzumab, lapatinib, 
pertuzumab and trastuzumab emtansine) based on a literature review and treatment 
guidelines. I populated the framework with information from official country websites, 
complemented and validated it by conducting interviews with oncologists. I obtained data on 
use of HER-2 targeted therapies from national authorities. Differences in the use of lapatinib, 
pertuzumab and trastuzumab emtansine are driven by lack of reimbursement in some 
countries (Estonia and Scotland). Trastuzumab is reimbursed in all countries and all new 
breast cancer patients are tested for HER-2 overexpression and prescribed trastuzumab if the 
tumour is invasive and larger than 1 cm or smaller but with risk factors. Yet, important 
differences exist in the use of trastuzumab (DDD per new case) between countries with high 
consumption (Belgium and Sweden) and countries with low consumption (Estonia and 
Scotland). This seems to be driven by differences in the use of trastuzumab beyond 
progression (only used in Belgium and Sweden). Estonia has a comparatively low incidence 
of breast cancer, the least comprehensive national breast cancer screening programme, and, 
despite progress, patients are diagnosed relatively late. If it is the case that a number of breast 
cancer cases are not diagnosed, Estonian patients could be worst off in terms of access 
despite similar levels of usage per patient to Scotland.  
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6.2! Introduction 
Variations in the level of utilisation of cancer medicines across Europe have been highlighted 
in various studies (Richards 2010, O’Neill and Sussex 2014, Kos, Obradovic, and Mrhar 
2008, Groot, Huijgens, and Uyl-de Groot 2006, Kelly et al. 2015, Jönsson et al. 2016). 
However, there is limited evidence on the underlying reasons for this variation. Studies have 
sought to explain these differences by discussing likely factors that may drive the observed 
variations (Kos, Obradovic, and Mrhar 2008, Kelly et al. 2015, Benjamin et al. 2014, 
Wilking, Jönsson, and Högberg 2009), conducting simple correlation analyses (Jönsson et al. 
2016), developing qualitative frameworks to analyse possible reasons for disparities (Groot, 
Huijgens, and Uyl-de Groot 2006), conducting literature reviews (Nolte and Corbett 2014, 
Nolte, Newbould, and Conklin 2010, Lublóy 2014, Chauhan and Mason 2008), and setting up 
an expert panel to identify possible determinants of variations (Richards 2010). While 
frameworks to analyse access to medicines exist, these have often been developed with a 
focus on low- and middle income countries (WHO 2004, Bigdeli, Jacobs, et al. 2013, Center 
for Pharmaceutical Management 2003). The primary objective of frameworks targeting 
developed countries (Cohen et al. 2007, Chauhan and Mason 2008), was not  to identify 
determinants of access to cancer medicines. For this reason, they may miss some of the 
peculiarities affecting access to this pharmacotherapeutic group. Notable exceptions include a 
study which proposes a conceptual framework of factors influencing patients’ access to oral 
anticancer medicines (Benjamin et al. 2014). However, this framework focuses variations at 
patient level rather than population level. 
 
In this study, I use the case of HER-211 targeted therapies to analyse differences in utilisation 
of breast cancer medicines at the population level, using a qualitative framework. My choice 
was motivated by the fact that trastuzumab, the first HER-2 targeted therapy for breast cancer 
to market, is well established as an effective treatment in early breast cancer (O'Sullivan et al. 
2015, Moja et al. 2012), though not necessarily cost-effective in all settings (Pichon-Riviere 
et al. 2015). This precludes the argument of poor or uncertain evidence on its effectiveness as 
the reason for disparities in use across countries. In the metastatic setting, trastuzumab was 
found to improve overall survival and progression-free survival in HER2-positive patients 
                                                
11 “HER2 (human epidermal growth factor) is a protein that can affect the growth of some cancer cells. It is 
found on the surface of normal breast cells. Some breast cancer cells have a very high number of HER2 
receptors. The extra HER2 receptors stimulate the cancer cells to divide and grow. When there are higher levels 
of the HER2 protein in a breast cancer, it is called HER2 positive breast cancer.” 
http://www.macmillan.org.uk/cancerinformation/cancertypes/breast/aboutbreastcancer/typesandrelatedcondition
s/her2%20positive.aspx (accessed 15 November 2016) 
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(Balduzzi et al. 2014). The cost-effectiveness of trastuzumab in metastatic patients in Europe 
was found to be mainly an issue of price until the first generic medicines would enter the 
market (Garattini, van de Vooren, and Curto 2015). I also included all follow-on HER-2 
targeted therapies for breast cancer, as they may explain a reduction in utilisation of 
trastuzumab after they enter the market.  
 
This study does not aim and is not designed to judge the quality of cancer care in the selected 
countries. While elements of quality of care like waiting times are explored, this is done in 
the context of understanding differences in utilisation of HER-2 targeted therapies. Further, 
higher utilisation does not necessarily mean better quality care. Quality of cancer care is a 
complex subject which is not determined solely by analysing utilisation of medicines alone. 
 
6.3! Methods 
6.3.1! Literature review 
A comprehensive review of the literature was conducted to identify studies on determinants 
of differences in use of cancer medicines across countries. Some of these determinants are 
also responsible for differences in use of cancer medicines at a subnational level. However, 
the focus of this study is on international differences in per capita utilisation, not on 
subnational or patient level differences, although these contribute to the overall level of 
utilisation at national level.  
 
6.3.2! Development of the framework 
A list of determinants was compiled and used to develop a framework to explore differences 
in use of HER-2 targeted therapies for breast cancer. The framework was built with the 
following logic in mind: there is a population of eligible patients according the EU-wide 
approved indication/s for these medicines. Within in this larger patient population there is a 
smaller group of patients who are eligible for treatment and actually receive it (Figure 10).  
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Figure 10: Treatment population versus eligible population 
 
 
This reality leads to two questions relevant to the utilisation of medicines: 1) what determines 
the size of the eligible treatment population? And 2) what determines access to HER-2 
targeted therapies among eligible patients?  
 
6.3.3! Data sources 
Annual data on utilisation of HER-2 targeted therapies (trastuzumab, lapatinib, pertuzumab, 
trastuzumab emtansine) between 2008 and 2014 were obtained from the relevant public 
authority holding this information in each country. This was the National Institute for Health 
and Disability Insurance (RIZIV-INAMI) in Belgium, the State Medicines Agency in 
Estonia, the Information Services Division (ISD) of NHS Scotland and the eHealth Agency 
(eHälsomyndigheten) in Sweden. Data covered medicines dispensed in both outpatient and 
inpatient settings. Variables included INN, the number of packs, pack size and strength of 
medicines dispensed in the respective countries. Total mg consumed were estimated and 
divided by the defined daily dose (DDD) for the four HER-2 targeted therapies with EU-wide 
marketing authorisation as of December 2014. As there were no DDD by the WHO 
Collaborating Centre for these four medicines, I used the DDD by the German Institute of 
Medical Documentation and Information (trastuzumab: 20 mg for parenteral form, 29 mg for 
parenteral subcutaneous form, trastuzumab emtansine: 12 mg, lapatinib: 1375 mg, 
pertuzumab: 20 mg), (DIMDI 2016). 
 
A number of data sources were used to populate the framework. These include the European 
Cancer Observatory (European Cancer Observatory (EUCAN) 2016); official websites of 
national competent authorities in pricing and reimbursement, national health insurers, 
 
Population*of*eligible*
patients*according*to*
the*approved*
indication/s 
 Treated*patients 
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medicines regulatory authorities and ministries of health (TLV 2016c, INAMI-RIZIV 2015, 
Janusinfo 2016, SMC 2016a, Esti Haigekassa 2016b, Läkemedelsverkets 2016, 
Socialstyrelsen 2016); national health information system websites (ISD 2016b), health 
systems reviews of the European Observatory (Gerkens and Merkur 2010, Lai et al. 2013, 
Anell, Glenngård, and Merkur 2012, Steel and Cylus 2012); peer-reviewed literature (Ferlay 
et al. 2013, Slamon et al. 1987, Burstein 2005), further electronic correspondence with 
competent authorities, national statistic units, and interviews with oncologists in the countries 
studied for information clarification. 
 
Up to two oncologists per country were interviewed (two in Belgium, Estonia, and Scotland; 
one in Sweden) using a semi-structured questionnaire based on the framework developed 
(Appendix 7). The oncologists interviewed were generally from the capital (Brussels, 
Edinburgh, and Tallinn) and another main oncological centre (Glasgow, Gothenburg, Leuven, 
and Tartu). Six of them were senior oncologists (i.e. head of Unit or Department) and one 
was a consultant oncologist; six were male and one was female. Given the difficulties in 
approaching oncologists (e.g. finding contacts and arranging the interviews), interviews were 
organised through contacts in the countries studied who introduced me to the interviewees. 
While I was introduced to three oncologists in Sweden, only one agreed to be interviewed. 
The objective of the interviews was to complement information from the desk review of 
national websites and the literature as well as update and validate some the information 
retrieved. The structure of the interview therefore varied according to the information gaps 
remaining in each country after conducting the desk review. The interviews were kept semi-
structured to enable going deeper into topics worth further investigation. For example, 
additional questions were asked to the oncologist in Sweden about the special fund available 
in one county to fund new hospital medicines. 
 
6.4! Results 
6.4.1! Development of a framework to analyse differences in use of HER-2 targeted 
therapies 
Use of HER-2 targeted therapies is determined by medical need (burden of disease) and a 
range of factors that can affect treatment decisions (Figure 11). The size of the eligible 
treatment population is determined by the incidence of breast cancer overexpressing HER-2. 
Incidence of breast is determined by genetic, demographic and life-style risk-factors (family 
history, age, smoking, physical activity, etc.). For a patient with breast cancer to start 
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treatment, a diagnosis has to be made. The extent to which breast cancer is diagnosed and the 
timing of diagnosis is influenced by the existence and nature of national screening policies 
(e.g. is there a national screening programme? Who is eligible for screening? How frequently 
is screening conducted? What is the actual uptake of screening programmes? Which 
screening method is used?). Referral practices and waiting lists can affect the time needed to 
access a specialist and start treatment. Finally, only breast cancers overexpressing HER-2 
should be treated with the corresponding targeted medicines. Therefore the scope of 
screening for HER-2 overexpression in all new breast cancer patients, the method, and the 
quality of testing can further affect the number of eligible patients. 
 
Patients diagnosed with breast cancer overexpressing HER-2do not automatically obtain a 
HER-2 targeted therapy prescription. A range of factors can influence oncologist’s decisions. 
These include clinical guidelines, patient related factors like age and diagnosis stage, side-
effects, and patient’s response may affect treatment initiation and continuation. The 
reimbursement status of the medicine is another important factor which is in turn determined 
by the assessment method/s (e.g. budget impact analysis, cost-utility analysis), the 
interpretation of the evidence, the price of the medicine and any special pricing arrangements 
offered by the manufacturer (e.g. managed entry and risk-sharing schemes), industrial policy 
considerations, and the role of patient representatives. Additional factors which may 
influence a clinician’s decisions relate to how medicines are financed (e.g. as part of 
diagnostic-related groups, hospital budget, retrospective reimbursement by health insurance, 
availability of earmarked funding or other special arrangements for high-cost medicines, 
whether patients are required to make a co-payment and whether there is a cap on the number 
of patients that can be treated or on total expenditure) and where the medicines are dispensed 
(different prices, co-payments and reimbursement arrangements may apply in hospital vs. 
ambulatory care). Different financial arrangements for medicines in hospitals vs. the 
community may affect where patients are treated and which formulation they are given. For 
example, there may be a disincentive to prescribe an oral cancer medicine to be taken at 
home instead of its intravenous equivalent to be administered in the hospital, if the hospital 
will make a financial loss due to reduced patient volume (per-case based system) (Benjamin 
et al. 2014). To avoid this, some countries have decided that independently of where the 
medicine is administered, some specialised medicine will always be funded by the hospital 
(Groot, Huijgens, and Uyl-de Groot 2006). This is the case for example in Denmark, Norway 
and Sweden. Finally, shortages of medicines can affect their availability for prescription and 
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may result in treatment delays or treatment switching (EAHP 2014). From a macro 
perspective, the extent to which the disease is perceived as a national priority and the budget 
allocation to health will determine the amount of resources available for breast cancer and 
enable or constrain funding allocation for medicines. 
 
Figure 11: Framework to analyse access to HER-2 targeted therapies for breast cancer 
 
 
 
 
 
6.4.2! Utilisation of HER-2 targeted therapies in Europe 
Trastuzumab was the first HER-2 targeted medicine to obtain EU-wide marketing 
authorisation in 2000 and as of December 2014 had 9 indications approved. In 2014, 
utilisation of trastuzumab was highest in Belgium (on average 65 DDD per new case), 
followed by Sweden (on average 57 DDD per new case), Scotland (on average 40 DDD per 
new case) and Estonia (on average 37.5 DDD per new case), (Figure 12). Lapatinib, 
pertuzumab and trastuzumab emtansine were approved in 2007, 2011 and 2012, respectively, 
and as of December 2014 had 3, 1 and 2 indications with EU-wide marketing authorisation, 
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respectively. In 2014, use of lapatinib was highest in Belgium (on average 2.4 DDD per new 
case), followed by Sweden (on average 0.9 DDD per new case), Scotland (on average 0.2 
DDD per new case) and Estonia (on average 0.04 DDD per new case). In Belgium, 
consumption of lapatinib after 2010 was probably displaced by pertuzumab and trastuzumab 
emtansine from 2010 onwards according to one of the interviewees. Lapatinib is now 
specifically used for brain metastasis. In 2014, utilisation of pertuzumab was highest in 
Sweden (on average 3.6 DDD per new case), followed by Belgium (on average 2.6 DDD per 
new case) and Scotland (0.05 DDD per new case), while for trastuzumab emtansine 
utilisation was highest in Sweden (on average 0.8 DDD per new case) followed by Belgium 
(0.2 DDD per new case) and Scotland (on average 0.08 DDD per new case). There was no 
utilisation of pertuzumab and trastuzumab emtansine in Estonia up to December 2014. 
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Figure 12: Utilisation of HER-2 targeted therapies 
 
 
 
 
 
Notes: Belgium (BE), Estonia (EE), Scotland (SCOT), and Sweden (SE). 
 
In all countries, trastuzumab remained dominant in the HER-2 targeted market as of 2014 
(nearly 100% market share in Estonia, 99% in Scotland, 96% Belgium and 91.5% Sweden). 
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Penetration of follow-on HER-2 therapies in 2014 was highest in Sweden (5.7% pertuzumab, 
1.4% lapatinib and 1.4% trastuzumab emtansine) and lowest in Estonia. 
 
6.4.3! Testing of the framework 
6.4.3.1! Incidence of breast cancer over-expressing HER-2 
In 2012, incidence of breast cancer was highest in Scotland (169 per 100,000) followed by 
Belgium (148 per 100,000), Sweden (108 per 100,000) and Estonia (69 per 100,000) (Ferlay 
et al. 2013). The percentage of breast cancer overexpressing HER-2 has been estimated to be 
around 15-30% of primary (node-negative) breast cancer cases depending on the source 
(SMC 2006, EMA 2004, Slamon et al. 1987, Burstein 2005). Indicative estimates during the 
interviews suggested that the percentage of all newly diagnosed breast cancer cases that 
overexpress HER-2 is approximately 15-18% in Belgium (unofficial data), about 15-20% in 
Estonia (unofficial data), and 15% in Greater Glasgow and Clyde (official data), which 
should be representative of the prevalence in Scotland.  
 
6.4.3.2! Diagnosis 
All countries have free national screening policies in place but their coverage differs. Sweden 
covers the widest age group of women from 40 to 74 years old whereas Estonia covers the 
narrowest age group of women from 50 to 62 years old every two years and does only cover 
insured patients (6% estimated uninsured patients (Esti Haigekassa 2016a), unemployed men 
aged 30 to 50 and individuals from households with the lowest expenditure quintile are more 
likely to be uninsured (Vork et al. 2010, Koppel et al. 2008)). Uptake among invited women 
(with health insurance, registered in the population registry, with correct address and no 
previous mammography in past 12 months) was 62% in 2014 (estimated based on (Esti 
Haigekassa 2015)). European guidelines recommend screening women aged 50-69 with 
mammography every two years (Health & Consumer Protection Directorate-General 2006) 
and this is currently practiced in Belgium (50-60 years old with insurance) and Scotland (50-
70 years old) (The Scottish Government 2016). In Belgium, 60% of eligible women were 
screened in 2009-10 (Agence Intermutualiste 2014). Some Belgian regions offer screening 
also to younger women down to age 40, this service is partially reimbursed by health 
insurance (Belgian Health Care Knowledge Centre (KCE) 2014) while the programme for 
women aged 50-69 years old is fully reimbursed. In 2010/11, 74.7% of eligible women had a 
mammography in Scotland (The Scottish Government 2016). Sweden has the most generous 
screening programme covering the widest age range (40 to 74 years old) and mammography 
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every 18-24 months (Socialstyrelsen 2016). Overall, 80% of invited women participate in the 
screening programme but coverage varies between geographical areas (Sveriges Kommuner 
och Landsting 2013). 
 
In all countries studied, all patients diagnosed with breast cancer are tested for HER-2 
overexpression, all cases are discussed during multidisciplinary consultations, and all 
countries have breast cancer units. In Estonia, all metastatic and early breast cancer patients 
have been tested since 2006 (although some hospitals may have started before). In Scotland 
testing of early breast cancer patient started following the positive recommendation by SMC 
in September 2006. Some time was required to reach nationwide coverage, due to more 
remote areas of Scotland. Licensing of trastuzumab for use in metastatic breast cancer 
preceded SMC’s establishment and as such it was not clear when nationwide testing for 
metastatic cancer was reached. In Sweden all patients diagnosed with breast cancer are tested 
for HER-2 overexpression no later than 2007 (for nationwide coverage of all patients early 
and metastatic). According to international guidelines, breast cancer patients are first tested 
with ImmunoHistoChemistry (IHC) to measure the level of HER-2 receptor protein 
expression (on a scale from 0 to 3+). Patients are considered HER-2 positive if the result of 
IHC is 3+. For patients with HER-2 levels 2+, a fluorescence in situ hybridization (FISH) or 
chromogenic in situ hybridization (CISH) is conducted to measure the level of gene HER-
2/neu gene which is responsible for the overproduction of HER protein. A study comparing 
the performance of FISH and CISH differences between the two tests do not affect the 
analytical performance of these genetic assays (Poulsen et al. 2013). The main difference 
between the tests was in the scanning speed (superior in CISH) (Poulsen et al. 2013). In 
Belgium all metastatic patients have been tested since at least 2000 and early breast cancer 
patients since 2004/5 with IHC followed by FISH for patients with 2+ and 3+ , and in several 
centres even for 1+ and 0 cases. This is an important difference in testing practices leading to 
a high number of FISH tests being conducted in Belgium as 3+ patients are not automatically 
classified as HER-2 positive based on IHC results, despite recommendations by the American 
Society of Clinical Oncology (Colpaert and Salgado 2007). The reason for this is that 
treatment with trastuzumab is only reimbursed if the HER-2 gene amplification is proved by 
FISH (Colpaert and Salgado 2007). 
 
In Sweden most suspected cases are detected during regular screening as part of the national 
programme (49% of breast cancers in the population, 64% of breast cancer for women aged 
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40 to 74 years old (Regionala Cancercentrum I Samverkan 2016)). These patients are sent to 
the specialized breast unit (they are located in each larger hospital) where a biopsy is 
performed. If the diagnosis is confirmed the patient is given an appointment with the 
oncologist. A treatment decision is usually made after surgery unless a decision to start with 
neoadjuvant treatment was taken at the meeting prior to the surgery. Long waiting times to 
access cancer care services have been report in Sweden, these affect mainly the time from 
disease suspicion to treatment initiation (Wilkens et al. 2016). Reducing these waiting times 
and standardising care delivered across different regions of Sweden are the aims of the 2015 
national cancer programme in Sweden (Wilkens et al. 2016). In Estonia, patients may be 
diagnosed through the national screening programme, referred for investigation by primary 
care doctors or gynaecologists (including women’s clinics in Tallinn which perform 
mammography outside the national screening programme) or diagnosed within hospital 
breast cancer units in the capital which patients can access without referral. Cancer care is 
concentrated in the North Estonia Medical Centre (Tallinn, capital) and in Tartu University 
Hospital. Tallinn Children’s Hospital and the East Tallinn Central Hospital also provide 
cancer care though in a smaller scale. Waiting times in oncology are shorter than for other 
speciality areas (Esti Haigekassa 2016a). There are national quality guidelines specifying the 
maximum waiting time (e.g. the maximum waiting time from registration to the first visit to 
the specialist should be less than 4 weeks, the same from diagnosis to treatment) and 
generally oncology waiting times are within these limits (Esti Haigekassa 2016a). In 
Belgium, waiting times do not seem to be an issue and patient do not need to see a family 
doctor to be referred to a specialist (Gerkens and Merkur 2010). There are national waiting 
targets for breast cancer, two weeks from diagnosis to treatment decision and two weeks from 
treatment decision to treatment initiation. In Scotland, while official data are not available, a 
large number of patients tend to be diagnosed through national screening, others with 
symptoms are sent by general practitioners. According to one interviewee, HER-2 positive 
patients are mostly referred by general practitioners since these breast cancers are more 
aggressive and more likely to have a palpable lump. Screening on the other hand is more 
likely to detect smaller breast cancer cases which are HER-2 negative. The NHS Scotland has 
set two standards for waiting times in cancer care, the 62 day standard and 31 day standard. 
The first target is that 95% of patients with a suspicion of cancer wait a maximum of 62 days 
from referral to first cancer treatment (ISD 2016a). This was met for 96.9% of all breast 
cancer (all cancer types 89.7%) during the time period 1 April to 20 June 2016 (ISD 2016a). 
The second target is that 95% of all patients should not wait more than 31 days from the time 
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a treatment decision is made to actual treatment start (ISD 2016a). During the time period 1 
April to 20 June 2016, this target was met for 96.9% of all breast cancer patients (all cancer 
types 95.7%) (ISD 2016a). 
 
6.4.3.3! Clinical guidelines 
All countries apart from Estonia have national treatment guidelines in place (Wildiers et al. 
2013, Scottish Intercollegiate Guidelines Network (SIGN) 2013, National Board for Health 
and Welfare 2014). In Belgium and Scotland these are clinical guidelines whereas in Sweden 
they are meant for managerial purposes particularly to guide resource allocation decisions. 
However, they may be used to guide clinical decision too. All six regions of Sweden have 
developed their own adaptation of the national guidelines (e.g. Regional adaptation Southern 
Sweden (Sydsvenska Bröstcancergruppen 2016)). These contain more details in terms of 
clinically relevant information for administering treatment and are expected be in line with 
the national guideline. Regional guidelines are also more often updated than the national 
guideline to reflect introduction of new treatments. The national clinical guidelines contain 
detailed information on early breast cancer and early metastatic breast cancer but are less 
detailed about the treatment of late metastatic breast cancer. As a result, there is more 
variation across the country in the treatment of late metastatic breast cancer while treatment 
of early breast cancer is much more uniform. Estonia follows the National Comprehensive 
Cancer Network (NCCN) and the European Society of Medical Oncology (ESMO) 
guidelines whose implementation is adapted to meet local budgetary requirements. For 
example, in Tallinn there is hospital level consensus practice on when to perform 
examinations, when to administer adjuvant treatment as well as initiation and discontinuation 
criteria for chemotherapy which may differ from NCCN or EMSO guidelines. Tartu has 
developed its own hospital guidelines based on ESMO and NCCN and adapted to the local 
context and budgetary possibilities (e.g. number of therapy regimens). In Belgium hospitals 
also develop their own guidelines based on the national guidelines and reimbursement status 
of medicines. Similar to Sweden, this is done to keep in line with the entry of new medicines 
as national guidelines are updated less frequently. Due to limited international consensus on 
treatment of metastatic breast cancer and the number of possible treatment options available, 
treatment practice varies across the country. Overall, it is common practice to start with the 
most effective therapeutic option available. If there is more than one option, the treatment 
causing fewer side effects is the preferred choice. All treatment decisions take into account 
the patient’s age, any co-morbidities, and patient’s preferences. There are three cancer 
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networks covering different geographical areas of Scotland. Hospitals use their regional 
cancer network guidelines which are based on national and international guidelines and local 
clinical practice.  
 
6.4.3.4! Pricing and reimbursement 
Belgium and Estonia use external reference pricing to inform pricing decisions, while 
Sweden uses value-based pricing. Free pricing applied in the United Kingdom until 2014 
subject to Pharmaceutical Price and Regulation Scheme restrictions including a 40% return 
on capital limit (Department of Health 2008). Figure 13 shows the prices for HER-2 
medicines in the four study countries. These are based on expenditure and volume (DDDs) 
information in Belgium, Estonia, and Sweden. For Scotland, these figures reflect list prices 
from the British National Formulary and as such, not include confidential discounts which 
may be offered by manufactures. Further, both pertuzumab and trastuzumab emtansine were 
part of confidential price agreements in Belgium and Sweden but further confidential 
discounts could potentially be offered to hospitals in all countries. 
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All countries use health technology assessment (HTA) and budget impact analysis to 
determine the reimbursement status of new medicines. There were nine indications of 
trastuzumab with EU-wide approval as of December 2014, four for early breast cancer, four 
for metastatic breast cancer and one for metastatic stomach cancer. Eight were accepted for 
reimbursement in Sweden (in Sweden, these were included in national treatment guidelines 
and widely used), seven in Scotland, five in Belgium and two in Estonia as of December 
2014 (Table 15). There were three indications of lapatinib with EU-wide approval as of 
December 2014. Three were reimbursed in Sweden, two in Belgium and zero in Estonia and 
Scotland as of December 2014. One indication of pertuzumab for metastatic or locally 
recurrent breast cancer had EU-wide approval and was reimbursed only in Belgium and 
Sweden as of December 2014. One indication of trastuzumab emtansine had EU-wide 
approval and was reimbursed only in Belgium and Sweden as of December 2014. 
 
In Scotland, the views of patient representatives were included through the Patient and 
Clinician Engagement (PACE) process during the appraisal of trastuzumab in combination 
with capecitabine or fluorouracil and cisplatin for the treatment of patients with HER2 
positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have 
not received prior anti-cancer treatment for their metastatic disease. This ultra-rare indication 
(SMC uses this term for medicines used to treat conditions with a prevalence of 1 in 50,000, 
or less, or a maximum of 100 people in Scotland (SMC 2016b)) was recommendation for 
restricted use. In contrast pertuzumab and trastuzumab emtansine were not recommended 
even though the views of PACE group were taken into account (SMC 2014a, b). Another 
example of how patient have influenced access to HER-2 targeted therapies in Scotland is the 
case of a Scottish nurse, who, after being denied access through an individual patient request, 
wrote a letter to the Scottish First Minister asking for access to trastuzumab emtansine in 
2016 (BBC 2016). The case was picked up the media and the former nurse was eventually 
granted access. Meanwhile the Government reported to have requested the manufacturer to 
resubmit an application to the SMC at ‘a fair price’ (BBC 2016). The hope is that the new 
price will improve the cost-effectiveness of the medicine to a level that SMC can make a 
positive recommendation for use and enable access to all eligible patients (BBC 2016). 
 
  
147 
 
Table 15: Recommended indications for use based on reimbursement recommendations and clinical practice 
Stage EU-wide approved indications In combination with Reimbursement as of December 2014 
Clinical guidelines / practice 
Trastuzumab (Herceptin®) BE EE SCOT SE BE EE SCOT SE 
early 
following adjuvant chemotherapy with 
doxorubicin and cyclophosphamide paclitaxel or docetaxel 
x √ √ √ x √ √ √ 
following surgery, chemotherapy 
(neoadjuvant or adjuvant) and radiotherapy 
(if applicable) 
- 
x √ √ √ x √ √ √ 
in combination with adjuvant chemotherapy docetaxel and carboplatin 
x √ √ √ x √ √ √ 
in combination followed by adjuvant 
Herceptin therapy, for locally advanced 
(including inflammatory) disease or tumours 
>2 cm in diameter 
neoadjuvant 
chemotherapy 
√ √ √ √ √ √ √ √ 
metastatic 
for the treatment of those patients who have 
received at least two chemotherapy regimens 
including at least an anthracycline and a 
taxane unless patients are unsuitable for 
these treatments. Hormone-receptor-positive 
patients must also have failed hormonal 
therapy, unless patients are unsuitable for 
these treatments; 
- 
√ √ √ √ √ √ √ √ 
in combination for the treatment of those 
patients who have not received 
chemotherapy and for whom an 
anthracycline is not suitable 
paclitaxel 
√ √ √ √ √ √ √ √ 
in combination for the treatment of those 
patients who have not received 
chemotherapy 
docetaxel 
√ √ √ x √ √ √ √ 
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Stage EU-wide approved indications In combination with Reimbursement as of December 2014 
Clinical guidelines / practice 
in combination for the treatment of 
postmenopausal patients with hormone-
receptor-positive metastatic breast cancer, 
not previously treated with trastuzumab 
an aromatase inhibitor 
x x x √ x x x √ 
 
metastatic 
stomach only used in combination 
cisplatin and either 
capecitabine or 
5-fluorouracil (other 
anticancer medicines) 
√ √ x  √ √ √ √ 
lapatinib (Tyverb®) BE EE SCOT SE BE EE SCOT SE 
advanced 
or 
metastatic 
in combination for patients with progression 
following prior therapy, which must have 
included anthracyclines and taxanes and 
therapy with trastuzumab in the metastatic 
setting 
capecitabine 
√ x x √ √ x x √ 
 
metastatic 
in combination for post-menopausal women 
with hormone-receptor-positive metastatic 
disease, not currently intended for 
chemotherapy 
with an aromatase 
inhibitor 
√ x x √ √ x x √ 
in combination for patients with hormone-
receptor-negative metastatic disease that has 
progressed on prior trastuzumab therapy or 
therapies in combination with chemotherapy 
trastuzumab 
x 
(ma
y be 
reim
burs
ed 
in 
very 
spec
ial 
situ
atio
x x √ x 
(ma
y be 
used 
in 
very 
spec
ial 
situ
atio
ns) 
x  x √ 
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Stage EU-wide approved indications In combination with Reimbursement as of December 2014 
Clinical guidelines / practice 
ns) 
pertuzumab (Perjeta®) BE EE SCOT SE BE EE SCOT SE 
metastatic 
or locally 
recurrent 
Only used in combination  trastuzumab and docetaxel (other cancer medicines) 
√ x x √ √ x x √ 
locally 
advanced, 
inflammato
ry, or early 
stage 
Neoadjuvant, only used in combination trastuzumab and chemotherapy 
x x x √ x x x √ 
ado-trastuzumab emtansine (Kadcyla®) BE EE SCOT SE BE EE SCOT SE 
locally 
advanced 
or 
metastatic 
the patient received prior therapy for locally 
advanced or metastatic disease - 
√ x x √ √ x x √ 
the patient developed disease recurrence 
during or within six months of 
completing adjuvant therapy 
- 
√ x x x √ x x √ 
 
Notes: recommended/used (√), not recommended/not routinely used (x); Belgium (BE), Estonia (EE), Scotland (SCOT), and Sweden (SE). In Estonia, no 
negative decisions are made for hospital medicines, either a positive decision is made or no decision at al
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6.4.3.5! Financing 
In Sweden the 21 county councils are responsible for funding medicines used in hospitals. 
The budget for hospitals is set each year. Medicines recommended for use by the NT-council 
(a body representing all the Swedish county councils) are generally funded by the county 
councils which, through the six regions they belong to, are represented in the NT-council. 
After a positive decision by the NT-council, the time new medicines are made available to 
patients differs across county councils. Generally within a maximum of one year the new 
medicine is made available in all counties. So far, the NT-council has released its first 
recommendation for a cancer medicine in 2012, the exact oncology indications recommended 
by the NT-council are funded by the county councils without imposition of additional 
restrictions. In the Västra Götaland region a special budget was set up to fund new cost-
effective medicines for the first two years after they have been introduced (Cancerfonden 
2015). At the end of the two years the hospitals are expected to take over the financing of 
these medicines. By the end of this time period, the new medicine is expected to have either 
replaced another treatment, generated savings on other procedures, reduced its use from when 
it was first introduced due to side effects and/or reduced effectiveness in clinical practice, or 
justified an increase in the hospital budget for medicines. Hospitals in the Västra Götaland 
region can apply twice per year for additional budget although the NT-council releases new 
recommendations more frequently. Options are currently discussed to align funding 
applications with the release of positive NT-council recommendations to avoid delays due to 
financial constraints in introducing new medicines. Before additional funding is made 
available for new medicines, a period of less than six months, if the hospital cannot otherwise 
fund the new medicine it may be necessary to prioritise access to the new cancer medicine for 
patients which, based on clinical criteria, are most likely to benefit from the treatment. In 
Sweden, co-payments only apply to medicines dispensed in the outpatient sector up to a limit 
of SEK 2,200 (approximately EUR 233) per year for all medicines purchased (TLV 2016b). 
Until September 2013, only lapatinib was available in a formulation suitable for community 
use (tablets). As of September 2013, trastuzumab is available as subcutaneous injection. 
Nevertheless, dispensing in the community for subcutaneous trastuzumab was negligible 
between September 2013 and December 2014 (32 DDD community pharmacies vs. 42,928 
DDD hospitals). In Sweden, most cancer medicines are paid by hospitals independently of 
where they are dispensed and administered.  
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In Estonia, Scotland and Sweden, medicines are paid from fixed hospital budgets, while in 
Belgium cancer medicines are retrospectively reimbursed. No co-payments for cancer 
medicines apply in Belgium, Estonia and Scotland. In Estonia, hospitals have annual 
contracts with the Estonian Health Insurance Fund for a certain volume of services to be 
provided, including cancer care. If hospitals overspend, there is negotiation with the 
Insurance Fund who may, depending on budget availability, cover part of the excess spending 
the remaining to be covered by the hospital. A prospective payment with tariffs for different 
types of oncology treatments (e.g. a course of breast cancer chemotherapy) - which also 
specifies the treatment regimens which can be used – is in place in Estonia. There is currently 
a unique tariff for breast cancer chemotherapy. The introduction of two payment tariffs, one 
for HER-2 positive patients and one for HER-negative patients is envisaged for next year to 
reflect their different costs. The current average reimbursement price works well for breast 
cancer chemotherapy, in other areas (e.g. colorectal cancer) it is more challenging to provide 
treatment within existing tariff due to the high cost of biologic medicines in this therapeutic 
area. These tariffs are updated as applications for inclusion of new medicines to the inpatient 
service list are made. However, assessment usually takes several months so there can be a 
delay in updating tariffs to reflect the entry of new medicines. In the interim, hospitals need 
to manage within existing budgets and reallocate savings from one cancer area to another 
where possible. It is not common for hospitals to fund medicines that are not reimbursed by 
the health insurance. That said there is some flexibility to reallocate patients between 
different indications of a reimbursed medicine as long as hospitals stay within the overall 
budget. If a medicine is not reimbursed the only other options for patients access is via 
occasional special early access programmes based on donations from the pharmaceutical 
industry (e.g. there was such programme in place for lapatinib but only covering a limited 
number of patients for a specific timeframe), through the support of a private Estonian 
foundation which covers the cost of non-reimbursed medicines for a limited number of 
patients or by paying out-of-pocket. When dealing with limited financial resources to make 
new medicines available, including trastuzumab, clinicians try, to the extent possible, to 
allocate treatment according medical criteria and the ability to benefit (considering for 
example the age of the patient and existing co-morbidities). These decisions are always taken 
as part of multidisciplinary group meetings.  
 
In Belgium, cancer medicines fall under ‘Category A” of vital medicines together with 
diabetes and HIV/AIDS medicines (INAMI-RIZIV 2016b). As such they are excluded from 
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prospective funding (75% prospective budget and 25% retrospective reimbursement), which 
other hospital medicines are subject to. There are therefore no budget limits on prescribing of 
hospital cancer medicines as long as they are prescribed for reimbursed indications. If a 
medicine is not yet reimbursed patients may access it through compassionate access 
programmes funded by the pharmaceutical industry (until a reimbursement decision is made), 
or, more rarely, due to timelines and uncertainty about the percentage of reimbursement, 
through a public solidarity fund for patients with high medical need (partial funding, the 
patient needs to co-pay). Hospitals do not fund not reimbursed medicines out of their own 
budget. A system of prior-authorisation is in place in Belgium whereby the hospital 
pharmacist has to confirm that the medicine is given for a reimbursed indication. 
 
In Scotland, medicines approved by the SMC are automatically included in the hospital 
formulary for the approved indication/s. If a medicine has not yet received a recommendation 
by the SMC or has received a negative recommendation, the treating oncologist can submit 
an individual patient request for access. A committee within the hospital will then decide 
whether or not to grant access on an individual patient basis. There are no limits to prescribe 
medicines-indications included in the hospital formulary but for individual patient requests 
funding considerations may play a role.  
 
No HER-2 targeted therapies were dispensed in the community in Belgium, Estonia and 
Scotland as of December 2014. While pertuzumab and trastuzumab emtansine require 
intravenous infusion, there are two EMA approved formulations of trastuzumab for 
subcutaneous use (approved 23 June 2013), one of which comes as cartridge, to the other as 
intravenous injection, and lapatinib comes in tables for oral use. There was no use of 
subcutaneous injections in Estonia as of December 2014, use of this formulation started in 
January 2014 in Scotland (hospital only), in 2014 in Belgium and in September 2013 in 
Sweden.  
 
6.4.3.6! Patient 
I did not find any study comparing age and stage at diagnosis across the study countries so I 
relied on statistics produced by each country. As a result, the interval used to monitor time 
trends as well as the metric for staging differs.  Nevertheless, some common trends can be 
observed across countries. All countries experienced a reduction in late stage detection and an 
increase in early stage detection. In Belgium between 2004 and 2013, there was an average 
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annual 0.5% decrease in the number of patients diagnosed at stage IV and a 12.5% decrease 
in the number of unclassified cases (Belgian Cancer Registry 2015). At the same time, the 
number of cancer cases detected at stage I increased by 2.3% on average per annum (Belgian 
Cancer Registry 2015). In Estonia, during the period 1995-1999, 12% of cases were 
diagnosed with distant spread, 8% were unclassified and 34% were localised (Baburin et al. 
2014). In 2005-2007, 8% of newly diagnosed cases showed distant spread, 3% were 
unclassified and 43% were localised (Baburin et al. 2014). In Scotland, during the period the 
2-year period 2011-2012, 6% of patients were diagnosed at stage IV, 5% were unclassified 
and 39% were diagnosed at stage I (ISD 2016b). During the 2-year period 2013-2014, there 
was a small reduction in the percentage of patients diagnosed at stage IV, to 5% of all new 
cases and of the percentage of unclassified cases, 4% (ISD 2016b). There was also a small 
increase in the percentage of patients diagnosed at stage I to 40% of all new diagnosed cases 
(ISD 2016b). Side-effects and treatment response can affect treatment continuation. The 
frequency with which such events occurred in the study countries was not available to me. 
 
6.5! Discussion 
This study tried to shed some light on factors affecting access to cancer medicines in Europe 
using the example of HER-2 targeted therapies for breast cancer in four European countries. 
While focusing on breast cancer, the proposed framework can be easily adapted to other 
therapeutic areas. The study demonstrates that a positive reimbursement decision is a 
necessary but not sufficient condition to ensure equitable access to cancer medicines. The 
following factors were found to be equally important: the ability to identify suspected cases 
early, promptly refer them for diagnosis, and then provide treatment; the way cancer is 
treated and financed.   
 
In particular, this study identified the following key determinants of differences in use of 
HER-2 targeted therapies in Belgium, Estonia, Scotland, and Sweden. These include whether 
a particular medicine-indication is covered by the national health care system, flexibilities in 
prescribing non-reimbursed indications of a medicine for which some other indications are 
reimbursed, financing of medicines at hospital level, availability of alternative access options 
of non-reimbursed medicines, and the ability of the health care system to identify breast 
cancer cases and promptly treat them.  
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Use of trastuzumab beyond progression seems to be the key driver of the variation in 
utilisation observed between Belgium and Sweden at the high end and Estonia and Scotland 
at the low end. The patent for Herceptin® in Europe expired on July 2014 (Derbyshire 2015). 
Yet, no biosimilar medicine has yet appeared on the market in the countries studied. A 
biosimilar is currently marketed by the South Korean biotechnology company Celltrion in 
South Korea  and the company has filed marketing authorisation request to the EMA in 
October 2016 (GaBi 2016). This was preceded by the application of Biocon and partner 
Mylan to the EMA in August 2016 (Taylor 2016). When the first biosimilar medicines of 
trastuzumab will enter the European market, and, if barriers limiting their use are lifted or at 
least reduced (e.g. limitations affecting substitution), there will be competition in a previously 
monopoly market. This will ultimately reduce the price of trastuzumab. This price reduction 
will improve the cost-effectiveness of the medicine and make it more affordable. At the 
moment, what limits the use beyond progression in Estonia and Scotland are financial 
constraints (fixed payment system per case in Estonia which does not cover for continuation 
of treatment beyond progression) and lack of cost-effectiveness in Scotland. As such, it is 
reasonable to expect that in the light of the evidence supporting use of trastuzumab beyond 
progression (Waddell et al. 2011, Von Minckwitz et al. 2009, Stemmler et al. 2005, Bartsch 
et al. 2007, Ménard and on behalf of the Demetra Group 2008), Estonia and Scotland may 
start to use the medicine in this indication following a price decrease for trastuzumab due to 
biosimilars entry. 
 
Screening is an essential component of national cancer strategies and plays an important role 
in reducing the burden of cancer mortality. A meta-analysis of 11 randomised controlled 
trials with 13 years of follow-up estimated a 20% reduction in breast cancer mortality in 
women over 50 years old invited for screening (Marmot et al. 2013). Key factors affecting 
this estimate were participation and rescreening rates (Marmot et al. 2013). Although in 
recent years, the burden of breast cancer in Estonia has transitioned towards the high 
incidence–low mortality type model, overall breast cancer incidence is much lower in Estonia 
than in more affluent European countries and mortality from breast cancer is still relatively 
high, particularly among elderly women (Baburin et al. 2016). While stage and tumour size at 
diagnosis have improved over time, still breast cancer is diagnosed relatively later in Estonia 
(Baburin et al. 2014). Low coverage (only insured women aged 50-62 years old) and uptake 
(62% of invited women) of the national screening programme and limited awareness (public 
campaigns for screening targeting the age group 50-62 years old send them message that it is 
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only this age group who is at risk) are likely to be important contributing factors to low 
incidence rates and late stage at diagnosis. Of course low incidence could also be, in part, 
explained by differences in genetic background, a risk factor for cancer. However, if a 
number of breast cancer patients remain underdiagnosed, Estonian patients could be worst off 
in terms of access despite consumption of trastuzumab per new case in Estonia is very similar 
to Scotland. Hence improving survival in Estonia will need to look beyond, without 
neglecting, access to new cancer medicines and take measures to increase the number of 
breast cancer cases which are diagnosed and focusing on improving early diagnosis. 
 
Currently there are no budgetary limitations of prescribing of cancer medicines in Belgium. 
Things are likely to change in the future as budgetary pressure keeps growing due to entry of 
new and expensive medicines, particularly biologics. A study projected that by 2020, the 
budget for oncology will need to more than double – from 454 million in 2014 to 1.124 
billion in 2020 - to enable access to innovative targeted and immunotherapies (Van Dyck et 
al. 2016). Existing price reductions can only fund 24% of the needed additional budget over 
the next five years calling for urgent measures to address this funding gap (Van Dyck et al. 
2016). Unless measures are taken to generate efficiencies (e.g. disinvestment, greater use of 
generic and biosimilar medicines) and the total budget for oncology medicines is increased 
(Van Dyck et al. 2016), current levels of access may not be guaranteed anymore. However, 
Belgium has already taken a number of steps towards ensuring continued high level of 
access. For example, a payback system is in place since 2006 to promote responsible use of 
medicines and prevent unexpected expenditure due to higher than forecasted volume, 
contracting between the INAMI-RIVIZ and industry to deal with issues of uncertainty around 
therapeutic value and budget impact which ensures reimbursement at the conditions agreed in 
the contract for a period of 1-3 year, and reassessment of clinical evidence and/or budget 
which could lead to a change in the reimbursement modalities after revision. Further, together 
with the Netherlands, Belgium is one of the founding members of Belenuxa, a voluntary 
collaboration between competent authorities in the area of horizon scanning, HTA and 
procurement, including pricing negotiation for new medicines (Ferrario, Kanavos, et al. 
2016a). Sweden is part of a similar voluntary collaboration called the Nordic Pharmaceutical 
Forum. These represent opportunities to work with other countries towards sustaining high 
levels of access, and improving access where needed, to new medicines. In the United 
Kingdom, a newer addition to the 2014 Pharmaceutical Pricing Regulation Scheme (PPRS) - 
a voluntary agreement between the pharmaceutical industry and the Department of Health - 
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was the branded medicines spend cap (sometimes referred to as pay back policy). In 
Scotland, the money paid back from companies via the PPRS is being put into the New 
Medicines Fund (set up in 2013 as the Rare Conditions Medicines Fund) that is helping fund 
treatments for end-of-life and rare conditions. 
 
This study has various limitations. For example, I adjusted utilisation (measured in DDDs) by 
the number of new cases in a particular year. Ideally, I would have wanted to adjust 
utilisation by the number of patients treated but this was not possible due to lack of data. 
Further, due to lack of data on prescribing by indication, I could not account for utilisation of 
trastuzumab for the treatment of stomach cancer. However, this is unlikely to be substantial 
due to the lower incidence of metastatic stomach cancer. Due to lack of data on patient 
diagnosis and prescribing decision, this study could not make any inferences on the 
appropriateness of prescribing. However, this was not the aim of the study, neither to judge 
quality of care. Instead, it aimed to identify possible determinants for variations in use of 
HER-2 targeted therapies. 
 
6.6! Conclusions 
Differences in use of lapatinib, pertuzumab and trastuzumab emtansine are driven by various 
factors including, but not limited to, lack of reimbursement in some countries (Estonia and 
Scotland). Trastuzumab is reimbursed in all countries and all new breast cancer patients are 
tested for HER-2 overexpression and prescribed trastuzumab if the tumour is invasive and 
larger than 1 cm or smaller but with risk factors. Yet, important differences exist in use of 
trastuzumab (DDD per new case) between countries with higher consumption (Belgium and 
Sweden) and countries with lower consumption (Estonia and Scotland). This seems to be 
driven by differences in the use of trastuzumab beyond progression (only used in Belgium 
and Sweden). Estonia has a comparatively low incidence of breast cancer, the least 
comprehensive national breast cancer screening programme and, despite progress, patients 
are diagnosed relatively late. If indeed a number of breast cancer cases are not diagnosed, 
Estonian patients could be worst off in terms of access despite similar levels of usage per 
patient to Scotland. 
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7! Dealing with uncertainty and high prices of new medicines: A 
comparative analysis of the use of managed entry agreements in 
Belgium, England, the Netherlands and Sweden (Paper 4) 
 
7.1! Summary 
Managed entry agreements are a set of instruments used to reduce the impact of uncertainty 
and high prices when introducing new medicines. In this chapter I develop a conceptual 
framework for these agreements and test it by exploring variations in their implementation in 
Belgium, England, the Netherlands and Sweden and over time as well as their governance 
structures. Using publicly available data from health technology assessment bodies and a 
survey I conducted with the European Medicines Information Network, I develop a database 
of agreements implemented between 2003 and 2012. I also conduct a review of governance 
structures for these agreements. In December 2012 there were 133 active MEAs for different 
medicine-indications across the four countries. These corresponded to 110 unique medicine-
indications. Over time there has been a steady growth in the number of agreements 
implemented, with the highest number in the Netherlands in 2012. The number of new 
agreements introduced each year followed a different pattern. In Belgium and England it 
increased over time, while it decreased in the Netherlands and fluctuated in Sweden. Only 19 
(17%) of the unique medicine-indication pairs identified were part of an agreement in two or 
more countries. England uses mainly discounts and free doses to influence prices. The 
Netherlands and Sweden have focused more on addressing uncertainties through coverage 
with evidence development and, in Sweden, on monitoring use and compliance with 
restrictions through registries. Belgium uses a combination of the above. Despite similar 
reasons being cited for managed entry agreements implementation, only in a minority of 
cases have countries implemented an agreement for the same medicine-indication; when they 
do, a different agreement type is often implemented. Differences in governance across 
countries partly explain such variations. However, more research is needed to understand 
whether e.g. risk-perception and/or notion of what constitutes a high price differ between 
these countries.    
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7.2! Introduction 
A combination of high prices of new patented medicines, uncertainties relating to their 
clinical effectiveness and use in real life represent a dilemma for decision-makers and a 
potential barrier to access. These challenges, complemented by patients’ demand for fast 
access to new medicines, have prompted countries to find ways to manage the introduction of 
new medicines and limit the impact of high prices and uncertainty. One way decision-makers 
are trying achieve this, is by implementing a heterogeneous group of instruments known as 
‘managed entry agreements’ (MEAs) (Klemp et al. 2011).  
 
The nature of MEAs can be very different between and within countries; some are 
conditional reimbursement decisions subject to reassessment of the relevant technology. 
Coverage with evidence development (CED) agreements require the manufacturer to provide 
additional data on a medicine’s performance in real-life. This is common requirement of the 
Swedish Dental and Pharmaceutical Benefits Agency (TLV). For ropinirole (a medicine for 
the treatment of moderate to severe idiopathic restless legs syndrome) for example, the 
available data on the long-term effects and side-effects of the medicine when it was first 
assessed were deemed insufficient because of large uncertainty around the cost per QALY. 
The medicine was therefore provisionally listed, on condition that the manufacturer would 
provide an updated economic model with real-life evidence (TLV 2006). The review showed 
that the medicine was not cost-effective at the current price and a small price reduction was 
implemented to keep the medicine on the reimbursement  list (TLV 2012). 
 
Other agreements represent a final coverage decision conditional on the provision of a MEA. 
When bortezomib (a medicine for multiple myeloma) was first assessed by the National 
Institute for Health and Care Excellence (NICE) in England, it was found to be effective but 
not cost-effective  with an estimated incremental cost-effectiveness ratio (ICER) of GBP 
38,000 per quality adjusted life year (QALY)(NICE 2006). The willingness to pay for a 
QALY in England is broadly known to be up to GBP 30,000 unless end-of-life criteria apply. 
Following a reassessment of the medicine and the proposal of a payment by result agreement 
by the manufacturer including treatment interruption if the medicine does not achieve the 
expected response after four treatment cycles and reimbursement for failure, the ICER 
declined to GBP 20,700 and the medicine was recommended for use within the national 
health service (NICE 2007). 
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Agreements are often divided into financial and health-outcome based agreements. The 
previous two examples would fall under the latter group although they both can have 
financial consequences. Purely financial agreements include price-volume agreements 
(PVAs) and dose/time capping schemes. PVAs define a threshold of expenditure after which 
a rebate is triggered and aim to limit budget impact or introduce certainty about a budget not 
being overrun. Capping schemes involve the establishment of either a time or dose cap after 
which the manufacturer pays for any additional doses required. This was the case for 
ranibizumab (for age-related macular degeneration) for which the manufacturer agreed to pay 
for any patients requiring more than 14 doses per affected eye (the scheme has now changed 
into a simple discount scheme following the introduction of a discount-based MEA for the 
diabetic macular oedema indication of ranibizumab) (NICE 2008). 
 
Defining MEAs is often complicated by the use of country-specific terms to define them, the 
context in which they operate and the different views as to what constitutes a MEA. In the 
United Kingdom (UK) they are known as patient access schemes (PAS), Belgium uses the 
term conventions, while they are not known under a specific name in Sweden. In the 
Netherlands they were initially part of funding policies to improve access to expensive 
hospital and orphan medicines (2006-2011) and referred to as ‘conditionally allowed 
specialist medicines’ (CVZ 2012b). Despite their diversity, MEAs have a common 
denominator, namely to facilitate access to new medicines in a context of uncertainty and 
high prices. 
 
The body of evidence on MEA implementation to date is weak. Apart from exploring the 
impact of MEA from a theoretical economic perspective (Gandjour 2009, Zaric and O'Brien 
B 2005, Zaric and Xie 2009, Barros 2011), few studies presenting cross-sectional evidence 
across settings exist (Carlson et al. 2010, Stafinski, McCabe, and Menon 2010, Adamski et al. 
2010, Carbonneil et al. 2009, Ferrario and Kanavos 2013); only one attempts an analysis of 
the therapeutic focus (Ferrario and Kanavos 2013), while another presents longitudinal data 
on MEAs for orphan medicines (Morel et al. 2013). Further, there are very few studies on the 
impact of MEAs (Willis et al. 2010, Pickin et al. 2009, Russo et al. 2010). Finally, there has 
been no published evidence comparing the different approaches used by countries to improve 
access and no comparison of governance structures around MEAs with the aim of explaining 
their implementation patterns.  
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A number of taxonomies have been proposed for their classification and some of them 
include only performance based risk-sharing agreements (Carlson et al. 2010, Casado et al. 
2009, Jaroslawski and Toumi 2011, Garrison et al. 2013, Towse and Garrison 2010, Launois 
and Ethgen 2013, Ferrario and Kanavos 2013), as well as evaluation frameworks (McCabe et 
al. 2010, Garrison et al. 2013, Towse and Garrison 2010). However, there is lack of an 
analytical framework that enables an understanding of how MEAs modulate key decision-
making variables. 
 
The aim of this study is to develop a conceptual framework for MEAs and to test it by 
exploring variations in MEAs implementation across countries and over time as well as their 
governance structures. 
 
7.3! Methods  
7.3.1! Data sources 
Data on the medicine-indication pairs subject to a MEA, the types of MEAs implemented and 
their governance structures (relevant legislation, policies, guidelines and submission 
templates) were sourced from websites of HTA agencies, health insurers and governments 
(NICE 2014b, TLV 2016c, INAMI-RIZIV 2015, Dutch National Health Care Institute 2014). 
Additional material based on primary data collection on MEA was used from a European 
survey of MEAs (Ferrario and Kanavos 2013), supplemented by personal contacts with 
competent health authorities mainly to clarify or complement information retrieved from the 
data sources described. All MEAs reported by countries, from the date the first official MEA 
was implemented in each country, up to December 2012, were included in the analysis.  
 
7.3.2! Study design 
The study countries include Belgium, England, the Netherlands and Sweden. These were 
selected because they implement MEAs, have either a publicly available list of MEAs or 
participated in a recent survey on MEAs (Ferrario and Kanavos 2013), use health technology 
assessment (HTA) to guide their coverage decisions and have publicly available HTA 
reports, reflect a diversity in health system organisational structure (tax-based single 
purchaser systems (NHS) vs. social health insurance systems) and different perspective of 
HTA analysis (health system vs. societal perspective). Countries such as Poland or Italy 
which are well known to implement MEAs could not be included because in the first all 
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agreements are in commercial confidence and in the second because complete up-to-date data 
on all MEAs implemented and HTA reports were not available.  
 
I only included MEAs for medicines with nationwide implementation or, in the case of 
England, MEAs with implementation within the entire devolved administration. For England, 
we included all PAS listed on NICE's website but we did not include information on PAS for 
medicines which had either not been reviewed by NICE or for medicines which had been 
rejected by NICE. Such cases exist (NHS Northern 2013) but may not be implemented across 
the country. For Sweden, in addition to MEAs concluded by the Dental and Pharmaceutical 
Benefit Agency (TLV) at national level, we also included agreements concluded by the New 
Medicinal Therapies group (NLT) at regional level because these have nationwide 
implementation. I did not consider, as some other studies did (Carlson et al. 2010, Carbonneil 
et al. 2009), ‘only in research’ recommendations by NICE to be CED schemes because use of 
medicines with such recommendation is limited to clinical trials.  
 
7.3.3! Analysis 
A database of MEAs in the four study countries was compiled using these data sources. The 
database includes information on: a) medicines involved in a MEA (brand name, 
international non-proprietary name (INN), anatomical therapeutic chemical (ATC) 
classification , therapeutic indication); b) type of MEA (e.g. coverage with evidence 
development, discount, dose/time-capping, payment by result, PVA and registry if linked to a 
specific data collection request by the public counterpart on which reimbursement was 
dependent) based on the European context tailored taxonomy proposed in the EMINet report 
(Ferrario and Kanavos 2013); c) MEA year of introduction of the MEA and expected year of 
completion. These data were used to analyse time trends in the number of MEAs 
implemented over time, the number of new MEAs introduced each year and their therapeutic 
focus. 
 
The development of the conceptual framework started with a review of the different types of 
MEAs implemented and the criteria for reimbursement decisions in the four study countries. 
After identifying the common elements between these two and decomposing the latter in their 
elements (clinical effectiveness, price and use), the mechanism of action of MEAs was 
established. The framework was then applied in the four study countries to explore 
differences in MEAs implementation.  
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The review of governance structures focused on the objectives countries are pursuing by 
introducing MEAs, the process for introducing MEAs and the stakeholders involved. This 
information was then related to the number, types and therapeutic focus of agreements 
implemented in the study countries to explore possible links.  
 
7.4! Results  
7.4.1! Trends in MEA implementation over time 
Among the four study countries, Sweden was the first to introduce MEAs in 2003 followed 
by the Netherlands in 2006, England in 2007 and Belgium in 2010. The number of MEAs has 
grown steadily over time across all countries reaching a peak of 53 active agreements in the 
Netherlands in 2012 (Figure 14). If we look at the number of new agreements introduced 
each year we can observe a different pattern. The number of MEAs introduced in the 
Netherlands has declined between 2008 and 2011, while it has kept increasing in Belgium 
and England between 2010 and 2012. MEA introduction follows a more irregular pattern in 
Sweden where peak years (e.g. 2007 and 2010) are followed by a sharp decline in subsequent 
years.   
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Figure 14: Trends in MEA implementation since the introduction of the first MEA in 
the four study countries 
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Notes: ATC classification: A: Alimentary tract and metabolism; B: Blood and blood forming organs; 
C: Cardiovascular system; D: Dermatologicals; G: Genito urinary system and sex hormones; H: 
Systemic hormonal preparations, excl. sex hormones and insulins; J: Anti-infectives for systemic use; 
L: Antineoplastic and immuno-modulating agents; M: Musculo-skeletal system; N: Nervous system; 
R: Respiratory system; S: Sensory organs; V: Various. Source: WHO Collaborating Centre, Oslo, 
ATC-index 2012. 
 
There is a clear focus on MEAs involving antineoplastic and immunomodulating medicines 
(ATC-L) in England and the Netherlands (89% and 74% of all agreements in 2012 
respectively). In Belgium and Sweden, while this preference is less strong, ATC-L is still the 
therapeutic group with most MEAs in place (35% in Belgium followed by 30% for blood and 
blood forming organs (ATC-B) and 23% in Sweden for each of ATC-L and nervous system 
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(ATC-N)). Countries are also implementing MEAs for orphan medicines (5 in Belgium, 7 in 
England and Wales, 13 in the Netherlands (three of these medicines have lost their orphan 
status by now but were initially included in the policy on orphan medicines) and in 5 
Sweden).  
 
7.4.2! Conceptual framework 
Countries mentioned different reasons to engage in MEAs. These include improving access, 
reducing uncertainty and prices, improving cost-effectiveness and personalising treatment. 
Access can be seen as the ultimate goal while reducing uncertainty and high prices and 
personalising treatment as the means to achieve this. The latter can be ascribed to two main 
policy objectives: improving cost-effectiveness (micro-efficiency) and limiting budget impact 
(macro-efficiency). To achieve these objectives, countries use a variety of MEAs to influence 
a set of target variables (effectiveness, price and use), which, in turn, have an impact on cost-
effectiveness and budget impact (Figure 15). 
 
Figure 15: Conceptual framework for managed entry agreements 
 
Source: The author
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7.4.3! Application of the conceptual framework 
The conceptual framework highlights the various ways the four countries studies have used 
MEAs to influence the three intermediate target variables to improve the two final target 
variables of cost-effectiveness and/or budget impact.  
 
England uses mainly discounts (16) and free doses (7) to influence one single target variable, 
price. The stated goal is to improve cost-effectiveness and access but in practice, modulating 
prices helps at the same time to contain budget impact. In the Netherlands, CED (52 
agreements) is extensively used to modulate effectiveness by generating real-life data on the 
medicine’s effectiveness and use. These data will be used to produce a final cost-
effectiveness estimate at the end of the agreement’s life-time and make a final reimbursement 
decision. As some of these agreements come to an end, one of these medicines has become 
part of a payment by result agreement (as of December 2012) (CVZ 2012a) while others are 
still under evaluation. A limited number of financial pilot arrangements have been concluded 
by the Ministry of Health and CVZ, thus hinting to a potentially new direction for MEAs in 
the Netherlands. Similar to the Netherlands, Sweden has a strong focus on reducing 
uncertainty around cost-effectiveness. This is achieved by implementing CED (20 CED 
agreements), complemented by monitoring use and compliance with restrictions (9 
registries). As a result, some of these agreements also target budget impact although the 
stated aim is only to address uncertainty affecting cost-effectiveness. The 29 agreements just 
described were all concluded at national level by TLV. In 2012, three agreements for cancer 
medicines were brokered by NLT on behalf of the county councils (which then signed 
individual contracts with the manufacturer). Belgium tends to adopt a combination of 
financial and health-outcomes based MEAs to limit budget impact and address uncertainty. 
Different combinations of PVAs, rebates, time cap, CED and registries are employed to target 
price, use and effectiveness and ultimately budget impact and cost-effectiveness.  
Some of the goals stated by countries may differ from the goals obtained by the application of 
the conceptual framework. This is because countries will tend to state their main goal for 
introducing MEAs but not always mention the secondary effects that their action on 
intermediate target variables can have. For example, the rationale for introducing MEAs in 
England is to improve a medicine’s cost-effectiveness and therefore enable patients to access 
new medicines (UK Department of Health and ABPI 2008). To achieve this, they mostly 
introduce discounts, which improve a medicine’s cost-effectiveness (i.e. the ICER) bringing 
it to a value which is within NICE’s willingness to pay threshold. However, introducing a 
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discount will also lead to lower expenditure in comparison to the full price originally asked 
by the manufacturer. So although not stated in national policy documents, this is an additional 
impact of introducing discounts. 
 
7.4.4! Differences in the ways countries engage in MEAs for the same medicine 
As of December 2012 we identified 133 active MEAs for different medicine-indications 
across the four countries (Figure 16). These corresponded to 110 unique medicine-
indications. Nineteen of these were part of a MEA in two countries, two in three countries 
and one in all four countries. Reflecting the higher number of agreements for ATC-L in the 
sample, twelve of the common agreements were for ATC-L, three for ATC-B, one for ATC-
R and another for ATC-S. However, not all the 110 medicine-indication pairs identified as 
part of a MEA in at least one of the four countries underwent HTA in all four countries. If we 
exclude the seventy-four medicine-indication pairs which did not undergo national HTA in 
one or more country, the remaining 36 medicine-indication pairs, which were assessed in all 
four countries, were part of a MEA in one (n=24), two (n=10), three (n=1) and four (n=1) 
countries.   
 
Figure 16: MEAs for the same medicine-indication across the four study countries 
 
Source: The author
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7.4.5! Governance of MEAs and process 
The rationale for introducing MEAs features common objectives in the four study countries 
(Table 16). These include improving access, addressing uncertainty and in some cases 
improving cost-effectiveness (England) or reducing prices and personalising treatment 
(county councils in Sweden). In the following tables (Table 16, Table 17), some of the key 
governance features of MEAs as implemented in the study countries will be reviewed.  
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Table 16: Objectives pursued by introducing MEAs and legal basis of policy 
 
 Objectives Legal or policy basis 
Belgium o! Address unmet medical need  
o! Provide patient access to 
promising new medicines  
o! To provide manufacturer with an 
additional option to access the 
market  
o! Manage risk and uncertainties  
o! Limit budget impact 
o! Law on compulsory health 
insurance (Royaume de Belgique 
21 décembre 2001) and the Royal 
Decree (RD) (14 juillet 1994). 
England o! Improve cost-effectiveness 
o! Facilitate patient access to 
medicines 
o! The 2009 Pharmaceutical Price 
Regulation Scheme (PPRS) (UK 
Department of Health and ABPI 
2008) 
Netherlands 2006-2011 (expensive hospital  and 
orphan medicine policy1) 
o! Improve access to expensive 
hospital and orphan medicines   
o! Reduce inequalities 
2012-2013 (add-ons policy2) 
o! Prevent geographical 
inequalities in availability of 
DRGs3 reimbursed medicines 
between different hospitals  
2014 onwards 
o! Ensure fast access by assessing 
only medicines with budget 
impact greater than EUR 2.5 
million per year 
2006-2011 
o! Expensive medicines and orphan 
medicines provided the policy 
framework for introducing CED 
schemes (Nederlandse 
Zorgautoriteit) 
2012-2013 
o! Add-ons policy (Nederlandse 
Zorgautoriteit 2012)  
2014 onwards 
o! As of December 2013, a new 
policy specialist medicines is in 
place (Dupree and Pasman 2013). 
Sweden TLV 
o! Alleviate uncertainties regarding 
cost-effectiveness at the point of 
decision  
Country councils 
o! Reduce costs  
o! Ensure that treatment is targeted 
to patients who are most likely 
to respond to a new medicine 
o! In Sweden there is no specific 
policy or framework for MEAs, 
however, the possibility of 
granting reimbursement subject 
to special reimbursement 
conditions is described in very 
generic terms in the Swedish 
reimbursement system (TLV 
2013). 
 
Notes: 1As part of this policy hospitals received additional funding to cover for 80% and 100% of the 
cost of expensive hospital and orphan medicines (included in the policy) from the Dutch Healthcare 
Authority (NZa) respectively. 2As part of this new interim policy hospitals receive extra funding (add-
on) for medicines costing more than EUR 10,000 per patient per year). 3Diagnostic-related groups 
(DRGs) 
Source: The author based on EMINet survey and personal contacts with competent health authorities 
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Table 17: The process of implementing MEAs 
 
 Rational for introducing a 
MEA 
 
Who can propose 
 
Who takes the final 
decision on whether to 
approve or reject a 
proposed MEA 
Belgium Negative reimbursement 
decision by the commission 
for reimbursement of 
medicines (CRM) or no 
decision by the CRM due to 
lack of 2/3 majority 
The CRM or 
manufacturer 
 
Minister of Social 
Affairs and Public Health 
provided the Minister of 
Budget approves the 
MEA 
England The drug is not cost-effective 
at the current price 
Only the manufacturer The Department of 
Health 
Netherlands Prior 2012: Expensive 
hospital and orphan drugs 
were eligible for additional 
funding (80% and 100% 
respectively) 
Organisations entitled to 
submit a medicine for 
inclusion in one of these 
two policies could send 
a request to the 
Supervisory Boards for 
Healthcare Insurance 
(CTZ) and the 
Healthcare Authority 
(ZAio) 
The Pharmaceutical 
Assistance Commission 
(CFH) within the CVZ 
reviews the medicine and 
makes a recommendation 
for inclusion to the CVZ 
who advises the 
CTG/ZAio. 
Sweden A MEA can be introduced as 
part of a conditional 
reimbursement decision by 
TLV (CED or registry only) 
or by the NLT (both financial 
and health-outcome based) 
TLV/NLT and the 
manufacturer can 
propose a MEA (though 
at TLV level is it 
generally requested by 
TLV) 
TLV or the NLT 
Source: The author based on EMINet survey and personal contacts with competent health authorities 
 
An important difference in the way MEAs are implemented in different countries relates to 
the type of decision and whether it is transitory and, therefore, subject to re-evaluation or 
permanent, and therefore lasts throughout the period during which a medicine is 
recommended. In Belgium, the Netherlands (CED) and in Sweden (for MEAs concluded by 
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TLV), MEAs lead to a temporarily decision to reimburse and the inclusion of a medicine in 
the reimbursement list is subject to re-evaluation at the end of the agreement’s lifetime. This 
means that if the medicine does not achieve the expected endpoints on e.g. effectiveness, 
reimbursement could be potentially withdrawn. In England and Sweden (for MEAs 
concluded by the county councils), MEAs are not linked to a conditional reimbursement 
decision but are still subject to reassessment as part of the regular re-evaluations conducted 
by NICE or the county councils.    
 
7.4.6! Do governance elements help explain variations in MEA uptake across countries? 
In England there is an explicit focus on improving cost-effectiveness more than addressing 
uncertainty. This is reflected by the instruments used, predominantly discounts and free doses 
rather than CED. Belgium mentions limiting budget impact complemented by addressing 
uncertainty as their main objectives. In an attempt to achieve that, PVAs, rebates and time 
cap schemes together with CED are implemented. Improving access to expensive hospital 
and orphan medicines and reducing geographical inequalities in access to these medicines is 
the main objective in the Netherlands. This was mainly achieved by the additional funding 
provided as part of the policies on expensive hospital and orphan medicines rather than on the 
use of CED. However, CED agreements are introduced for medicines with an initial added 
therapeutic value but an uncertain ICER, which explains the use of CED. In the case of 
Sweden, the objective of TLV to alleviate uncertainties around cost-effectiveness is clearly 
reflected in the use of CED and registries (it is worth noting that in Sweden registries are 
often the enabling factor to implement a MEA, i.e. they were already in place before a MEA 
was introduced). The use of discounts and registries for agreements concluded by the county 
councils is also reflected in the objectives the latter are pursuing. 
 
It is difficult to make any links between the rationale of introducing MEAs and the number of 
existing and new MEAs and the therapeutic focus as the objectives are rather generic and 
difficult to translate into expected numbers or therapeutic preferences. However, at least in 
the Netherlands, the objective of reducing inequalities in access to high-cost and orphan 
medicines made all such medicines eligible for inclusion in the related funding policies. To 
be included in these policies and receive extra-funding, a medicine had to be subject to 
outcome research (CED) thus explaining the large number of CED implemented in the 
Netherlands. Regarding the types of MEAs and their therapeutic focus, they seem more likely 
to be linked with the rationale for introducing MEAs and the types of MEAs foreseen in the 
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law and policies on MEAs in the respective countries, rather than on the process for 
introducing MEAs. 
 
7.5! Discussion  
The conceptual framework for MEAs we developed enabled us to highlight differences in the 
types of MEAs implemented in four European countries. Our comparison of medicine-
indication revealed that only in a minority of cases two or more countries engaged in a MEA 
for the same medicine- indication. When comparing the MEA used for the same medicine-
indication, only 10 agreements used at least one common MEA across the two or more 
countries. Our findings are supported by a study on orphan medicines which found that only 
nine of the twenty-six orphan medicines part of MEA in either Belgium, England and Wales, 
Italy, the Netherlands or Sweden were part of a MEA in more than two countries (Morel et al. 
2013). 
 
A number of conclusions can be drawn from this analysis. First, while the total number of 
MEAs implemented in each country has increased over time, the number of new agreements 
introduced each year has followed a different trend in some countries. Further, we showed 
how in some countries there is a strong focus on introducing MEAs for antineoplastic and 
immunomodulating medicines. Second, whereas countries have similar objectives when 
introducing MEAs, only in a minority of cases are MEAs introduced for the same medicine-
indication; and even when this is the case, different MEA types are used. Third, there is 
generally no clear link between governance around MEAs and the number, types and 
therapeutic focus of the agreements implemented. 
 
The first finding raises questions about the drivers behind these trends in MEA 
implementation. Policy changes are unlikely to have played a role. There were no policy 
changes in Sweden which could have impacted MEA introduction over the time period 
studied. In England there were two events of relevance. The first was the release in 2009 of a 
report on the uptake of PAS highlighting the burden on front line health workers in 
administering these schemes (Williamson 2009). This led to changes in the types of schemes 
implemented from ex-post rebates to ex-ante price discounts and avoidance of schemes which 
require performance monitoring. The second was the creation of the Cancer Drugs Fund in 
2010 which could have potentially led to a greater propensity not to recommend a medicine if 
uncertainty was high (since access could still be granted on an individual basis provided the 
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medicine-indication was to be included in the Cancer Drugs Fund). The policy on expensive 
hospital and orphan medicines in the Netherlands came to an end in 2011, yet the decline in 
the number of new MEAs introduced each year commenced after 2008.  
 
In terms of therapeutic focus, the largest proportion of MEAs across all countries is on 
antineoplastic and immunomodulating products (ATC-L). In Sweden this percentage was 
only 23% in 2012 which is probably explained by the fact that most of the MEAs currently 
implemented until 2012 had been concluded at national level by TLV (which makes 
decisions only for outpatient medicines). However, since the introduction of a national review 
process for inpatient medicines led by the NLT, three MEAs have been concluded for cancer 
medicines (out of a total of 9 medicines reviewed between 2010 and 2012) foreshadowing a 
possible new trend.  Another important factor in determining numbers and therapeutic groups 
is the scope of the MEA policy. This is evident in the Netherlands where the highest number 
of agreements was observed. To obtain additional funding as part of the Dutch policies on 
expensive hospital and orphan medicines, manufacturers had to engage in CED. This 
provided an incentive to manufacturers of expensive hospital products (often belonging to 
ATC-L group) and orphan medicines, to engage in CED to be included in these policies. In 
Belgium the focus on ATC-L and ATC-B seems also to be linked with the scope of MEAs, 
which includes only class I medicines (innovative medicines) for which the manufacturer has 
claimed an added therapeutic value. 
 
The second finding raises questions as to why significant differences arise across countries 
for the same medicine. Even acknowledging that different types of MEAs can be used to 
achieve either better cost-effectiveness or limiting budget impact, this does not explain why 
they so often implement MEAs for different medicine-indications. Common medicines, 
assessed by all countries, for MEAs included antineoplastic agents (cabazitaxel, bortezomib, 
pazopanib, ipilimumab), immunosuppressants (tocilizumab), antithrombotic agents 
(dabigatran and rivaroxaban), endocrine therapies (abiraterone), immunostimulants 
(mifamurtide), antihaemorrhagics (romiplostim), antiasthmatics (omalizumab) and 
ophthalmologics (ranibizumab). More similarities would have been likely to arise if more 
countries were included. While complete information on MEAs implemented in France is not 
available, the French Transparency Commission has asked for postlaunch studies to verify 
whether the medicine performance in real-life in the light of a potential future rebate if this 
was lower than expected for risperidone (schizophrenia), dipeptidyl peptidase-4 (DPP4) 
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inhibitors and glitazones (diabetes) (Garrison et al. 2013). DPP4 inhibitors and risperidone 
were also part of CED Sweden and DDP4 of monitoring registries in Italy (Siviero 2014, 
Arnberg 2014).  
 
MEAs are not the only instrument to facilitate access to new high cost medicines and this 
may help explaining some of the identified differences in MEA engagement across countries. 
In England, the Cancer Drug Fund provides Government funding for medicines which have 
either not yet been reviewed by NICE or have received a negative recommendation.  Belgium 
also has a special fund to reimburse medicines for rare conditions which would otherwise not 
be reimbursed (INAMI-RIZIV 2016a). The English Cancer Drugs Fund provides a list of 
medicines and indications for which clinicians can apply on behalf of their patient. Between 
April 2013 and March 2014, 21% of all notifications were for non-approved or not reviewed 
indications of bevacizumab, 16% abiraterone (1st line use, 2nd line is recommended as part of 
a PAS), 8% bendamustine, 8% for cetuximab (1st line treatment of head and neck cancer, the 
colorectal cancer indication is part of a PAS) and 5% for everolismus (NHS England 2014). 
So while in England these medicines-indications were made accessible through the Cancer 
Drugs Fund, in the Netherlands different indications of bevacizumab and cetuximab are part 
of CED schemes. 
 
Another way to make medicines available which would not be normally considered as cost-
effective is through end-of-life criteria. NICE has specific end-of-life guidance (NICE 2009) 
and if a medicine is considered eligible to be reviewed under these criteria, higher cost per 
QALY than the usual willingness to pay threshold would prescribe may be accepted. One 
example is vemurafenib which was accepted and an ICER between GBP 44, 000- 51,800 
(after the application of a confidential discount through PAS) under end-of-life criteria (NICE 
2012). If one country applied end-of-life criteria for a medicine while another opts for a 
MEA, this may also be a reason for the differences identified. However, at least in the case of 
vemurafenib in England, end-of-life criteria were applied in conjunction with a PAS.  
The third finding suggests that the regulatory frameworks around MEAs may partly explain 
variations in therapeutic focus and overall numbers, but there must be other factors 
influencing their existence and implementation. One such factor is definitely the time since 
the first MEA was introduced as indicated by the catch-up effect in (Figure 14). Whether only 
one party (either the manufacturer or the competent health authority and which authority) is 
able to propose a MEA could potentially have an impact on the number of MEAs in place. 
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However, the process of developing a MEA and the benefits for the parties involved are 
likely to play a more important role. In the Netherlands for example, the manufacturer had a 
strong incentive to engage in CED to obtain additional funding as part of the 2006-2011 
expensive hospital or orphan medicine policy. 
 
Depending on the stakeholders involved and their roles, the process of introducing a MEA 
varies substantially across countries. In Belgium, the Netherlands and Sweden for example, 
the introduction of MEAs is a more reactive process. This can only be initiated after the 
initial assessment as a result of uncertainty or high prices. In England, in addition to the 
reactive approach, PAS can also be proposed proactively by manufacturers when they make 
their first submission to NICE. They can also be proposed at the end of the appraisal process 
although the current trend seems to be for manufacturers to propose them in a proactive way. 
This is likely due to the fact that NICE decisions are to a certain extent predictable (the 
willingness to pay threshold is well known to the applicant), meaning that the manufacturer is 
in a position of judging whether its submission is likely to be successful or not given the cost-
effectiveness ratio. The applicant can therefore decide to proactively propose a PAS, which 
will bring the ICER to a level considered acceptable by NICE, with the obvious advantage of 
introducing the medicine more quickly into the market than if they had opted for a more 
reactive approach.  
 
The analysis on the links between governance elements and engagement in MEAs was only 
of explorative nature given the limited sample size. Despite this limitation, it did permit us to 
highlight important features of MEAs across the four study countries, such as the similarities 
of their objectives and conversely, the diversity in the ways countries employ MEAs. This 
analysis did not include MEAs implemented in only one or a few regions due to the lack of 
data on most of these agreements. Nevertheless, the analysis did include all MEAs (according 
to definition presented in the methods section) with nationwide application and which are 
linked to a HTA.  
 
One issue related to MEA which has not received much attention to-date is the impact of 
price confidentiality on priority setting and the development of clinical guidelines. In 
countries such as the UK, where priority setting as part of clinical guidelines is based on the 
ICER and, while discounts are confidential, the published ICER does incorporate the 
confidential discount, this does not distort priority setting. However, if these decisions are 
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based on an ICER which does not incorporate the discount given on the list price, this can 
have a distortionary effect. Further, even in countries where the ICER does incorporate the 
confidential discount, the problem remains for comparator medicines as the competitor 
manufacturer does not officially know the amount of the discount and can only submit a best 
estimate (usually including some sensitivity analysis with different prices) of the ICER of the 
new medicine.  A survey among policy makers in Canada highlighted the various potential 
threats in countries in which MEAs are negotiated at subnational level and rebates are 
confidential (Morgan et al. 2013b) . These include inequities in medicines pricing and 
coverage across regions and, where pharmaceutical coverage is not universal, the issue of 
uninsured or underinsured patients not being able to benefit of the lower price negotiated by 
the health insurance plan (Morgan et al. 2013b). Similarly, price confidentiality means it is 
not possible to assess the impact of financial agreements on price and budget impact as 
highlighted for the case of post-launch studies in France (Garrison et al. 2013). This issue of 
price confidentiality is part of broader debate on implementing differential pricing to 
facilitate access to new high cost medicines in less wealthy countries. Opinions on how this 
should be best achieved, particularly on the need, strongly advocated by industry, for price 
confidentiality are currently divided (Kalo, Annemans, and Garrison 2013, Ridley 2005, 
EFPIA 2014, Danzon, Towse, and Mestre-Ferrandiz 2015). 
 
Finally, another issue is the use of different pricing and/or reimbursement arrangements for 
different indications of the same medicine. In England and Scotland there has been an 
attempt to minimise this problem by requiring manufacturers offering a simple discount for a 
particular indication, to apply the same pricing conditions to all current and future indications 
of that particular medicine. This applies, irrespective of whether these other indications are 
recommended or not by NICE or SMC, including NICE not recommended indications 
available through the CDF, as long as the medicine is purchased by the NHS. Different 
approaches across indications may arise for medicines with PAS other than simple discounts 
which are a minority. For example, bortezomib for multiple myeloma in patients at first 
relapse is part of a response scheme in England. However, other indications are not part of 
scheme and only available through the Cancer Drugs Fund (e.g. treatment of 
relapsed/refractory mantle cell lymphoma, treatment of naïve relapsed multiple myeloma and 
treatment of Waldenstrom’s Macroglobulinaemia).  
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7.6! Conclusion 
This chapter has shed light on patterns in MEAs implementation across countries and 
identified some factors which may explain the identified variations using a new conceptual 
framework. I find that despite citing similar reasons for using MEAs, countries employ 
MEAs for the same medicines in a minority of cases, and even in such cases countries often 
implement different MEAs. This raises questions as to the reasons for such variations. My 
analysis showed that health system specific features relating to governance (the scope of the 
MEA policy and the mandate of the agency assessing medicines) explain some of the 
identified variations. However, more research is needed to understand whether for example, 
different weight assigned to uncertainty, difference willingness to pay and/or the relative 
importance of cost-effectiveness vs. budget impact could play a role. As countries worldwide 
are dealing with the same issue and increasingly look at MEA to manage the introduction of 
new and expensive medicines, there is definitely scope for sharing lessons.   
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8! The role of strategic procurement in increasing access to cancer 
medicines (Paper 5) 
8.1! Summary 
Strategic procurement encompasses all activities aimed at increasing the efficiency of 
procurement. The aim of this chapter is to identify  procurement practices that can improve 
availability of affordable cancer medicines for patients. I conducted a comprehensive 
literature review on the impact of pharmaceutical procurement on price, volume, expenditure, 
stock-outs, and quality use of medicines using the PICOST framework. I identified a number 
of good practices which, if more widely applied to cancer medicines, could lead to better 
procurement outcomes. These include preparing the market for entry of new on-patent 
medicines, leveraging on horizon scanning to inform pricing negotiations with the 
pharmaceutical industry, implementing procurement practices and policies to enhance or 
create competition (in the case of originator markets), promoting rapid entry and uptake of 
generic and biosimilar medicines, and using therapeutic equivalence based formularies to 
inform prescribing and procurement decisions. Several challenges remain to be addressed to 
be able to reap the full potential of strategic procurement, most importantly greater 
implementation of procurement practices which have shown to deliver good procurement 
outcomes. 
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8.2! Introduction 
High prices of new medicines have long been a worry for the public, payers and policy 
makers (Leopold, Chambers, and Wagner 2016) but in recent years these concerns have 
escalated due to the release of a number of medicines which are unaffordable to treat patients 
in low-income as well as high-income countries (Iyengar, Tay-Teo, et al. 2016b). While the 
international and national debates have focused on pricing and reimbursement methods, less 
attention has been given to how different models of strategic procurement can contribute to 
lower prices for medicines, reaching more patients, sustainable supply and quality of care. 
Strategic procurement encompasses all efforts to increase the efficiency of procurement by 
for example reducing the number of repetitive orders, generating economies of scale, etc. 
(WHO 2000).  
 
In this Chapter, I review the literature on the impact of different procurement methods on 
price, availability and responsible use of medicines in high-income countries. I use this 
information to identify lessons learned which could be applicable to the procurement of 
cancer medicines.  
 
An affordable price (affordable according to the definition of affordability as the “ability to 
purchase a necessary quantity of a product or level of a service without suffering undue 
financial hardship” (Kessides et al. 2009)) is a mean towards an end which is access to 
medicines to improve patients’ health outcomes and quality of life. If affordably priced 
medicines cannot be used due to regulations against substitutions (e.g. biosimilar medicines) 
or because products are not available (e.g. shortages), having an affordable price is not 
achieving its purpose. In this Chapter I will therefore look beyond prices and the procurement 
life-cycle to identify factors which, through procurement, affect the availability of affordable 
medicines for patients. 
 
8.3! Methods 
Using the PICOST framework presented in Chapter 3 (Table 8), I conducted a comprehensive 
literature review on the impact of different pharmaceutical procurement methods on the 
following procurement outcomes: price, volume, expenditure, stock-outs and quality use of 
medicines. I searched the following search engines: PubMed, Web of Science, and Google 
Scholar. Relevant peer-reviewed and grey literatures were included. This was complemented 
by information on relevant examples from a survey conducted by the World Health 
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Organization (WHO) Regional Office for Europe in 2016 (Ferrario, Kanavos, et al. 2016a) 
and personal contacts with representatives of competent authorities in pricing and 
reimbursement or procurement who participated to one of the following consultations 
organised by WHO (the consultation on strategic procurement of medicines in Copenhagen 
on 22-24 September 2016 or consultation on fair pricing 22-24 November 2016 in Geneva). 
 
The following keywords were used for the literature review: (tender OR tendering OR 
procurement OR “preference policy” OR "rebate contracts" OR rabattvertäge OR 
rabattvertraege OR negotiation OR "reverse auction") AND (pharmaceuticals OR drugs OR 
medicines) AND (price OR prices OR expenditure OR availability OR “sustainable supply” 
OR “stock-outs” OR shortage OR “quality use” OR “rational use” OR “quality of care” OR 
“appropriateness of care”). The literature review included papers published between January 
2000 and September 2016 published in English, German, Italian or French. 
 
Inclusion criteria are presented in the PICOST framework, studies not meeting these 
inclusion criteria (e.g. focus on low- and middle-income countries) were excluded. Although 
the aim of this paper is to provide recommendations to improve procurement of cancer 
medicines, the scope of the literature review was not limited to cancer medicines. 
 
8.4! Results 
I retrieved 1190 papers and reports across three databases (PubMed, Web of Science and 
Google Scholar). 341 were excluded because duplicates. Following title and abstract 
screening to exclude papers that did not meet the inclusion criteria outlined in the PICOST 
framework, another 820 articles were excluded. A total of 29 papers were selected for 
inclusion. Follow-up of references let to the inclusion of another 8 papers. The final number 
of articles and reports included was 37 (Figure 17). 
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Figure 17: Prisma diagram 
        
 
            
         
A variety of procurement methods are used worldwide. These can be summarised into three 
main groups: competitive tenders (open or restricted), negotiation (competitive and non-
competitive) and direct purchasing. In the following subchapters I will describe these 
different experiences with the aim of highlighting lessons learned which could be applicable 
in other settings. As I did not find any examples of direct purchasing, I will focus on the first 
two by providing a short description of studies reviewed and their main conclusions. 
 
8.4.1! Competitive tenders 
Economic theory suggests that creating economies of scale can bring prices of products 
down. The application of this principle in the pharmaceutical sector is confirmed by a number 
of studies on the impact of pulling volume across health facilities and/or administrative areas 
(Baldi and Vannoni 2015, Castellblanch 2003, Tordoff, Norris, and Reith 2005, Vogler et al. 
2013). Many variations of centralised (at national or subnational level) have been 
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implemented with positive results. When trying to identify success factors, one should 
consider the specific features of these centralised tendering systems. Further, it is important 
to notice that in most of the cases when centralised tendering was introduced, this was done 
as part of broader set of reforms than just pulling volume. Analysing country’s experiences 
with centralised or joint tenders in the context of these broader changes is essential to 
understand any positive as well as negative outcomes. 
 
8.4.1.1! Centralised tenders in the hospital sector 
The requirement for all hospitals and health programmes in Chile to use the national 
electronic platform for procurement resulted in direct savings of 8.3% for medicines 
procurement and indirect saving of 2.8% through greater aggregation and 0.4% through better 
rules (Raventós and Zolezzi 2015). 
 
Cyprus uses tendering in the inpatient and outpatient sectors covering both branded and 
generic medicines (Petrou and Talias 2014).  An evaluation of the savings generated in 2011 
for 178 products in comparison to pharmacy purchasing prices found an overall 60.6% 
reduction in expenditure. Reduction in expenditure was greatest for generics (94.8% 
reduction in comparison to pharmacy purchasing prices). Savings achieved for branded 
products were 33.4% of the equivalent volume purchased at pharmacy purchasing prices. 
These findings were confirmed by a long-term study on price reduction of branded medicines 
in Cyprus (Petrou 2016). 
 
In 2008 the national Health Procurement Committee was re-established in Greece. It is 
responsible to formulate a plan to reduce procurement costs, shorten payment time, make 
uniform medical requests, transfer redundant materials from one hospital to another and 
improve management of expired products and the introduction of e-procurement (Kastanioti 
et al. 2013). The work of the national Committee resulted in 80% savings on 4 active 
ingredient purchased on behalf of three hospitals and 57% savings on 23 active ingredient 
purchased on behalf of all Greek hospitals in 2011 (Kastanioti et al. 2013). 
 
In Denmark two initiatives have been key for the good procurement outcomes in the hospital 
sector: a centralised procurement organisation, Amgros, conducting procurement for all 
Danish hospitals and the Danish Council for the Use of Expensive Hospital Medicines. The 
latter assesses the cost-effectiveness of these medicines and provides guidance in the 
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selection process by Amgros and clinicians (Bartels 2016). Through these two process, 314 
million euro savings were achieved in 2015 (Bartels 2016).  
 
Both Denmark and Norway conduct tenders are therapeutic class level. In Norway, for 
specialised medicines tenders are conducted at condition level (e.g. rheumatoid arthritis, 
psoriasis, Crohn’s disease, melanoma, prostate cancer, hepatitis C). All tender offers for 
specialised medicines are accepted since all medicines will be used (on-patent sector), the 
volume consumed of each medicine will depend on the recommendations by the national 
procurement body LIS. There is high compliance with LIS recommendations among 
clinicians which is why manufacturers are willing to provide discounts to obtain a better 
position in LIS guidelines (i.e. to achieve a higher sales volume). 
 
In Norway switching to biosimilar infliximab enabled to increase the number of patients 
treated and even generated savings on total spending on this medicine. Very positive results 
were also achieved in Denmark where by the end of 2015, the biosimilar version of 
infliximab, had 99% market share, generating 2.6 million Euros (DKK 20 millions) savings 
(Amgros 2016a). In both countries, information was key to overcome initial scepticism 
among doctors and patients. In Denmark, information leaflets were developed and distributed 
to doctors and patients early in the process, further, the Danish Council for the Use of 
Expensive Hospital Medicines recommended switching new and existing patients to the 
biosimilar (Amgros 2016a). In Norway, an annual conference on anti-TNF alpha is organized 
every year since 2007. This conference is well attended by specialists and offered an 
opportunity to familiarize doctors early on with biosimilar medicines and discuss any 
concerns. Most importantly, the NOR-SWITCH study confirmed the safety of switching 
patients from the reference biologic to its currently marketed biosimilars (Moe 2016).Savings 
generated in other health system areas should be taken into account when conducting 
procurement as well as quality of care.  
 
Greater price reductions in Italian regions with higher levels of corruption or lower levels of 
institutional quality suggesting  that centralisation contributes to reduce favouritism and 
corruption leading to higher prices (Baldi and Vannoni 2015),. 
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8.4.1.2! Tender like system in the ambulatory sector 
The examples above mostly focused on hospital procurement. Some countries are applying 
tendering-like procedures in the outpatient sector. These include for example Cyprus, 
Denmark, Germany, Malta, the Netherlands, Romania, Slovenia and Sweden (Dylst, Vulto, 
and Simoens 2011). Some evidence on the impact of tenders is available for Germany, the 
Netherlands and Sweden. The impact of these tendering-like procedures on shortages is 
unclear, in particular whether the very low prices achieved may cause manufacturers exit and 
supply problems. 
 
Rebate contracts were introduced in Germany in 2003 and since 2007 pharmacists are 
required to dispensed the medicine with which the insurance company has a rebate in place 
unless the prescriber has explicitly asked to dispense a specific brand on medical grounds 
(German Ministry of Health 2016). These rebate contracts are another variation of preferred 
supplier contracts and can be negotiated at active ingredient level or for a portfolio of 
products. 1A study on preferred supplier contracts in post-patent market in Germany finds that 
– from a manufacturer’s perspective - these contracts are a powerful strategic instrument for 
generic manufacturers in a highly competitive environment (Blankart and Stargardt 2016). 
Signing such contracts has a positive effect on a brand’s own market share and a negative 
effect on the market shares of competitors (Blankart and Stargardt 2016). Further, the authors 
find that the time period between signing the first and the following preferred supplier 
contracts positively affects market share gained in the short-term while in the medium-long 
term this advantage disappears (Blankart and Stargardt 2016). No information on shortages 
was found in the literature. Since pharmacists are allowed to dispense a non-preferred 
medicine if the preferred one is not available and that different health insurers have different 
preferred medicines, this may prevent any shortages of the preferred medicine to impact on 
access. In principle this seems to be the case also in The Netherlands but it seems that 
substitution options are limited by the insurers’ preferences and first search for an alternative 
wholesaler who may supply the preferred medicine. 
 
In The Netherlands the preference policy has been introduced mid-2008 whereby health 
insurers design a preferred product, usually the least expensive, for each molecule included in 
the policy, to be the product of choice to their insurees for the duration of the contract. 
Substantial price reductions (more than 90%) for high volume generics like on omeprazole, 
simvastatin and amlodipine were observed between May 2008 and February 2012 (Kanavos, 
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Seeley, and Vandoros 2009, Kanavos 2012). During the first year savings well above Euro 
300 million were achieved (Kanavos, Seeley, and Vandoros 2009, Kanavos 2012). However, 
complaints from pharmacies who lost the income generated through discounts (now 
benefitting the health insurers who directly contract with manufacturers) led to an increase in 
the pharmacy fee which cost an excess of Euro 225 million (Kanavos, Seeley, and Vandoros 
2009, Kanavos 2012). Still there is a positive saving margin for health insurers. The seize of 
the savings has grown over time and totalled to nearly 680 million Euro in 2014 
(Zorginstituut Nederland 2015). Supply problems affecting preferred medicines have been 
documented. A case of a local manufacturer withdrawing several products due to tender 
pressure as well as individual cases of shortages of preferred medicines were reported 
(Carradinha 2009). According to data from the Dutch Foundation of Pharmaceutical 
Statistics, on average, the preferred medicine was not available in 4.3% prescription cases in 
2013 (SFK 2015). This means that the pharmacist has to find another wholesaler or another 
medicine, bearing in mind the preferred alternatives specified by the health insurer (SFK 
2015). Overall the long-term impact of the preference policy in the Netherlands is positive. 
Individual products may occasionally not be available in all pharmacies but this is a 
negligible issue if compared with the size of the savings generated and the contained nature 
of shortages. 
 
The short-term nature of the savings accrued is highlighted by a study on the effect of being 
the exclusive supplier for a generic product in Sweden. The study finds that while increasing 
the market share of the lowest-cost product beyond about 50% of the market generates 
significant short-term savings, these savings are lost relatively quickly over time, due to exit 
of competitors and the associated reduced price competition (Bergman, Granlund, and 
Rudholm 2015). Their findings also suggest that increasing the number of sellers from two to 
three reduces average prices by about one third (Bergman, Granlund, and Rudholm 2015). 
 
8.4.2! Negotiation 
Price negotiation is used in a number of countries in an attempt to obtain lower prices for on-
patent medicines. Notable exceptions include Medicare in the United States (US). Lack of 
price negotiation and the requirement for most Government programmes to cover most new 
medicines are widely thought to be some of the key issues why Medicare Part D pays higher 
prices than other Federal programmes (De Lott et al. 2016, Kesselheim, Avorn, and 
Sarpatwari 2016, Outterson and Kesselheim 2009).  
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In 2010, the pan-Canadian Pharmaceutical Alliance (pCPA, formerly known as the pan-
Canadian Pricing Alliance) was established for the joint negotiation of brand name medicines 
between Canadian Provinces and Territories and industry. The aims of the Alliance are to 
reduce differences in coverage decisions across the country and improve access to new 
medicines by increase purchasing power (IBM 2014). As of 30 September 2016, 11812 joint 
negotiations for brand name medicines have been completed (Canada’s Premiers 2016c) and 
37 were underway (Canada’s Premiers 2016b). In January 2013 the Value Price Initiative was 
established to reduce the cost of generic medicines (now collectively referred as pCPA). In 
the first three years of work up to April 2015, a price reference for commonly prescribed 
medicines at 18% of the equivalent brand name product was established for 14 medicines 
(Canada’s Premiers 2016a). An independent review of the functioning of the pCPA was 
conducted in 2013 and some of the recommendations made, including greater transparency 
and standardisation (IBM 2014), have been implemented. Available evidence on the impact 
of the Alliance shows that there was no overall change in the proportion of new medicines 
listed across jurisdictions and a varied impact on time-to-listing across provinces and 
territories (Milliken et al. 2015). These conclusions are based on a limited number of 
medicines reviewed at the time of the study. Further evaluations are needed to establish 
whether the pCPA is meeting its objectives.  
 
Australia uses information from horizon scanning to inform its pricing negotiations with 
manufacturers. This information is particularly important to prepare for the entry of new high 
cost medicines. In the case of Hepatitis C, it was also used to negotiate a favourable 
agreement for the treatment of all patients due to knowledge of competitors coming to the 
market in the near future. 
 
A study on factors influencing the size of the discount obtained during closed doors pricing 
negotiations in Germany found that medicines without additional benefit and non-orphan 
medicines correlated with higher discounts (Theidel and von der Schulenburg 2016). On the 
                                                
12 “A1completed1pan>Canadian1negotiation1refers1to1those1for1which1a1Letter1of1Intent1(document1which1
outlines1the1agreed1upon1terms1and1conditions1for1listing)1has1been1signed1between1the1lead1jurisdiction1for1
the1negotiation1and1the1manufacturer1OR1negotiations1have1been1closed1without1a1Letter1of1Intent.”1p.31
(Canada’s1Premiers12016c) 
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contrary, small population size, no deviation from recommended appropriate comparative 
therapy and inclusion of quality of life data correlated with lower discounts on the list price 
(Theidel and von der Schulenburg 2016). Despite these factors were associated with smaller 
or greater discounts, they were not sufficient to predict the final price. The authors concluded 
that other factors such as negotiation tactics, the political climate and other soft factors are 
likely to play a more influential role in the determining the final discount (Theidel and von 
der Schulenburg 2016). 
 
8.4.3! Other factors that affect procurement outcomes 
A number of factors outside the procurement cycle can affect its outcomes. These include 
pricing and reimbursement regulations like the impact of Medicare reimbursement rules on 
prices of generics in the US (Alpert, Duggan, and Hellerstein 2013), the influence of 70/90 
reimbursement regulation on the price of generics in Ontario (Anis, Guh, and Woolcott 
2003), the implementation of a reimbursement price cap for high-cost medicines in French 
hospitals (Degrassat-Théas et al. 2012); clinical guidelines and clinicians’ involvement in the 
procurement process (Amgros 2016b, Bartels 2016); the ability to substitute for generics, 
biosimilar medicines or to implement therapeutic substitution13 (Outterson and Kesselheim 
2009, Kesselheim, Avorn, and Sarpatwari 2016, Bocquet et al. 2014, European 
Biopharmaceutical Enterprises 2015); the implementation of managed entry agreements 
(Ferrario and Kanavos 2013, Russo et al. 2010); the ability to parallel import products from 
lower-priced markets (Chaumont et al. 2015); shortages and their causes (Iyengar, Hedman, 
et al. 2016) including parallel exports (Kawalec et al. 2016) and existing policies (Tan, 
Moles, and Chaar 2016b); knowledge of prices in other markets (Hinsch, Kaddar, and 
Schmitt 2014); ability to collaborate with other countries to share information and 
experiences (Blau et al. 2015); and potentially joint negotiation of prices and managed entry 
agreements (Morgan et al. 2013a). Below a few examples are illustrated in more details. 
 
 
A collaborative approach to procurement, consensus guidelines and regular audit were the 
key ingredients for maintaining access to cost-effective ARV medicines in London in the 
midst of budgetary pressures (Foreman et al. 2012). While antiretroviral collaborative 
                                                
13 “Therapeutic substitution is the replacement of the originally-prescribed drug [medicine] with an alternative 
molecule with assumed equivalent therapeutic effect” p. 728 (Johnston et al. 2011). “The alternative drug 
[medicine] may be within the same class or from another class with assumed therapeutic equivalence” p. 728 
(Johnston et al. 2011). 
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procurement across London had been in place for a number of years and successfully 
delivering competitive prices, financial constraints required to achieve further price 
reductions (Foreman et al. 2012). To achieve these, the London HIV Drugs and Treatment 
Sub Group - a clinically led engagement structure bringing together commissioners, 
clinicians and patient representatives to plan, deliver and evaluate HIV care and treatment 
services - agreed to include therapeutic tender14 in the procurement for 2011/2 (Foreman et 
al. 2012). First-line medicines options were identified with the aim of stimulating volume 
growth and securing lower prices without negatively impacting on efficacy or tolerability of 
treatment (Foreman et al. 2012). This, for the UK, novel approach to tendering has been 
characterised by greater clinical leadership and involvement of patient representatives to 
ensure its successful implementation and acceptance.  From 2011 to 2014, at least GBP 10.5 
million (recurring full year savings) were achieved through therapeutic tendering for branded 
ARV medicines in London, equivalent to about 5.2% annual reduction in ARV expenditure 
(i-base 2014). 
 
8.5! Discussion  
Managing entry of new medicines includes pre-launch activities (e.g. horizon scanning), peri-
launch activities (e.g. HTA, pricing and reimbursement) and post-launch activities (e.g. 
updating of formularies and clinical guidelines, disinvestment) (WHO 2015a). Findings from 
this study highlighted the role of these different activities on procurement outcomes.  
 
Preparing for entry of new on-patent medicines through horizon scanning was instrumental in 
negotiating a competitive deal for the procurement of medicines for the treatment of Hepatitis 
C in Australia. Once a product is on the market it is important to choose an efficient 
procurement method which leverages on economies of scale and takes into account the 
product characteristics (on-patent vs. off-patent, in-patient vs. out-patient, etc.). In the on-
patent market, examples from Denmark and Norway showed that it is possible to create a 
competitive market through tenders at therapeutic class level. Voluntary collaborations in 
pricing negotiations have started among various European countries (Ferrario, Kanavos, et al. 
2016a). While the impact of these initiatives in improving access needs yet to be evaluated, 
combining intelligence, skills and market power is likely to put participating countries in a 
stronger negotiation position. Examples from Germany, the Netherlands, and (in the short-
                                                
14 Tenders usually conducted at ATC-4 (chemical subgroup) level instead of ATC-5 (substance) level to 
enhance competition 
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term) Sweden, showed that preferred supplier contracts can generate savings in the post-
patent market. Careful monitoring of supply issues and product exit is needed to avoid 
interruption in treatment and decreased competition. Further, it is crucial to prepare the 
system for entry of off-patent products. A number of barriers exist in some countries 
preventing fast generic entry and uptake. These include data exclusivity provisions, limited 
generic substitution, very limited therapeutic and biosimilar substitution. Finally, 
disinvestment in low-value medicines can generate some financial space for entry of new and 
more cost-effective ones (Parkinson et al. 2015). Disinvestment can also be seen from the 
perspective of disinvesting in branded medicines following generic entry (Hughes and Ferner 
2010). In this case, disinvestment can generate both savings and increased access (Elek et al. 
2017). 
 
Studies on the impact of different procurement methods on prices, volume, supply security, 
etc. have used a variety of methods and due to the diversity in the way the same procurement 
methods are implemented in different countries, caution is needed when aggregating 
conclusions from different studies. Another limitation is that a certain number of evaluation 
studies were conducted by those in charge of procurement and therefore potentially biased 
towards showcasing mainly positive results.  
 
8.6! Conclusions 
This chapter set out to identify ways in which strategic procurement can contribute to 
improve access to cancer medicines. I identified a number of examples where countries, 
through smart procurement practices aimed at generating efficiencies, can improve 
availability, reduce prices and expenditure and improve quality use of medicines. These 
include leverage on horizon scanning to inform pricing negotiations with the pharmaceutical 
industry, the implementation of procurement practices and policies to enhance or create 
competition (in the case of originator markets) and promote uptake of biosimilar medicines. 
 
I also identify a number of challenges which are currently hampering efforts to take full 
advantage of strategic procurement. Based on these findings, I conclude that national 
regulatory changes should be identified which, if introduced at country level, can improve 
access to medicines (e.g. provisions to speed-up generic entry post-patent expiry and 
substitution for biosimilar medicines where the risk-benefit is positive). There is a need to 
create a competitive market, which can be achieved in different ways depending on the 
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product life-cycle (on-patent through therapeutic tendering and negotiation; post-patent: 
tendering either INN or therapeutic group level).  
 
The following factors can contribute to more competitive prices, greater access and quality 
use of medicines: greater use of horizon scanning to inform strategies to manage entry of new 
medicines and negotiations with manufacturers, leveraging on economies of scale (at national 
and international level), being proactive in improving the efficiency of procurement, 
preparing the system for entry of off-patent medicines, minimise barriers to entry of off-
patent medicines (both generic and biosimilar medicines), and use of evidence-based clinical 
guidelines to inform procurement. It is important that countries perform well on all 
components in order to improve their procurement outcomes and ultimately access to cancer 
medicines. 
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9! Conclusions, policy implications, limitations, future research 
9.1! Findings from this thesis 
Access to new and potentially more effective cancer medicines is challenged by very high 
entry prices and uncertainty around their effectiveness in routine clinical practice as opposed 
to the controlled conditions of clinical trials. Studies on access to cancer medicines have 
tended to focus on reimbursement decisions as these are more readily available than data on 
the use of cancer medicines. In this thesis, I aimed to determine whether access to cancer 
medicines varies across a sample of European countries/administrative areas (Belgium, 
Estonia, Scotland, and Sweden), why it varies and what countries are doing to improve 
access. To this end, I analysed data on the use of cancer medicines in the hospital and 
outpatient sectors and the use of managed entry agreements and strategic procurement to 
improve access. 
 
I used a variety of quantitative and qualitative methods to address the research questions of 
this thesis. Survival analysis and the complementary log-log transformation of the Cox 
proportional hazard model were used to study times to launch of new cancer medicines and 
their determinants across and within the countries studied. I used longitudinal multilevel 
models to analyse determinants of differences in utilisation across and within the study 
countries. Based on the literature I reviewed, I developed a framework to identify 
determinants of the use of cancer medicines. I populated the framework by conducting a 
documentary review and interviews with oncologists. I conducted a comparative longitudinal 
analysis of the implementation of MEAs on managed entry agreements and developed a 
conceptual framework to understand their impact on key end-points for decision-makers. 
Finally, I reviewed the literature to identify good practices and challenges of different 
procurement methods in improving access to medicines.  
 
In the following sub-sections, I will revisit the hypotheses outlined in Chapter 2 in the light of 
the findings of this thesis. 
 
9.1.1! Hypothesis 1: Variations exist in access to cancer medicines across European 
countries and these can be substantial 
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This hypothesis was tested in Chapter 4, 5 and 6. This thesis used two main indicators, time 
to entry of new cancer medicines and the levels of use of cancer medicines, to study access to 
cancer medicines. These indicators were also the basis against which determinants of access 
were tested. Chapter 4 analysed time to entry of 46 new cancer medicines and its 
determinants in Belgium, Estonia, Scotland and Sweden. There were large differences in time 
to entry of new cancer medicines between Belgium, Scotland and Sweden. On average, the 
expected time from EU-wide marketing authorisation, to first use of a medicine, was shortest 
in Sweden, with an average of 14.3 months (43 launches, 3 non-launches), and Belgium, with 
an average of 26.8 months (39 launches, 7 non-launches). For medicines which obtained EU-
wide marketing authorisation after April 2007, the average time to launch in Scotland was 
12.7 months (29 launches, 2 non-launches). In the full sample of 46 medicines (including 
medicines launched before April 2007 whose date of first use was not known), only two 
medicines were not used between April 2007 and June 2015 in Scotland. Differences in time 
to access and number of launches were even larger when comparing these three countries 
with Estonia where the average time to launch was 63.9 months (27 launches, 19 non-
launches).  
 
Chapter 5 analysed the use of 31 cancer medicines in Belgium, Scotland and Sweden. It 
showed that marked differences in the use of cancer medicines exists across this sample of 
western European countries with comparable income levels and spending on health per 
capita. Belgium had the highest utilisation of other antineoplastic agents in 2013 (120 DDD 
per 1000 capita in Belgium vs. 94 DDD per 1000 capita in Sweden vs. 49 DDD per 1000 
capita in Scotland), the group to which most study medicines belong. Sweden had the highest 
utilisation of alkylating agents, plant alkaloids and analogues, and hormone antagonist and 
related agents (34 DDD per 1000 capita in Sweden vs. 27 DDD per 1000 capita in Belgium 
vs. 10 DDD per 1000 capita in Scotland). Scotland, closely followed by Sweden, had the 
highest utilisation of antimetabolites included in the study sample (41 DDD per 1000 capita 
in Scotland vs. 40 DDD per 1000 capita in Sweden vs. 36 DDD per 1000 capita in Belgium).  
 
In Chapter 6, I analysed the use of HER-2 targeted therapies for breast cancer in Belgium, 
Estonia, Scotland and Sweden. I found that utilisation of HER-2 targeted therapies per new 
breast cancer case was higher in Sweden and Belgium compared to Scotland and Estonia. 65 
DDD of trastuzumab per new breast cancer case were consumed in Belgium, 57 in Sweden, 
40 in Scotland and 37 in Estonia in 2014. While trastuzumab was widely used in all four 
193 
 
countries (more than 91% market share among HER-2 targeted medicines in all countries), 
lapatinib, pertuzumab and trastuzumab emtansine were not routinely available in Scotland 
and Estonia as of December 2014 (and not even as of 2016). Sweden was the first of study 
countries to introduce newer HER-2 targeted therapies following trastuzumab, confirming 
findings from Chapter 4 that Sweden is an early launch country and adopter of new 
medicines.  
 
Empirical evidence from this PhD thesis confirmed that marked differences exist in access to 
cancer medicines in a sample of European countries. 
 
9.1.2! Hypothesis 2: Differences in access are determined by HTA recommendations, which 
influences the reimbursement status, prices of medicines, how medicines are financed 
including special funding arrangements and limitations on the number of patients 
treated, and the sector/s where they dispensed 
 
This hypothesis was tested in Chapters 4, 5 and 6. In Chapter 4, I found that medicines with 
shorter times to submission for reimbursement, local manufacturers headquarter (or local 
sales representative), an FDA priority review or a combination of expedited approval 
programmes, and medicines launched in Scotland and Sweden, were associated with higher a 
hazard of launch (probability of launch). Longer times since EU-wide approval initially 
correlated with an increased hazard of launch but as time further elapses they negatively 
affected the hazard of launch. The added clinical value of medicines explained shorter time to 
launch in Estonia but not in the other countries.  
 
In Chapter 5, I found that in Belgium, Scotland and Sweden, the most important correlates of 
increased utilisation in a sample of 31 cancer medicines which received EU-wide marketing 
authorisation between 2000 and 2012 were medicines coverage and time since EU-wide 
marketing authorisation. Medicines dispensed in both hospital and ambulatory sectors in 
Sweden were correlated with higher use than medicines dispensed in hospital settings only. 
Sweden was the country with the highest number of medicines used in both hospital and 
ambulatory sectors (N=26), followed by Belgium (N=6) and Scotland (N=2). Prices had a 
negative effect on utilisation in Belgium and Sweden but not in Scotland. Instead, financial 
managed entry agreements, in the form of confidential discounts, were positively correlated 
with increased utilisation of cancer medicines in Scotland. One possible interpretation is that 
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the financial managed entry agreements in Scotland remove the regressive effect of high list 
prices on utilisation.  
 
In Chapter 6, I found that trastuzumab was reimbursed in all countries and all new breast 
cancer patients are tested for HER-2 overexpression and prescribed trastuzumab if the tumour 
was invasive and larger than 1 cm or smaller but with risk factors. Yet, important differences 
existed in use of trastuzumab (DDD per new case) between Belgium and Sweden at the high 
end and Estonia and Sweden at the lower end. This seemed to be driven by differences in the 
use of trastuzumab beyond progression (only used in Belgium and Sweden). In Estonia 
hospital medicines were funded as part of a diagnostic related group type of system which 
prospectively paid the hospital based on a fixed cost per breast cancer patient. This system 
did not distinguish between HER-2 positive patients (higher treatment cost) and HER-2 
negative patients (lower treatment cost). The level at which the payment for breast cancer 
was set did not seem to be sufficient to cover for treatment with trastuzumab beyond 
progression which explained why it was not used despite common practice in other countries. 
In Scotland, use of trastuzumab beyond progression was not considered cost-effective and 
therefore not recommended for routing use. Estonia had a comparatively low incidence of 
breast cancer, the least comprehensive national breast cancer screening programme and, 
despite progress, patients were diagnosed relatively late. If indeed a number of breast cancer 
cases were not diagnosed, Estonia could be worse off in terms of access despite similar levels 
of usage per patient in Estonia and Scotland. 
 
Lapatinib, pertuzumab and trastuzumab emtansine were not routinely used in Estonia and 
Scotland as of 2016) due to the lack of a positive reimbursement decision. This confirmed the 
findings from Chapter 5 that the number of reimbursed indications affected the use of 
medicines. Alternative access options for non-reimbursed medicines included individual 
patient request in Scotland, special access programmes funded by the pharmaceutical industry 
(one such programme was in place for a limited amount of time for lapatinib in Estonia for 
example), and funding through a private foundation or out-of-pocket payment in Estonia. 
However, the limited coverage in terms of number of patients benefiting from these 
alternative access options limited their impact on access to non-reimbursed medicines as 
confirmed by utilisation data.  
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The findings of this thesis thus confirmed the importance of positive reimbursement decisions 
and HTA recommendations, as well as different  financing methods for medicines, in 
enabling access. The thesis also highlighted the regressive effect of prices on access which 
was offset by confidential pricing arrangements, and the need to consider the whole spectrum 
of patients who would potentially be eligible for treatment when evaluating the level of 
access. Utilisation of the cancer medicines included in this study largely occurred in hospitals 
(including day-units). The effect of the dispensing channel (hospital only or hospital and 
ambulatory sectors) was thus limited and only significant in Sweden the country with the 
largest number of medicines dispensed in both sectors. Further, this thesis found that time to 
entry of new cancer medicines was affected by time to submission, whether the manufacturer 
had a local headquarter or sales representative, whether the medicine was granted an 
expedited review by the FDA and the added clinical value based on the rating by Prescrire 
(the latter only in Estonia). 
 
9.1.3! Hypothesis 3: Differences in access to medicines do not always reflect the added 
clinical value of new medicines 
 
This hypothesis was tested in Chapter 4 and 5. In Chapter 4, four models were developed to 
study time to entry of new cancer medicines. In the all country model 1 (full sample, 46 
medicines, four countries) and model 3 (subsample of medicines with added clinical value 
rating by the independent drug bulletin Prescrire, 43 medicines, four countries), medicines 
granted an FDA priority review or a combination of expedited approval programmes were 
associated with higher hazard of launch (probability of launch) but not with added clinical 
value measured by the rating assigned by Prescrire (model 3). This means that higher ratings 
of clinical added value – in comparison to previously approved medicines - by Prescrire were 
not associated with higher hazard of launch. Model 4 (subsample of medicines with ESMO-
MCBS rating), the hazard of launch was not affected by the ESMO-MCBS rating but this 
model had also the smallest sample given that ESMO-MCBS ratings were only defined for 
solid tumours at the time the study was conducted. 
 
In the country level model 1 (full sample, 46 medicines, individual country) and model 3 
(subsample of medicines with Prescrire rating, 43 medicines, individual country), FDA 
expedited approval programmes increased the hazard of launch in Scotland and Sweden. 
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Higher additional clinical value, as estimated post-launch by Prescrire, was only significantly 
correlated with a higher hazard of launch in Estonia.  
 
This thesis thus found limited correlation between time to launch and added clinical value on 
one hand and levels of use and added clinical value on the other hand.  
 
9.1.4! Hypothesis 4: Managed entry and risk-sharing agreements are increasingly used to 
facilitate entry of new medicines however their impact on time to entry, use and 
reduction of uncertainty is still largely unknown 
 
This hypothesis was tested in Chapter 7 which analysed the use of managed entry and risk-
sharing agreements in Belgium, England, the Netherlands and Sweden. The countries’ 
studied implement managed entry agreements in an attempt to introduce new medicines 
which may have otherwise not been introduced because of their high cost and/or uncertainty 
regarding their performance in real-life. I found an increased use of managed entry and risk-
sharing agreements between 2003 and 2012 with a focus on oncology and immune-
modulating treatments and the implementation of financial agreements. However, very little 
was known on their impact in reducing prices and containing budget impact, improving cost-
effectiveness and quality use of medicines and facilitating access to new medicines. This was 
due to the confidential nature of most pricing arrangements and difficulties in accessing 
patient-level data to evaluate the patient response and use according to recommended 
indications. Two issues can limit access to these data: data storage systems and restrictions in 
access to the data. For example, I contacted several hospitals in England to access data on 
patient response to bortezomib for multiple myeloma. The medicine was part of a health 
outcome based agreement whereby the manufacturer refunds or provides equivalent free 
stock for patients not achieving a minimal response – defined as a reduction of at least 50% 
in serum M protein after 4 cycles of chemotherapy (NICE 2007) – but because a number of 
hospitals were still using non-electronic prescription systems, this would have required a 
rather laborious review of paper records which only NHS staff can perform. Further, one 
hospital commented that they do not use the medicine because the scheme was too 
burdensome to implement and they only treated a very limited number of patients with 
multiple myeloma. Another hospital had introduced a system of vial-sharing (the size of the 
single does vial does not correspond to the standard treatment dose for one patient leading to 
wastage (Bach et al. 2016)) which they concluded was more cost-saving and simpler to 
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implement than the NICE-approved patient access scheme (Hills et al. 2010). Additional 
barriers were likely to have been the time required for the hospital pharmacist to extract these 
data even if electronically available, the possibilities that some hospitals may not have 
wanted to provide data which could show that they did not submit the refund request on time 
and therefore missed the opportunity to recoup treatment costs for patients in whom the 
medicine did not elicit the expected response and unclear governance regarding access to 
anonymised patient level data. Hypothesis 4 was thus confirmed by evidence from this thesis. 
 
9.1.5! Hypothesis 5: A number of countries have used elements of strategic procurement to 
increase access to medicines. However, more efforts are needed at national and 
international levels to increase the efficiency of procurement and ensure sustainable 
access to medicines at affordable prices  
 
This hypothesis was tested in Chapter 8 which conducted a literature review, complemented 
by information from key informants, on the impact of different procurement methods on 
price, volume, sustainable supply, and responsible use of medicines. Good practices 
identified included the use of horizon scanning to inform negotiation with manufacturers of 
on-patent products and budgeting at hospital level; measures to promote rapid uptake of 
generic and biosimilar medicines post-patent expiry; focus on prescribing and procurement 
on high value and cost-effective medicines through the implementation of clinical guidelines 
and formularies; and the creation a competitive market where this would otherwise not exist, 
due to active patents, through therapeutic tenders among others.  
 
This thesis confirmed that a number of challenges in implementing strategic procurement 
(which includes all efforts aimed at increasing efficiency in the procurement process). These 
included restrictions on switching to generic and biosimilar medicines, non-evidence based 
concerns on their safety and efficacy leading to their low uptake; short budgeting processes; 
and non-inclusion of information from horizon scanning in budget negotiation for hospitals. 
Pharmaceutical procurement was an important lever towards better access to cancer 
medicines. Increased evaluation of existing procurement and negotiation practices and 
sharing of best practices among countries represents an opportunity to improve procurement 
outcomes and increase access to medicines. 
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9.2! Contribution of this thesis 
This thesis has made various methodological and empirical contributions to the literature. 
These include: (1) the analysis of access to cancer medicines in Europe from a quantitative 
and qualitative perspective which provides a blueprint for similar analyses in other countries; 
(2) the identification of likely determinants of differences in access to cancer medicines 
which can guide policy-makers efforts in managing access to new therapies; (3) the 
development of a conceptual framework for managed entry agreements which can guide their 
design and evaluation; (4) the development of a framework to study determinants of access to 
cancer medicines.  
 
These findings have a number of practical and policy implications.  
 
9.3! Policy implications: What do these findings mean for policy and practice? 
1)! The need for better data to identify disparities in access and monitor efforts to address 
them 
First of all, in order to study access to cancer medicines, data on medicines utilisation 
covering both inpatient and outpatient sectors are needed. At the moment this information is 
not readily available and accessible - from non-commercial sources - in most countries. The 
Organization for Economic Development and Cooperation (OECD) publishes data on defined 
daily doses (DDDs) per 1,000 individuals per day for selected therapeutic groups including 
alimentary tract and metabolism (ATC-A), blood and blood forming organs (ATC-B), 
cardiovascular system (ATC-C), genito-urinary system and sex hormones (ATC-G), systemic 
hormonal preparations, excluding sex hormons and insulins (ATC-H), anti-infectives for 
systemic use (ATC-J), musculo-skeletal system (ATC-M), nervous system (ATC-N) and 
respiratory system (ATC-R) (OECD 2016b). In 2016, no utilisation data were available for 
cancer medicines. Out of 34 OECD countries, 12 had data on medicines dispensed in 
hospitals in 2016. Comparative data on medicines utilisation across and within countries are 
important to identify disparities and investigate reasons behind them. In the 1990s for 
example, use of prescription-only medicines (measured in DDDs) in Estonia was found to be 
one third of that reported in the Nordic countries (WHO 2003). Further investigation revealed 
that this was due to underutilisation of chronic disease medicines, in particular hypertension 
and schizophrenia (WHO 2003). With this information, it was therefore possible to take steps 
to increase availability and use of cardiovascular and antipsychotic medicines (WHO 2003). 
Data on medicines utilisation can also be benchmarked against other interventions to study 
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the impact of introducing new medicines on use of other services. Another example from 
Estonia showed overuse of ulcer surgery due to limited availability of anti-ulcer medicines 
during Soviet times (WHO 2003). Comparative utilisation statistics are a key component of 
the European Surveillance of Antimicrobial Consumption Network’s efforts to improve use 
of antimicrobials in Europe and beyond (Versporten et al. 2014, ECDC 2016). Indicators of 
antimicrobial utilisation (DDD per 1000 capita per day) are collected annually from countries 
and used to provide feedback and monitor countries’ progress in reducing inappropriate use 
of antibiotics (ECDC 2016). Lack of routinely collected data on utilisation of cancer 
medicines at national and subnational level severely limits efforts to improve access to cancer 
medicines as it prevents monitoring the impact of interventions to improve patient access. 
This information is important to identify interventions that are working, those that work but 
need to be improved and those that are not working.  
 
When available, utilisation data are usually aggregated with no information on the treatment 
indication and treatment intention (e.g. curative vs. palliative), or if used in combination with 
other medicines. Further, available data on utilisation often needs substantial cleaning before 
they can be used for analysis. Another issue is which metric of comparison to use. For most 
medicines, DDDs per 1000 capita are used to compare medicines use across and within 
countries. Due to highly individualised treatment regimens and wide differences in dosages 
used in chemotherapy, DDDs are mostly not defined by the WHO Collaborating Centre on 
Drug Statistics (WHO Collaborating Centre for Drug Statistics Methodology 2016). Some 
countries have established their own (e.g. Belgium (2016) and Germany (DIMDI 2016)), 
other countries express their utilisation of cancer medicines in grams of active ingredient (e.g. 
Denmark and Norway). These data limitations hinder the conduction of cross-country studies 
on use of cancer medicines. Some initiatives are starting to address this issue. The systemic 
anti-cancer therapies (SACT) dataset in England for example claims to be the first national 
database collecting comprehensive information on systemic oncological therapies (SACT 
2016). For each patient, information on clinical status (primary diagnosis and stage 
grouping), programme and regimen (regimen, treatment intent, performance status, etc.), 
treatment cycle, medicine’s details (medicines name and dosage) and outcome (dose 
reduction, delayed start or reduced duration, etc.) are collected (NHS 2016). Despite existing 
limitations in available data, more value could be extracted from existing data, while in 
parallel working towards improving the level of information collected. A requirement for 
hospitals (and/or wholesalers) to report data on use of cancer medicines that allows to 
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calculate grams consumed and DDDs is the first step in that direction. If made publicly 
available, this information can be benchmarked against use in other countries. Comparison of 
utilisation of cancer medicines can help identifying outliers in terms of very high or very low 
use in comparison to the average use per capita in the other countries, or different 
geographical areas within one country, and spur investigation into what drives these 
differences. If these differences are not driven by medical need, then it is important to verify 
whether clinical practice is in line with current best available evidence and clinical 
guidelines. Such exercise can therefore help identifying gaps in access to medicines or 
shortcomings in responsible use of medicines.  
 
2)! Prices represent a barrier to access to medicines and efforts to address their impact are 
needed at national and international levels 
High prices can hinder access to medicines. Several developments at international and global 
level have the potential to affect prices of new cancer medicines. The UN High-Level Panel 
on Innovation and Access to Health Technologies recommended increased use of TRIPS 
flexibilities, including compulsory licensing and higher requirements to grant patents, to 
tackle high prices (United Nations Secretary-General's high-level panel on access to 
medicines 2016). Strategic procurement and collaboration is one of the focus areas of the 
work of the WHO Regional Office for Europe in the area of medicines (Ferrario, Kanavos, et 
al. 2016b) and the Maltese EU Presidency (Espín et al. 2016). More recently, the WHO has 
launched a consultation on fair pricing (WHO 2017).  
 
Strategic procurement has an important role to play in increasing access to medicines and 
preventing shortages. Efficient procurement of medicines means more than just obtaining the 
lowest price. It is about creating a healthy market where quality products are available at 
affordable prices on a sustainable basis at the right time (UNICEF 2016). In this context, a 
strategic approach to procurement is vital. Strategic procurement encompasses all activities 
aimed at improving the efficiency of procurement. These include, for example, activities to 
minimize low-value repetitive purchases, to increase the benefit of economies of scale and to 
reduce the transaction and transport costs (WHO 2000). In pharmaceutical procurement there 
are additional instruments which can be leveraged to improve efficiency. Examples include 
switching from branded medicines to non-branded generics or biosimilar products once the 
patent on the branded medicine expires, reducing the number of different medicines procured 
in a particular therapeutic area through the implementation of clinical guidelines and 
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formularies, and creating a competitive market where this would otherwise not exist, due to 
active patents, through analogue competition among others.  
 
To the extent that the resources freed through increased efficiency are reinvested to into the 
health care system, strategic procurement can contribute to improve access to medicines. 
Examples from Norway and Denmark showed substantial savings being achieved by 
substituting the reference biologic product of infliximab for its biosimilars. In Norway, these 
savings were used to expand access to TNF-alpha medicines to a wider patient group.  
 
In cases where a new product is coming to the market and there are no competitors yet, 
negotiation and, where possible, therapeutic tendering provides possible ways forward. 
Therapeutic tendering is based on therapeutic substitutability between molecules with 
assumed equivalent therapeutic effect (Johnston et al. 2011). Medicines considered to be 
substitutable may be from the same therapeutic class or from another class with assumed 
therapeutic equivalence (Johnston et al. 2011). In London, therapeutic tendering has been 
implemented with success in the procurement of HIV medicines. Denmark also implements 
therapeutic tendering. The latter relies on the availability of clinical guidelines to guide 
choice of medicines considered as therapeutic equivalent and to manage patients with the 
medicines procured. Results from the London HIV procurement group achieved savings of at 
least GBP 10.5 million (recurring full year savings) between 2011 and 2014, equivalent to 
about 5.2% reduced expenditure on anti-retroviral medicines procurement in London (i-base 
2014). 
 
Where these measures are not enough to ensure access to cost-effective medicines, additional 
interventions may be required. There is particular concern about limited use of TRIPS 
flexibilities to tackle issues of evergreening and unaffordable prices which preclude access to 
patients in Europe. Evergreening describes the process whereby the life of a patent on a 
particular molecule or the effective period of market exclusivity is extended through e.g. 
secondary patents, for minor variations or indications of the same compound, or other 
marketing strategies. The primary patent for treatment of chronic myeloid leukaemia with 
imatinib has expired in Cyprus and one month of treatment with generic imatinib costs EUR 
117.6 (personal communication with procurement staff at the Ministry of Health of Cyprus). 
The existence of a secondary patent for the treatment of gastrointestinal stromal tumors 
(GIST) with imatinib means that treating patients with the same medicine, strength and 
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formulation, but a different diagnosis, GIST, costs EUR 2 168.4 (personal communication 
with procurement staff at the Ministry of Health of Cyprus). Unaffordable prices have led to 
countries at all income levels, to limit access to direct acting antiretrovirals for Hepatitis C to 
the most severe cases despite the high effectiveness of these medicines and their decreased 
side effects in comparison to standard treatment with interferons. This has led to strong 
reactions from medical professionals and civil society calling for payers and Governments to 
take action to increase access (Cattaneo and Maciocco 2016, Silverman 2016a). 
 
While it is crucial to work towards a fairer pricing model, to generate efficiencies through 
strategic procurement and to take advantage of existing policy space to secure affordable 
prices, a certain level of investment in health systems is needed. Countries spending well 
below the average per capita spending on health are unlikely to achieve the same level of 
access. Estonia for example spent 6.3% of its gross domestic product on health in 2015 
(OCED average 9%), which is equivalent to USD 1824 per capita at purchasing power parity 
(OCED average USD 3814 per capita at purchasing power parity) (OECD 2016a). At these 
levels of spending, it is difficult to achieve comparable access to other European countries 
which have decided to make a greater investment in health. 
 
3)! The need for a more comprehensive approach to entry of new medicines 
Current efforts to improve access to cancer medicines in Europe have focused on price 
control, value assessment to guide prioritisation and coverage decisions, and more recently, 
on international collaboration. In contrast, the way medicines are financed and how this 
impacts on access has been given much less attention. While value assessment has been 
central in discussions around access to high cost medicines, more efforts are needed to 
implement models of managed introduction of new medicines. These should start with 
horizon scanning (pre-launch), use this information together with health technology 
assessment (peri-launch) to negotiate competitive prices for medicines which bring added 
clinical value to current standards of care and are affordable, and continue post-marketing 
activities including ensuring quality use of medicines and sustainable supply (WHO 2015a). 
Elements of this continuum are implemented in a number of countries, however, few perform 
well along the continuum. Examples from Australia (horizon scanning to plan the negotiation 
of directly acting antiretroviral medicines for the treatment of Hepatitis C), Denmark and 
Norway (fast uptake of the biosimilar infliximab for the treatment of rheumatoid arthritis post 
patent expiry of the reference product) have shown the importance of preparing the system 
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for entry of new medicines, to ensure their affordability and use. In addition, international 
collaborative initiatives (e.g. the Nordic pharmaceutical forum and the Beneluxa group) have 
started working together on various elements of this continuum (e.g. horizon scanning, HTA, 
and negotiation) with an aim of sharing experiences and leveraging on combined market 
power.  
  
4)! An evaluation of the contribution of managed entry agreements in improving access is 
needed 
Managed entry and risk-sharing agreements are arrangements between manufacturers and 
payers aiming to address issues of high prices, uncertainty around effectiveness and uptake, 
and/or appropriate use of new medicines. Pure financial agreements include various forms of 
confidential discounts and rebates and dose capping schemes. Health-outcome based 
agreements may be performance-based, with refund for under-performance, or coverage with 
evidence development schemes whereby the new medicine is conditionally reimbursed for a 
certain period of time until sufficient evidence is available to make a final coverage decision. 
Registries are also used in this context to monitor appropriate use of medicines and to support 
the implementation of coverage with evidence development schemes.  
 
Financial agreements have increasingly become price discrimination tools to offer 
confidential discounts off-list prices without touching reference prices. They are the preferred 
type of agreement in a number of countries as they offer a clear return, price reduction, and 
are generally simpler to implement than performance-based agreements. Their impact is 
largely unknown due to the confidentiality surrounding discounts and rebates and difficulties 
in accessing patient level data for agreements which cap the number of doses paid by the 
payer. Price-volume agreements in France have generated a net clawback between Euro 236 
million in 2009 and Euro 386 million in 2014 (Comité économique des produits de santé 
2015). By lowering the net price, financial agreements improve the cost-effectiveness of a 
medicine. In countries where cost-effectiveness is the main decision-making criterion for 
reimbursement, financial agreements can help bringing the incremental cost-effectiveness 
ratio (ICER) within the willingness to pay of a country. 
 
At the time a reimbursement decision needs to be made, most of the evidence available is on 
efficacy and safety from randomised clinical trials. Little evidence is available therefore 
available on the effectiveness of the medicine in real life which is what decision-makers 
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ideally would want. To address issues of uncertainty, coverage with evidence development 
schemes have been introduced in some countries. As part of these schemes, a new medicine 
is initially funded for a certain time after which its reimbursement is re-evaluated using real-
life data. Health-outcome based agreements are more demanding to implement as they 
require registries to collect information on the performance of the medicine in real-life and, 
for coverage with evidence development, additional data such as quality of life may be 
collected to complement RCT data in the context of cost-effectiveness analysis. The limited 
evidence on their implementation is mixed. Sweden seems to have been successful (i.e. data 
requests by TLV were satisfied by the manufacturer) in the implementation of coverage with 
evidence due to the simple nature of the additional data collection request (e.g. how the 
medicine is used in real-life) and availability of patient registries to support their 
implementation. The latter has also been the success factor in Italy (Montilla et al. 2015). 
Initial experience with these schemes has encountered a number of challenges in the 
Netherlands in terms of data collection and reversing decisions once a medicine has been 
introduced in clinical practice (Chapter 7). This is likely to be due to the more demanding 
nature of the additional data to be collected (efficacy and quality of life) and the need to set 
up registries. A limited number of performance-based agreements has been implemented in 
France. The manufacturer of glitazones for example claimed that they were equally effective 
as other dipeptidyl peptidase 4 (DPP-4) inhibitors but the claim was no attained in real-life 
and the price was decreased (Garrison et al. 2013). In contrast, the manufacturer’s claim that 
risperidone would lead to better patient compliance and less hospitalisations was realised and 
the conditionally granted initial price was maintained (Garrison et al. 2013). 
 
Uncertainty around effectiveness, safety, and uptake of a new medicine in real-life (i.e. 
outside the controlled conditions of clinical trials) will always be present at the time a 
reimbursement decision needs to be made. Learning from the experience of coverage with 
evidence development schemes will allow on one hand to improve the way these schemes are 
implemented. On the other hand, an evaluation of these schemes is likely to provide useful 
lessons learned for the implementation of EMA adaptive pathways to licensing in the 
European Union. Through adaptive pathways, selected medicines addressing high unmet 
medical need will be first authorised for a small patient population, based earlier data than 
usually required e.g. phase 2 clinical trials data, for which there is sufficient evidence of a 
positive benefit-risk balance. As new evidence on use of the medicine in real-life is being 
collected to supplement clinical trials data, the eligible patient population may be widened 
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through progressive licensing adaptations in process of evidence collection and re-evaluation 
of the benefit-risk balance (EMA 2016a). Such process will require some flexible forms of 
early reimbursement to support the introduction of new medicines earlier in the evidence 
generation process towards marketing authorisation. Lessons learned from real-work 
evidence collection through coverage with evidence development can thus provide lessons 
for the implementation of adaptive pathways and at the same time provide a flexible 
instrument of early reimbursement as more evidence on benefit-risk is generated.  
 
Managed entry agreements, whether discount based or performance-based, contribute to a 
lack of transparency in pricing. Financial agreements generally grant an ex-ante discount on 
the list price or limit the number of doses paid by the payer irrespective of treatment length. 
Performance-based agreements are based on ex-post-refund or free additional stock but both 
effectively change the average price paid per dose used. With very limited information on the 
conditions offered to other countries, it is difficult for policy-makers to judge whether they 
could have been offered a better deal. Manufacturers on their side are left the discretion of 
offering the best deals to which country they prefer, probably countries with large markets, 
and not necessarily the countries which would most need a discount to provide access to their 
patients. Countries with more limited resources are also likely not to have the existing 
infrastructure in place to collect data (e.g. patient registries) and the negotiation skills to 
secure more competitive deals. As such there is a threat that MEAs could favour countries 
with larger markets and with existing resources data collection systems and good negotiation 
skills. 
 
When deciding whether to engage in managed entry agreements, decision-makers should 
consider what their objective is (e.g. reduce uncertainty, reduce budget impact, improve cost-
effectiveness). This will inform the choice of which managed entry agreement/s may be more 
suitable to meet the objective. Further, they should consider the requirements to implement 
different types of agreements, particularly those involving additional data collection, and 
whether existing data collection and reimbursement systems, would support their smooth 
implementation. If data collection systems are patchy and/or paper based, ex ante confidential 
discounts on the list price are likely to be the easiest scheme to implement. 
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5)! Access to medicines as a means towards better health outcomes for all patients 
Access to cancer medicines is a means towards better health outcomes for cancer patients. 
From a health system perspective, medicines, vaccines and health technologies are only one 
input towards better health outcomes. Other inputs include human resources, health services, 
including timely access to diagnosis, treatment (surgery, radiotherapy and chemotherapy) and 
palliative care, and financing. All these efforts need to be monitored by an efficient health 
information system, which allows to assess the impact of interventions to improve access, 
quality of care and financial protection against catastrophic expenditure or impoverishment as 
a result of seeking care. This can only be achieved through strong national and international 
governance and resilient policies. Through their action, these inputs and processes can 
influence coverage of interventions, including access to diagnosis and treatment, and the 
prevalence of risk factors, which, in turn, will impact health outcomes, equity and system 
responsiveness. If medicines have to contribute to better health outcomes for all patients, 
efforts to increase access to medicines should adopt a health system perspective when 
assessing existing barriers to access. This was highlighted in Chapter 6, where, despite 
similar levels of use of trastuzumab per new breast cancer case in Scotland and Estonia, 
access is likely to be worse in Estonia due to evidence suggesting possible under-diagnosis of 
breast cancer. 
 
9.4! Limitations of this research 
This thesis has several limitations. Specific limitations to each paper are discussed in 
Chapters 4-8. Here, I will summarise the main limitations of the overall thesis. 
 
9.4.1! Data 
The data used in this thesis were constrained by information available in the public domain or 
obtainable upon request from competent authorities.  
 
9.4.1.1! Dependent variable: Utilisation 
The majority of the 31 cancer medicines analysed in Chapter 5 were approved for the 
treatment of different cancer indications which are associated with different incidence levels. 
No data on utilisation of cancer medicines by indication were available which would have 
allowed me to adjust utilisation by incidence of different types of cancer in Chapter 5. Instead 
that adjustment was limited to population size in different countries. On the other hand, 
adjusting for the number of new cancer cases was possible in Chapter 6 given HER-2 
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targeted therapies are mainly used for breast cancer. Data on medicines use in hospitals were 
only available from April 2007 which means that I had to limit the observation time for 
Scotland from April 2007 to December 2014 in Chapter 4. The data used in this study are 
dispensing data, the quantity administered to patients may have been lower. Considering the 
high cost of new cancer medicines and the severity of cancer, it is unlikely that wastage 
(difference between dispensing and utilisation) will have significantly affected the results.  
 
9.4.1.2! Independent variables 
Limitations also apply to the independent variables. For example, data on medicines prices in 
Scotland represent list prices from the British National Formulary and as such does not 
include any confidential discounts which may apply. This has most likely led to an 
overestimation of prices paid in Scotland. That said, list prices are still the starting point for 
negotiation and the presence of special pricing arrangements at national level is captured by 
the MEA variable in Chapter 5. Prices in the other countries were calculated by dividing 
expenditure data by volume. In Sweden, the candidate was informed by the competent 
authority that this may actually represent the real price paid by providers. In Estonia, further 
discounts may apply at point of purchase. In Belgium, depending on whether hospitals report 
gross or net expenditure, some of discounts may have been included. It would have been 
interesting to include as a variable in the model the incremental cost-effectiveness ratio 
estimated for different indications in each country. This was not possible due to lack of data 
at indication level but also lack of cost-utility estimates for all the medicines in each country.  
 
9.4.2! Methods of analysis 
Cancer is a vast therapeutic area including many different types of tumours with different 
pathogenesis, affecting different parts of the body and treated in different ways. Of the three 
Chapters analysing use of cancer medicines (Chapter 4-6), only Chapter 6 could take into 
account factors specific to access to HER-2 targeted therapies for breast cancer like diagnosis 
of HER-2 overexpression and explore issues of use beyond progression. Chapters 4 and 5, 
which used quantitative methods to study time to entry and its determinants and determinants 
of differences in utilisation of different cancer medicines, had to rely on testing a limited 
number of determinants of entry and use.  
 
Interviews were often difficult to arrange, particularly when the interviewees were busy 
oncologists. In Chapter 6, I conducted up to two interviews per country with medical 
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oncologists from different geographical areas (usually the capital and another major cancer 
centre). However, this is still a limited number of interviewers to fully represent the clinical 
perspective of treating breast cancer in the countries studied. Including oncologists from 
other areas, for example more remote areas of the country, may have provided a different 
perspective. Furthermore, all interviewees apart from one were senior oncologists (e.g. head 
of Department or Unit). Interviewing more junior oncologists may have provided a different 
picture though the one included in the study did not provide a different picture from the 
senior counterpart interviewed in the same country. Chapter 8 relies mainly on the literature, 
complemented by personal contacts with procurement bodies either on the telephone, email 
or in person, to review the impact of different procurement strategies on price, volume, 
expenditure, supply security and responsible use of medicines. Results published in the 
literature are likely to be affected by publication bias and over-represent positive results. 
Further, procurement staff may not see publication in peer-reviewed journals or translation of 
their annual reports into English as a priority, which prevented inclusion of relevant 
experiences in the literature review. Moreover, there may be a disincentive to publish too 
much information on how positive outcomes (e.g. competitive prices) were achieved (some 
countries may want to keep successful strategies of negotiating with industry for themselves) 
or negative outcomes as they would signal bad performance of those in charge of 
procurement. Speaking with more procurement bodies to learn about their efforts in obtaining 
better procurement outcomes for cancer medicines would have probably highlighted several 
good practices and challenges in the area. However, because the interviewees would have 
been procurement staff, the limitations just mentioned would still apply. In practice, time 
constraints and difficulties in arranging interviews with busy procurement staff prevented 
more primary data collection.   
 
The analysis on governance factors and possible links with the way countries implement 
MEAs in Chapter 7 was only of explorative nature due to the limited sample size. 
Nevertheless, it did enable to identify important differences and similarities in the way MEAs 
are implemented across the four study countries. These include similarities in the countries’ 
objectives for implementing MEAs and at the same time differences in the ways countries 
employ MEAs. This analysis did not include MEAs implemented in only one or a few 
regions due to the lack of data on most of these agreements. This is likely to have affected 
only England where there is evidence of some schemes being offered at sub-national level for 
medicines which had not yet received a recommendation for use by NICE. No such evidence 
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was available for the other countries. That said, all MEAs negotiated at national level were 
included in the analysis.  
 
9.4.3! Interpretation 
In Chapter 4, analysis of time from EU-wide marketing authorisation to first use gives an 
indication of the time interval between licensing and first use of a medicine in a particular 
country. However, at the time of first use the medicine may not yet be available to all eligible 
patients according to the licensed treatment indication. This can be the case for medicines 
which have not yet obtained a positive reimbursement decision and which continue to be 
temporarily funded through temporary access programmes financed by the manufacturer or 
the public health system (e.g. temporary authorisation for use in France) (Degrassat-Théas et 
al. 2013). Further, first use does not provide information about the overall level of use and 
possible inequalities in access to medicines within a country. It is therefore important to 
analyse also actual utilisation levels and subnational disparities in access.  
 
The studies on the impact of different procurement methods on prices, volume, supply 
security and responsible use of medicines reviewed in Chapter 8 have used a variety of 
methods. Due to the diversity in the methods used to evaluate the impact of different 
procurement methods, the way the same procurement method (e.g. tendering) is implemented 
in different countries, and other reforms which may have been ongoing in the pharmaceutical 
sector affecting procurement outcomes, caution is needed when aggregating conclusions from 
different studies. Further, some of the studies reviewed were conducted by those in charge of 
procurement and therefore, potentially biased towards showcasing mainly positive results.  
 
9.5! Recommendations and future research 
In my thesis, I identified a number of issues with existing data on use of cancer medicines 
which limits research on access to cancer medicines and its determinants. Studies on 
determinants of access to cancer medicines need to take a broader perspective and include 
factors affecting access to health services such as diagnosis, clinical practice, and health 
financing. A number of interventions and initiatives are implemented to improve access to 
cancer medicines, however, their evaluation and sharing of experiences with other countries 
is limited. These limitations represent a missed opportunity to generate evidence and share 
experiences which are useful for policy and practice. 
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First of all, basic indicators of access to cancer medicines (e.g. grams of active ingredient per 
1000 capita) should be routinely collected and published across Europe. These should be used 
to identify disparities, question what may drive them and monitor the impact of interventions 
to improve access. As data on medicines utilisation per indication and treatment intention 
become more widely available, more refined indicators can also be reported and compared 
across Europe (e.g. use per patient, diagnosis, and treatment intention). Available data on 
cancer medicines utilisation have a number of challenges including limitations to public 
access, lack of standardisation in the way it is collected and reported and the need to clean the 
data before they can be used for analysis. To be fit for use, data need to be more easily 
accessible in a user-friendly format which supports analysis of utilisation across and within 
countries    
 
While this thesis confirmed the importance of reimbursement to ensure access, it also 
highlighted that other factors like financial arrangements have been given less attention 
despite their important role enabling access to patients. More analyses of access to cancer 
medicines looking beyond reimbursement are needed to improve access and health outcomes. 
Future studies may want to focus on analyses of individual cancers (e.g. breast cancer, 
melanoma) and compare how the condition is treated in different countries including surgery, 
radiotherapy, chemotherapy, targeted therapies and immunotherapies. This would allow to 
highlight differences in the overall treatment of the condition rather than just focusing on new 
cancer medicines.  
 
Finally, evaluation of existing efforts and initiatives to improve access to cancer medicines is 
needed. More evidence on the performance of country’s experiences with strategic 
procurement and managed entry agreements is needed to inform policy and practice. Price is 
a key determinant of access and the latter is influenced by procurement. More evidence is 
needed on the impact of different procurement methods on price, volume, supply security  
and appropriate use of medicines. A number of initiatives, often pursued in a collaborative 
manner between different countries, to manage entry of new medicines have been 
implemented or are being introduced (e.g. adaptive pathways, horizon scanning, health 
technology assessment). Their evaluation and sharing of experience with other countries is 
important for mutual learning and identification of successful initiatives.  
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Appendices 
 
Appendix 1: Key indicators and health system information on the study countries 
 
 Belgium Estonia Scotland Sweden 
Gross domestic 
product (GDP) , 
in US$ PPP  
40,023  37,041 (UK) 43,254 
Total health care 
spending as % of 
GDP 
11% 6% 
 
9% (UK) 12% 
Health care 
spending per 
capita, US$ PPP  
4,392 1,668 3,277 (UK) 5,219 
Spending on 
medicines (both, 
outpatient and 
inpatient) per 
capita, Euro 
410 (2013) N/A 314 (2013) 401 (2013) 
Main source of 
health system 
financing 
Social security 
contributions and 
subsidies from the 
federal 
government 
Social health 
insurance 
contributions in 
the form of an 
earmarked social 
payroll tax 
Taxation Taxation 
Population 
(million) 
11,203 1,315 5,327 (2013) 9,644 
     
Notes: purchasing power parity (PPP) 
Sources: WHO Global Health Expenditure Database (http://apps.who.int/nha/database, 
accessed on 15 November 2016), data from Chapter 5, (Steel and Cylus 2012, Anell, 
Glenngård, and Merkur 2012, Lai et al. 2013, Gerkens and Merkur 2010) 
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Appendix 2: List of medicines analysed in Chapter 4 
 
Medicine Name Active Substance ATC-5 
Marketing Authorisation 
Holder 
Authorisation 
date 
Afinitor everolimus L01XE10 Novartis Europharm Limited 03/08/2009 
Alimta pemetrexed L01BA04 Eli Lilly Nederland B.V. 20/09/2004 
Ameluz 
5-aminolevulinic acid 
hydrochloride L01XD04 Biofrontera Bioscience GmbH 14/12/2011 
Avastin bevacizumab L01XC07 Roche Registration Limited 12/01/2005 
Caprelsa vandetanib L01XE12 AstraZeneca AB 17/02/2012 
Erbitux cetuximab L01XC06 Merck KGaA 29/06/2004 
Erivedge vismodegib L01XX43 Roche Registration Ltd 12/07/2013 
Faslodex fulvestrant L02BA03 AstraZeneca UK Ltd 10/03/2004 
Firmagon degarelix L02BX02 Ferring Pharmaceuticals A/S 17/02/2009 
Foscan temoporfin L01XD05 biolitec pharma Itd. 24/10/2001 
Giotrif afatinib L01XE13 
Boehringer Ingelheim 
International GmbH 25/09/2013 
Glivec imatinib L01XE01 Novartis Europharm Ltd 07/11/2001 
Halaven eribulin L01XX41 Eisai Europe Ltd. 17/03/2011 
Herceptin trastuzumab L01XC03 Roche Registration Limited 28/08/2000 
Inlyta axitinib L01XE17    
Pfizer Ltd 
  03/09/2012 
Iressa gefitinib L01XE02 AstraZeneca AB 24/06/2009 
Jakavi ruxolitinib (as phosphate) L01XE18 Novartis Europharm Ltd 23/08/2012 
Javlor vinflunine L01CA05 Pierre Fabre Médicament 21/09/2009 
Jevtana cabazitaxel L01CD04 
sanofi-aventis groupe 
  17/03/2011 
Kadcyla trastuzumab emtansine L01XC14 Roche Registration Ltd 15/11/2013 
Lysodren mitotane L01XX23 Laboratoire HRA Pharma 28/04/2004 
Mekinist trametinib L01XE25 Novartis Europharm Limited 30/06/2014 
Panretin alitretinoin L01XX22 Eisai Ltd 11/10/2000 
Perjeta pertuzumab L01XC13 Roche Registration Limited 04/03/2013 
Pixuvri pixantrone dimaleate L01DB11   CTI Life Sciences Limited 10/05/2012 
Removab catumaxomab L01XC09 Neovii Biotech GmbH 20/04/2009 
Stivarga regorafenib L01XE21 Bayer Pharma AG 26/08/2013 
Sutent sunitinib L01XE04 Pfizer Limited 19/07/2006 
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Medicine Name Active Substance ATC-5 
Marketing Authorisation 
Holder 
Authorisation 
date 
Afinitor everolimus L01XE10 Novartis Europharm Limited 03/08/2009 
Tafinlar dabrafenib L01XE23 Novartis Europharm Limited 26/08/2013 
Tarceva erlotinib L01XE03 Roche Registration Limited 19/09/2005 
Targretin bexarotene L01XX25 Eisai Ltd 29/03/2001 
Teysuno 
tegafur / gimeracil / 
oteracil L01BC53 Nordic Group BV 14/03/2011 
Trisenox arsenic trioxide L01XX27 Teva B.V. 05/03/2002 
Tyverb lapatinib L01XE07 Novartis Europharm Limited 10/06/2008 
Vargatef nintedanib L01XE31 
Boehringer Ingelheim 
International GmbH 21/11/2014 
Vectibix panitumumab L01XC08 Amgen Europe B.V. 03/12/2007 
Velcade bortezomib L01XX32 Janssen-Cilag International NV 26/04/2004 
Votrient pazopanib L01XE11 
Novartis Europharm Limited 
 
 
  14/06/2010 
Xalkori crizotinib L01XE16   Pfizer Ltd 23/10/2012 
Xeloda capecitabine L01BC06 Roche Registration Limited 02/02/2001 
Xtandi enzalutamide L02BB04 Astellas Pharma Europe B.V. 21/06/2013 
Yervoy ipilimumab L01XC11 
Bristol-Myers Squibb Pharma 
EEIG 13/07/2011 
Zaltrap aflibercept L01XX44 Sanofi-Aventis Groupe 01/02/2013 
Zelboraf vemurafenib L01XE15 Roche Registration Ltd 17/02/2012 
Zydelig idelalisib L01XX47 
Gilead Sciences International 
Ltd 18/09/2014 
Zytiga abiraterone acetate L02BX03 
Janssen-Cilag International 
N.V. 05/09/2011 
 
Notes: Extracted from EMA website on 20 July 2015 
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Appendix 3: Time to launch and distribution of launches and non-launches by ESMO-
MCBS rating 
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Appendix 4: Individual country models, Probability of launch T3-T0, Chapter 4 
 
Model 1: Belgium Coefficient 
Standard 
error 
z P>z 
[95% 
Confidence 
Interval] 
T1-T0, quarters -0.37*** 0.12 -3.10 0.00 -0.60 -0.14 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with CMA 0.63 0.57 1.10 0.27 -0.49 1.75 
Local manufacturer headquarter or sales representative (Estonia), baseline (no local 
headquarter/representative) 
-Local headquarter/representative 2.72 1.45 1.87 0.06 -0.13 5.57 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites -1.43 1.34 -1.06 0.29 -4.06 1.20 
-L01C Plant alkaloids and other 
natural products -2.21 1.16 -1.91 0.06 -4.48 0.06 
-L01D Cytotoxic antibiotics and 
related substances             
-L02B Hormone antagonists and 
related agents -0.11 1.04 -0.11 0.92 -2.16 1.93 
Expected price in the therapeutic 
class (ATC-3), lagged one quarter 0.01* 0.003 2.30 0.02 0.001 0.01 
Expected volume at therapeutic 
class (ATC-3) in thousands DDDs, 
lagged one quarter 0.002 0.001 1.41 0.16 
-
0.001 0.005 
FDA expedited approval programme (EAP, baseline: no EAP) 
-Fast track only 0.56 0.91 0.61 0.54 -1.22 2.33 
-Priority review only -0.24 0.62 -0.38 0.70 -1.45 0.98 
-Combination 0.17 0.51 0.33 0.74 -0.84 1.18 
Year of marketing authorisation 0.01 0.08 0.13 0.90 -0.15 0.17 
Time since EU-wide approval 
(quarters) 0.66*** 0.15 4.52 0.00 0.38 0.95 
Time since EU-wide approval 
(quarters), squared -0.02*** 0.01 -3.22 0.00 -0.03 -0.01 
Constant -5.33 1.27 -4.21 0.00 -7.81 -2.85 
Log likelihood = -92.560633 
LR test of rho = 0: chibar2(01) = 0.00                   Probability >= chibar2 = 1.000 
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Number of observations = 395 
Number of groups = 43 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
 
Model 1: Estonia Coefficient 
Standard 
error 
z P>z 
[95% 
Confidence 
Interval] 
T1-T0, quarters -0.28*** 0.06 -4.84 0.00 -0.39 -0.16 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with CMA -0.35 0.75 -0.47 0.64 -1.81 1.11 
Local sales representative, baseline (no local representative)  
-Local representative 3.33*** 0.92 3.63 0.00 1.53 5.14 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites 0.49 0.94 0.52 0.61 -1.36 2.34 
-L01C Plant alkaloids and other 
natural products 2.83* 1.03 2.74 0.01 0.80 4.85 
-L01D Cytotoxic antibiotics 
and related substances             
-L02B Hormone antagonists 
and related agents 3.02* 1.07 2.83 0.01 0.93 5.12 
Expected price in the 
therapeutic class (ATC-3), 
lagged one quarter 0.00 0.00 0.75 0.46 0.00 0.01 
Expected volume at therapeutic 
class (ATC-3) in thousands 
DDDs, lagged one quarter 0.02* 0.01 2.80 0.01 0.01 0.03 
FDA expedited approval programme (EAP, baseline: no EAP) 
-Fast track only 0.12 1.25 0.10 0.92 -2.33 2.57 
-Priority review only -1.11 0.89 -1.25 0.21 -2.84 0.63 
-Combination 1.04 0.74 1.42 0.16 -0.40 2.49 
Year of marketing 
authorisation -0.29*** 0.08 -3.76 0.00 -0.44 -0.14 
Time since EU-wide approval 
(quarters) 0.58*** 0.14 4.27 0.00 0.32 0.85 
Time since EU-wide approval -0.01* 0.00 -2.82 0.01 -0.02 0.00 
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(quarters), squared 
Constant -4.87 1.52 -3.20 0.00 -7.85 -1.88 
Log likelihood  = -69.404113 
LR test of rho=0: chibar2(01) = 0.00                   Prob >= chibar2 = 1.000 
Number of obs     =        622 
Number of groups  =         45 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
 
 
Model 1: Scotland Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.18* 0.08 -2.20 0.03 -0.34 -0.02 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with 
CMA -0.08 0.90 -0.09 0.93 -1.85 1.68 
Local manufacturer headquarter, baseline (no local headquarter) 
-Local headquarter -0.36 0.73 -0.49 0.62 -1.78 1.07 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites -2.16 1.25 -1.72 0.09 -4.62 0.30 
-L01C Plant alkaloids and 
other natural products -5.86*** 1.68 -3.49 0.00 -9.15 -2.57 
-L01D Cytotoxic antibiotics 
and related substances -2.87 1.51 -1.90 0.06 -5.84 0.10 
-L02B Hormone antagonists 
and related agents -1.67 0.86 -1.94 0.05 -3.35 0.02 
Expected price in the 
therapeutic class (ATC-3), 
lagged one quarter -0.02*** 0.00 -3.18 0.00 -0.03 -0.01 
Expected volume at 
therapeutic class (ATC-3) in 
thousands DDDs, lagged one 
quarter -0.001 0.001 -1.01 0.31 0.003 0.001 
FDA expedited approval programme (EAP, baseline: no EAP) 
-Fast track only 0.40 1.09 0.37 0.71 -1.73 2.53 
-Priority review only 2.94* 1.23 2.39 0.02 0.53 5.36 
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-Combination 2.66* 0.96 2.77 0.01 0.78 4.54 
Year of marketing 
authorisation 0.10 0.16 0.64 0.52 -0.22 0.43 
Time since EU-wide approval 
(quarters) 0.96*** 0.22 4.42 0.00 0.53 1.38 
Time since EU-wide approval 
(quarters), squared -0.03* 0.01 -2.52 0.01 -0.05 -0.01 
Constant -5.03* 2.18 -2.30 0.02 -9.31 -0.75 
Log likelihood  = -52.749765 
LR test of rho=0: chibar2(01) = 1.8e-05                Probability >= chibar2 = 0.498 
Number of observations = 173 
Number of groups = 31 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
 
 
Model 1: Sweden Coefficient 
Standard 
error 
z P>z 
[95% 
Conf. Interval] 
T1-T0, quarters -0.09*** 0.02 -3.72 0.00 -0.14 -0.04 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with CMA 0.93 0.63 1.47 0.14 -0.31 2.17 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites 1.57 0.89 1.76 0.08 -0.17 3.31 
-L01C Plant alkaloids and other 
natural products 1.95 1.10 1.77 0.08 -0.22 4.11 
-L01D Cytotoxic antibiotics and 
related substances 2.31 1.47 1.58 0.12 -0.56 5.19 
-L02B Hormone antagonists and 
related agents 1.09 0.85 1.29 0.20 -0.57 2.75 
Expected price in the therapeutic 
class (ATC-3), lagged one 
quarter 0.01* 0.00 2.41 0.02 0.00 0.01 
Expected volume at therapeutic 
class (ATC-3) in thousands 
DDDs, lagged one quarter 0.00 0.00 -0.26 0.79 0.00 0.00 
FDA expedited approval programme (EAP, baseline: no EAP) 
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-Fast track only 1.39 0.87 1.60 0.11 -0.31 3.10 
-Priority review only 3.03*** 0.81 3.75 0.00 1.45 4.61 
-Combination 2.82*** 0.74 3.81 0.00 1.37 4.27 
Year of marketing authorisation -0.13 0.07 -1.71 0.09 -0.27 0.02 
Time since EU-wide approval 
(quarters) 2.93*** 0.59 4.95 0.00 1.77 4.09 
Time since EU-wide approval 
(quarters), squared -0.31*** 0.08 -3.94 0.00 -0.46 -0.16 
Constant -6.37 1.44 -4.42 0.00 -9.20 -3.54 
Log likelihood  = -54.453156 
LR test of rho=0: chibar2(01) = 8.9e-06                Probability >= chibar2 = 0.499 
Number of observations = 279 
Number of groups = 46 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
 
Model 2: Belgium Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.44*** 0.13 
-
3.41 0.00 -0.70 -0.19 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with 
CMA 0.73 0.59 1.22 0.22 -0.44 1.89 
Local manufacturer headquarter, baseline (no local headquarter) 
-Local 
headquarter/representative 2.90 1.59 1.82 0.07 -0.23 6.03 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites -2.25 1.50 
-
1.50 0.13 -5.18 0.68 
-L01C Plant alkaloids and 
other natural products -2.03 1.16 
-
1.75 0.08 -4.31 0.24 
-L01D Cytotoxic antibiotics 
and related substances             
-L02B Hormone antagonists 
and related agents -0.51 1.16 
-
0.44 0.66 -2.78 1.76 
Expected price in the 0.01* 0.003 2.67 0.01 0.002 0.01 
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therapeutic class (ATC-3), 
lagged one quarter 
Expected volume at 
therapeutic class (ATC-3) in 
thousands DDDs, lagged 
one quarter 0.000003 0.000001 1.81 0.07 
-
0.0000002 0.00001 
FDA expedited approval programme (EAP, baseline: no EAP) 
-Fast track only 0.83 0.95 0.88 0.38 -1.02 2.69 
-Priority review only -0.09 0.64 
-
0.13 0.89 -1.35 1.18 
-Combination 0.29 0.57 0.50 0.61 -0.83 1.41 
Year of marketing 
authorisation -0.01 0.08 
-
0.08 0.94 -0.17 0.16 
Time since EU-wide 
approval (quarters) 0.76*** 0.16 4.68 0.00 0.44 1.07 
Time since EU-wide 
approval (quarters), squared -0.02*** 0.01 
-
3.41 0.00 -0.03 -0.01 
Prescrire rating -0.18 0.20 
-
0.87 0.39 -0.58 0.22 
Constant -4.88 1.73 
-
2.81 0.01 -8.28 -1.48 
Log likelihood = -86.799008 
LR test of rho=0: chibar2(01) = 2.2e-05                Probability >= chibar 
Number of observations = 387 
Number of groups = 40 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
 
Model 2: Estonia Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.27 0.06 
-
4.76 0 -0.38 -0.16 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with 
CMA -0.37 0.75 
-
0.49 0.62 -1.83 1.10 
Local sales representative, baseline (no local representative) 
222 
 
-Local representative 3.18 0.93 3.40 0 1.35 5.01 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites 0.48 0.94 0.51 0.61 -1.35 2.31 
-L01C Plant alkaloids and 
other natural products 2.91 1.08 2.70 0.01 0.80 5.02 
-L01D Cytotoxic antibiotics 
and related substances             
-L02B Hormone antagonists 
and related agents 2.71 1.16 2.34 0.02 0.44 4.98 
Expected price in the 
therapeutic class (ATC-3), 
lagged one quarter 0.002 0.003 0.71 0.48 -0.004 0.01 
Expected volume at 
therapeutic class (ATC-3) in 
thousands DDDs, lagged one 
quarter 0.00002 0.00001 2.68 0.01 0.000005 0.00003 
FDA expedited approval programme (EAP, baseline: no EAP) 
-Fast track only 0.09 1.24 0.08 0.94 -2.34 2.53 
-Priority review only -1.13 0.88 
-
1.29 0.20 -2.85 0.59 
-Combination 1.03 0.74 1.40 0.16 -0.41 2.48 
Year of marketing 
authorisation -0.26 0.09 
-
2.97 0.003 -0.44 -0.09 
Time since EU-wide 
approval (quarters) 0.58 0.14 4.15 0 0.31 0.86 
Time since EU-wide 
approval (quarters), squared -0.01 0.00 
-
2.78 0.01 -0.02 0.00 
Prescrire rating -0.12 0.23 
-
0.51 0.61 -0.58 0.34 
Constant -4.32 1.72 
-
2.51 0.01 -7.69 -0.95 
Log likelihood  =  -69.05327 
LR test of rho=0: chibar2(01) = 0.00                   Probability >= chibar2 = 1.000 
Number of observations = 602 
Number of groups = 42 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
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Model 2: Scotland Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.15 0.09 -1.68 0.09 -0.32 0.02 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with 
CMA -0.80 0.99 -0.81 0.42 -2.73 1.13 
Local manufacturer headquarter, baseline (no local headquarter) 
-Local headquarter -0.56 0.84 -0.66 0.51 -2.21 1.10 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites -3.05 1.68 -1.82 0.07 -6.33 0.24 
-L01C Plant alkaloids and 
other natural products -7.59*** 2.04 -3.72 0.00 -11.59 -3.59 
-L01D Cytotoxic 
antibiotics and related 
substances -3.49 1.91 -1.83 0.07 -7.23 0.25 
-L02B Hormone 
antagonists and related 
agents -2.46 1.32 -1.86 0.06 -5.05 0.14 
Expected price in the 
therapeutic class (ATC-3), 
lagged one quarter -0.02*** 0.01 -3.45 0.00 -0.04 -0.01 
Expected volume at 
therapeutic class (ATC-3) 
in thousands DDDs, 
lagged one quarter -0.000003 0.000001 -1.86 0.06 -0.00001 0.0000001 
FDA expedited approval 
programme (EAP, 
baseline: no EAP)             
-Fast track only 0.27 1.43 0.19 0.85 -2.53 3.07 
-Priority review only 3.45* 1.48 2.32 0.02 0.54 6.36 
-Combination 2.90* 1.29 2.26 0.02 0.38 5.42 
Year of marketing 
authorisation 0.11 0.19 0.62 0.54 -0.25 0.48 
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Time since EU-wide 
approval (quarters) 1.08*** 0.25 4.30 0.00 0.59 1.57 
Time since EU-wide 
approval (quarters), 
squared -0.03* 0.01 -2.50 0.01 -0.06 -0.01 
Prescrire rating 0.31 0.25 1.21 0.23 -0.19 0.81 
Constant -6.25 2.74 -2.28 0.02 -11.63 -0.88 
Log likelihood  = -46.860869 
LR test of rho=0: chibar2(01) = 0.00                   Probability >= chibar2 = 1.000 
Number of observations = 160 
Number of groups = 28 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
 
 
Model 2: Sweden Coefficient 
Standard 
error 
z P>z 
[95% Confidence 
Interval] 
T1-T0, quarters -0.09*** 0.03 -3.30 0.00 -0.14 -0.04 
Conditional marketing authorisation (CMA, baseline: no CMA) 
-Medicine approved with 
CMA 0.94 0.68 1.38 0.17 -0.39 2.28 
Therapeutic group (baseline: other antineoplastic agents L01X)  
-L01B Antimetabolites 1.18 0.96 1.23 0.22 -0.71 3.07 
-L01C Plant alkaloids and 
other natural products 2.07 1.16 1.78 0.08 -0.21 4.35 
-L01D Cytotoxic 
antibiotics and related 
substances 1.90 1.57 1.21 0.23 -1.19 4.99 
-L02B Hormone 
antagonists and related 
agents 0.68 0.95 0.71 0.48 -1.19 2.55 
Expected price in the 
therapeutic class (ATC-3), 
lagged one quarter 0.01* 0.003 2.39 0.02 0.001 0.01 
Expected volume at 
therapeutic class (ATC-3) 
-
0.0000002 0.000001 -0.36 0.72 
-
0.000001 0.000001 
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in thousands DDDs, 
lagged one quarter 
FDA expedited approval programme (EAP, baseline: no EAP) 
-Fast track only 3.32 1.25 2.65 0.01 0.86 5.77 
-Priority review only 3.10*** 0.88 3.53 0.00 1.38 4.82 
-Combination 2.81*** 0.85 3.32 0.00 1.15 4.47 
Year of marketing 
authorisation -0.07 0.09 -0.83 0.41 -0.25 0.10 
Time since EU-wide 
approval (quarters) 3.30*** 0.66 4.97 0.00 2.00 4.60 
Time since EU-wide 
approval (quarters), 
squared -0.35*** 0.09 -4.11 0.00 -0.52 -0.18 
Prescrire rating -0.16 0.23 -0.68 0.50 -0.61 0.29 
Constant -6.55 1.86 -3.53 0.00 -10.19 -2.91 
*p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 
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Appendix 5: List of medicines analysed in Chapter 5 
 
Medicine 
Name Active Substance 
ATC 
code 
Marketing Authorisation 
Holder 
Authorisation 
date 
Alimta pemetrexed L01BA04 Eli Lilly Nederland B.V. 20/09/2004 
Xeloda capecitabine L01BC06 Roche Registration Ltd. 02/02/2001 
Teysuno 
tegafur / gimeracil / 
oteracil L01BC53 Nordic Group BV 14/03/2011 
Javlor vinflunine L01CA05 Pierre Fabre Médicament 21/09/2009 
Jevtana cabazitaxel L01CD04 
sanofi-aventis groupe 
  17/03/2011 
Herceptin trastuzumab L01XC03 Roche Registration Ltd. 28/08/2000 
Erbitux cetuximab L01XC06 Merck KGaA 29/06/2004 
Avastin bevacizumab L01XC07 Roche Registration Limited 12/01/2005 
Vectibix panitumumab L01XC08 Amgen Europe B.V. 03/12/2007 
Removab catumaxomab L01XC09 Neovii Biotech GmbH 20/04/2009 
Yervoy ipilimumab L01XC11 
Bristol-Myers Squibb Pharma 
EEIG 13/07/2011 
Foscan temoporfin L01XD05 biolitec pharma Itd. 24/10/2001 
Glivec imatinib L01XE01 Novartis Europharm Ltd 07/11/2001 
Iressa gefitinib L01XE02 AstraZeneca AB 24/06/2009 
Tarceva erlotinib L01XE03 Roche Registration Ltd. 19/09/2005 
Sutent sunitinib L01XE04 Pfizer Limited 19/07/2006 
Tyverb lapatinib L01XE07 Glaxo Group Limited 10/06/2008 
Afinitor everolimus L01XE10 Novartis Europharm Ltd. 03/08/2009 
Votrient pazopanib L01XE11 
Glaxo Group Ltd. 
  14/06/2010 
Caprelsa vandetanib L01XE12 AstraZeneca AB 17/02/2012 
Zelboraf vemurafenib L01XE15 Roche Registration Ltd. 17/02/2012 
Xalkori crizotinib L01XE16   Pfizer Ltd.   23/10/2012 
Inlyta axitinib L01XE17    
Pfizer Ltd. 
  03/09/2012 
Lysodren mitotane L01XX23 Laboratoire HRA Pharma 28/04/2004 
Targretin bexarotene L01XX25 Eisai Ltd. 29/03/2001 
Trisenox arsenic trioxide L01XX27 Teva Pharma B.V. 05/03/2002 
Velcade bortezomib L01XX32 Janssen-Cilag International NV 26/04/2004 
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Medicine 
Name Active Substance 
ATC 
code 
Marketing Authorisation 
Holder 
Authorisation 
date 
Alimta pemetrexed L01BA04 Eli Lilly Nederland B.V. 20/09/2004 
Halaven eribulin L01XX41 Eisai Europe Ltd. 17/03/2011 
Faslodex fulvestrant L02BA03 AstraZeneca UK Ltd. 10/03/2004 
Firmagon degarelix L02BX02 Ferring Pharmaceuticals A/S 17/02/2009 
Zytiga abiraterone acetate L02BX03 Janssen-Cilag International N.V. 05/09/2011 
 
Notes: Extracted from EMA website on 26 February 2015 
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Appendix 6: Estimated age-standardised rates (European standard) of cancer incidence by sex, cancer site and country, 2012 
 
!! Oesophagus!(C15)! Stomach!(C16)! Colon!(C18)! Rectum!(C20)! Liver!(C22)!
!! M! F! M! F! M! F! M! F! M! F!
Sweden! 4.8! 1.6! 6.7! 4.2! 29.2! 24.4! 19.1! 12.6! 6.3! 2.8!
Scotland! 24.9! 10.2! 15.6! 6.7! 23.9! 16.4! 10.5! 5.9! 11.7! 6.6!
Belgium! 10.8! 3.1! 13.3! 5.5! 42.5! 29.8! 21.3! 11.5! 8.7! 3.0!
 
!! Pancreas!(C25)! Larynx!(C32)! Bronchus!and!lung!(C34)! Melanoma!(C43)!
Breast!
(C50)!
Cervix!
(C53)!
!! M! F! M! F! M! F! M! F! F! F!
Sweden! 8.6! 7.5! 2.0! 0.6! 28.8! 27.1! 25.4! 25.8! 113.2! 9.4!
Scotland! 17.5! 13.7! 3.5! 0.8! 100.3! 76.8! 5.3! 2.7! 168.9! 4.1!
Belgium! 11.7! 8.6! 7.4! 1.3! 82.5! 31.5! 17.2! 21.4! 147.2! 10.6!
 
Data sources: Belgium (http://www.kankerregister.org/), Scotland (http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/), 
Sweden (http://www-dep.iarc.fr/NORDCAN/)
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Appendix 7: General semi-structured questionnaire for interviews with oncologists, 
Chapter 6 
 
Diagnosis 
1.! Do you have national estimates of the percentage of patients with primary breast cancer 
overexpressing HER-2?  
2.! Who is tested for HER-2 among breast cancer patients? 
2.1.!Is this fully implemented in practice?  
2.2.!If yes, since when is this the case?  
2.3.!Which diagnostic method is used?  
Referral and waiting times 
3.! Where are the majority of breast cancer cases detected or sent for referral (e.g. primary 
care, national screening programme, self-referral)?  
4.! Do patients need to visit their family doctor to be referred to an oncologist?  
5.! Is there evidence on waiting times for oncology and are there targets? If yes, to what 
extent are they met?  
Clinical guidelines 
6.! Which guidelines are followed in the country for the treatment of breast cancer (national, 
international, institutional)?  
7.! Do these include also criteria to start/stop treatment (e.g. side effects, response) for 
trastuzumab, lapatinib, pertuzumab, trastuzumab emtansine?  
Clinical practice 
8.! Within the field of breast cancer treatment, does clinical practice closely match clinical 
guidance? If not, in which aspects does it differ?  
Financing 
9.! How are inpatient medicines financed? 
10.!Are there additional mechanisms for funding expensive medicines (e.g. special funds)? 
11.!Are there any limits imposed on the number of patients that can be treated with HER-2 
targeted therapies? 
12.!Can you prescribe medicines which do not have a positive reimbursement decision or for 
which a decision is still pending?  
13.!How do you work within a finite budget, i.e. how do you set priorities? E.g. age, stage, 
fitness of the patient, presence of co-morbidities, fixed cap on patients treated with certain 
expensive medicines, prior authorization, etc. 
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